<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/233265-a-polypeptide-comprising-an-immunogenic-portion-of-a-prostate-protein by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:36:49 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 233265:&quot;A POLYPEPTIDE COMPRISING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;A POLYPEPTIDE COMPRISING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence recited in SEQ ID NO: 10 or 110, or a variant of said polypeptide that differs only in conservative substitutions and/or modifications, and exhibits at least 90% identity thereto, wherein the therapeutic, antigenic and/or immunogenic properties of the variant are retained.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE<br>
TECHNICAL FIELD<br>
The present invention relates generally to compositions and methods for the treatment of prostate cancer. The invention is more particularly related to polypeptides comprising at least a portion of a prostate protein and to DNA molecules encoding such polypeptides. Such polypeptides may be used in vaccines and pharmaceutical compositions for treatment of prostate cancer.<br>
BACKGROUND OF THE INVENTION<br>
Prostate cancer is the most common form of cancer among males, with an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.<br>
In spite of considerable research into therapies for the disease, prostate cancer remains difficult to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins - prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) - have limited therapeutic and diagnostic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with prostate volume, and do not indicate the level of metastasis.<br>
Accordingly, there remains a need in the art for improved vaccines and treatment methods for prostate cancer.<br><br>
SUMMARY OF THE; INVENTION<br>
The present invention provides compounds and methods for immunotherapy of prostate cancer. In one aspect, polypeptides are provided comprising at least an immunogenic portion of a prostate tumor protein or a variant of said protein that differs only in conservative substitutions and/or modifications, wherein the prostate tumor protein comprises an ami no acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177, the complements of said nucleotide sequences and variants thereof.<br>
In related aspects, DNA molecules encoding the above polypeptides are provided. In specific embodiments, such DNA molecules include sequences provided in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177. The present invention further provides expression vectors comprising the above DNA molecules and host cells transformed or transfected with such expression vectors. In preferred embodiments, the host cells are selected from the group consisting of E. coli, yeast and mammalian cells.<br>
In another aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, an inventive polypeptide and a known prostate antigen.<br>
The present invention also provides pharmaceutical compositions comprising one or more of the above polypeptides, or a DNA molecule encoding such polypeptides, and a physiologically acceptable carrier, together with vaccines comprising one or more of such polypeptide or DNA molecules in combination with a non-specific immune response enhancer.<br>
In related aspects, pharmaceutical compositions for the treatment of prostate cancer comprising one or more polypeptides and a physiologically acceptable carrier are provided, wherein the polypeptide comprises an immunogenic portion of a prostate tumor protein or of a variant of said protein that differs only in conservative substitutions and/or modifications, the prostate tumor protein being encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO:<br><br>
5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106 and 161-170, the complements of said nucleotide sequences and variants thereof. The invention also provides vaccines for the treatment of prostate cancer comprising such polypeptides in combination with a non-specific immune response enhancer, together with pharmaceutical compositions and vaccines comprising one or more DNA molecules having a sequence provided in SEQ ID NO: 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106 and 161-170. Pharmaceutical compositions and vaccines comprising one or more of the above fusion proteins are also provided.<br>
In yet another aspect, methods are provided for inhibiting the development of prostate cancer in a patient, comprising administering an effective amount of at least one of the above pharmaceutical compositions and/or vaccines.<br>
These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
As noted above, the present invention is generally directed to compositions and methods for the immunotherapy of prostate cancer. The inventive compositions are generally polypeptides that comprise at least a portion of a prostate tumor protein. Also included within the present invention are molecules (such as an antibody or fragment thereof) that bind to the inventive polypeptides. Such molecules are referred to herein as "binding<br>
agents."<br>
In particular, the subject invention discloses polypeptides comprising at least a portion of a human prostate tumor protein, or a variant of such a protein that differs only in conservative substitutions and/or modifications, wherein the prostate tumor protein includes an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 2, 3, 8-29, 41-45, 47-52, 54-65, 70, 73-74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111 and 115-160, the complements of said nucleotide sequences and variants thereof. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins,<br><br>
wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising a portion of one of the above prostate proteins may consist entirely of the portion, or the portion may be present within a larger polypeptide that contains additional sequences. The additional sequences may be derived from the native protein or may be heterologous, and such sequences may be immunoreactive and/or antigenic.<br>
As used herein, an "immunogenic portion" of a human prostate tumor protein is a portion that is capable of eliciting an immune response in a patient inflicted with prostate cancer and as such binds to antibodies present within sera from a prostate cancer patient. Immunogenic portions of the proteins described herein may thus be identified in antibody binding assays. Such assays may generally be performed using any of a variety of means known to those of ordinary skill in the art, as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. For example, a polypeptide may be immobilized on a solid support (as described below) and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, '^-labeled Protein A. Alternatively, a polypeptide may be used to generate monoclonal and polyclonal antibodies for use in detection of the polypeplide in blood or other fluids of prostate cancer patients.<br>
The compositions and methods of the present invention also encompass variants of the above polypeptides and DNA molecules. A polypeptide "variant," as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the therapeutic, antigenic and/or immunogenic properties of the polypeptide are retained. Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity to the identified polypeptides. For prostate tumor polypeptides with immunoreactive properties, variants may, alternatively, be identified by modifying the amino acid sequence of one of the above polypeptides, and evaluating the immunoreactivity of the modified polypeptide. For prostate tumor polypeptides useful for the generation of diagnostic binding agents, a variant may be identified by evaluating a modified polypeptide for the ability to generate antibodies that detect the presence or absence of prostate cancer. Such modified<br><br>
sequences may be prepared and tested using, for example, the representative procedures described herein.<br>
As used herein, a "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptlde to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, tip, his.<br>
Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.<br>
A nucleotide "variant" is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (DNA, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and most preferably at least about 90% identity to the recited sequence. Such variant nucleotide sequences will generally hybridize to the recite nucleotide sequence under stringent conditions. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65 °C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in IX SSC, 0.1% SDS at 65 "C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65 °C.<br><br>
"Polypeptides" as used herein also include combination, or fusion, polypeptides. A "combination polypeptide" is a polypeptide comprising at least one of the above immunogenic portions and one or more additional immunogenic prostate tumor-specific sequences, which are joined via a peptide linkage into a single amino acid chain. The sequences may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linked sequence (e.g., Gly-Cys-Gly) that does not significantly diminish the immunogenic properties of the component polypeptides.<br>
The prostate tumor proteins of the present invention, and DNA molecules encoding such proteins, may be isolated from prostate tumor tissue using any of a variety of methods well known in the art. DNA sequences corresponding to a gene (of a portion thereof) encoding one of the inventive prostate tumor proteins may be isolated from a prostate tumor cDNA library using a subtraction technique as described in detail below. Examples of such DNA sequences are provided in SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Partial DNA sequences thus obtained may be used to design oligonucleotide primers for the amplification of full-length DNA sequences in a polymerase chain reaction (PCR), using techniques well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 57:263, 1987; Erlich ed., PCR Technology, Stockton Press, NY, 1989). Once a DNA sequence encoding a polypeptide is obtained, any of the above modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (DNA, 2:183, 1983).<br>
The prostate tumor polypeptides disclosed herein may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (see, for example, Merrifield, J. Am. Chem. Soc. 55:2149-2146, 1963). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.<br><br>
Alternatively, any of the above polypeptides may be produced recombinantly by inserting a DNA sequence that encodes the polypeptide into an expression vector and expressing the protein in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line, such as CHO cells. The DNA sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.<br>
In general, regardless of the method of preparation, the polypeptides disclosed herein are prepared in substantially pure form (i.e., the polypeptides are homogenous as determined by amino acid composition and primary sequence analysis). Preferably, the polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. In certain preferred embodiments, described in more detail below, the substantially pure polypeptides are incorporated into pharmaceutical compositions or vaccines for use in one or more of the methods disclosed herein.<br>
In a related aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known prostate antigen, together with variants of such fusion proteins. The fusion proteins of the present invention may also include a linker peptide between the first and second polypeptides.<br>
A DNA sequence encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and second polypeptides into an appropriate expression vector. The 3' end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a<br><br>
single fusion protein that retains the biological activity of both the first and the second polypeptides.<br>
A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Arnino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 53:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.<br>
The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons require to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.<br>
Polypeptides of the present invention that comprise an immunogenic portion of a prostate tumor protein may generally be used for immunotherapy of prostate cancer, wherein the polypeptide stimulates the patient's own immune response to prostate tumor cells. In further aspects, the present invention provides methods for using one or more of the immunoreactive polypeptides encoded by a DNA molecule having a sequence provided in SEQ1DNOS: 1-107, 109-111, 115-171, 173-175 and 177 (or fusion proteins comprising one or more such polypeptides and/or DNA encoding such polypeptides) for immunotherapy of<br><br>
prostate cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease. Accordingly, the above immunoreactive polypeptides (or fusion proteins or DNA molecules encoding such polypeptides) may be used to treat prostate cancer or to inhibit the development of prostate cancer. The polypeptides may be administered either prior to or following surgical removal of primary tumors and/or treatment by administration of radiotherapy and conventional chemotherapeutic drugs.<br>
In these aspects, the polypeptide or fusion protein is generally present within a pharmaceutical composition and/or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. The vaccines may comprise one or more of such polypeptides and a non-specific immune response enhancer, such as an adjuvant, biodegradable microsphere (e.g., polylactic galactide) or a liposome (into which the polypeptide is incorporated). Pharmaceutical compositions and vaccines may also contain other epitopes of prostate tumor antigens, either incorporated into a combination polypeptide (i.e., a single polypeptide that contains multiple epitopes) or present within a separate polypeptide.<br>
Alternatively, a pharmaceutical composition or vaccine may contain DNA encoding one or more of the above polypeptides, such that the polypeptide is generated in situ. In such pharmaceutical compositions and vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerriri) that expresses an epitope of a prostate cell antigen on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus: Suitable systems are disclosed, for example, in Fisher-Hoch et al., PNAS 86:311-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 5(59:86-103, 1989; Flexner et al., Vaccine 5:17-21, 1990; U.S. Patent<br><br>
Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques (5:616-627, 1988; Rosenfeld et al., Science 252:431-434, 1991; Kolls et al., PNAS 91:215-219, 1994; Kass-Eisler et al., PNAS 90:11498-11502, 1993; Guzman et al., Circulation 55:2838-2848, 1993; and Guzman et al., dr. Res. 75:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in published PCT application WO 90/11092, and Ulmer et al., Science 259:1745-1749, 1993, reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.<br>
Routes and frequency of administration, as well as dosage, will vary from individual to individual arid may parallel those currently being used in immunotherapy of other diseases. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses may be administered over a 3-24 week period. Preferably, 4 doses are administered, at an interval of 3 months, and booster administrations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that is effective to raise an immune response (cellular and/or humoral) against prostate tumor cells in a treated patient. A suitable immune response is at least 10-50% above the basal (i.e., untreated) level. In general, the amount of polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 jig. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.01 mL to about 5 rnL.<br>
While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax and/or a buffer. For oral administration, any of the above carriers or a solid carrier, such as<br><br>
mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and/or magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic glycolide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.<br>
Any oi" a variety of non-specific immune response enhancers may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune response, such as lipid A, Bordella pertussis or Mycobacterium tuberculosis. Such adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ).<br>
Polypeptides disclosed herein may also be employed in ex vivo treatment of prostate cancer. For example, cells of the immune system, such as T cells, may be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as CellPro Incorporated's (Bothell, WA) CEPRATE™ system (see U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). The separated cells are stimulated with one or more of the immunoreactive polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T cells. The population of tumor antigen-specific T cells is then expanded using standard techniques and the cells are administered back to the patient.<br>
Polypeptides of the present invention may also, or alternatively, be used to generate binding agents, such as antibodies or fragments thereof, that are capable of detecting metastatic human prostate tumors. Binding agents of the present invention may generally be prepared using methods known to those of ordinary skill in the art, including the representative procedures described herein. Binding agents are capable of differentiating between patients with and without prostate cancer, using the representative assays described herein. In other words, antibodies or other binding agents raised against a prostate tumor protein, or a suitable portion thereof, will generate a signal indicating the presence of primary or metastatic prostate cancer in at least about 20% of patients afflicted with the disease, and<br><br>
will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without primary or rnetastatic prostate cancer. Suitable portions of such prostate tumor proteins are portions that are able to generate a binding agent that indicates the presence of primary or rnetastatic prostate cancer in substantially all (i.e., at least about 80%, and preferably at least about 90%) of the patients for which prostate cancer would be indicated using the full length protein, and that indicate the absence of prostate cancer in substantially all of those samples that would be negative when tested with full length protein. The representative assays described below, such as the two-antibody sandwich assay, may generally be employed for evaluating the ability of a binding agent to detect rnetastatic human prostate tumors.<br>
The ability of a polypeptide prepared as described herein to generate antibodies capable of detecting primary or metastatic human prostate tumors may generally be evaluated by raising one or more antibodies against the polypeptide (using, for example, a representative method described herein) and determining the ability of such antibodies to detect such tumors in patients. This determination may be made by assaying biological samples from patients with and without primary or metastatic prostate cancer for the presence of a polypeptide that binds to the generated antibodies. Such test assays may be performed, for example, using a representative procedure described below. Polypeptides that generate antibodies capable of detecting at least 20% of primary or melastatic prostate tumors by such procedures are considered to be useful in assays for detecting primary or metastatic human prostate tumors. Polypeptide specific antibodies may be used alone or in combination to improve sensitivity.<br>
Polypeptides capable of detecting primary or metastatic human prostate tumors may be used as markers for diagnosing prostate cancer or for monitoring disease progression in patients. In one embodiment, prostate cancer in a patient may be diagnosed by evaluating a biological sample obtained from the patient for the level of one or more of the above polypeptides, relative to a predetermined cut-off value. As used herein, suitable "biological samples" include blood, sera, urine and/or prostate secretions.<br>
The level of one or more of the above polypeptides may be evaluated using any binding agent specific for the polypeptide(s). A "binding agent," in the context of this<br><br>
invention, is any agent (such as a compound or a cell) that binds to a polypeptide as described above. As used herein, "binding" refers to a noncovalent association between two separate molecules (each of which may be free (i.e., in solution) or present on the surface of a cell or a solid support), such that a "complex" is formed. Such a complex may be free or immobilized (either covalently or noncovalently) on a support material. The ability to bind may generally be evaluated by determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to "bind" in the context of the present invention when the binding constant for complex formation exceeds about l()'L/mol. The binding constant may be determined using methods well known to those of ordinary skill in the art.<br>
Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome with or without a peptide component, an KNA molecule or a peptide. in a preferred embodiment, the binding partner is an antibody, or a fragment thereof. Such antibodies may be polyclonal, or monoclonal. In addition, the antibodies may be single chain, chimeric, CDR-grafted or humanized. Antibodies may be prepared by the methods described herein and by other methods well known to those of skill in the art.<br>
There are a variety of assay formats known to those of ordinary skill in the art for using a binding partner to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In a preferred embodiment, the assay involves the use of binding partner immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a second binding partner that contains a reporter group. Suitable second binding partners include antibodies that bind to the binding partner/polypeptide complex. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding partner after incubation of the binding partner with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding partner is indicative of the reactivity of the sample with the immobilized binding partner.<br><br>
The solid support may be any material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 p.g, and preferably about 100 ng to about 1 ug, is sufficient to immobilize an adequate amount of binding agent.<br>
Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).<br>
In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody<br><br>
(containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.<br>
More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeplide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily detennined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.<br>
Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of antibody to reporter group may be achieved using standard methods known to those of ordinary skill in the art.<br>
The second antibody is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound second antibody is then removed and bound second antibody is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups,<br><br>
scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.<br>
To determine the presence or absence of prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without prostate cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for prostate cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for prostate cancer.<br>
In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described<br><br>
above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of prostate cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 )^g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.<br>
Of course, numerous other assay protocols exist that are suitable for use with the antigens or antibodies of the present invention. The above descriptions are intended to be exemplary only.<br>
In another embodiment, the above polypeptides may be used as markers for the progression of prostate cancer. In this embodiment, assays as described above for the diagnosis of prostate cancer may be performed over time, and the change in the level of reactive polypeptide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, prostate cancer is progressing in those patients in whom the level of polypeptide detected by the binding agent increases over time. In contrast, prostate cancer is not progressing when the level of reactive polypeptide either remains constant or decreases with time.<br>
Antibodies for use in the above methods may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the antigenic polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptides of this invention may serve as the immunogen without modification.<br><br>
Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.<br>
Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells arc then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.<br>
Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.<br><br>
Monoclonal antibodies of the present invention may also be used as therapeutic reagents, to diminish or eliminate prostate tumors. The antibodies may be used on their own (for instance, to inhibit metastases) or coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include 90Y, 123I, 125I, ml, '86Re, 188Re, 21'At, and 212Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.<br>
A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.<br>
Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus mcrease the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.<br>
It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-mnctional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Patent No. 4,671,958, to Rodwell et al.<br><br>
Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Patent No. 4,671,958, to Rodwell etal.), and acid-catalyzed hydrolysis (e.g., U.S. Patent No. 4,569,789, to Blattler et al.).<br>
It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.<br>
A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable earners include proteins such as albumins (e.g., U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.<br><br>
A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.<br>
Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify prostate tumor-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a prostate tumor protein of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a DNA molecule encoding a prostate tumor protein of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.<br>
As used herein, the term "oligonucleotide primer/probe specific for a DNA molecule" means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule having a sequence selected from SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule having a sequence provided in SEQ ID NOS: 1-107, 109-111, 115-171, 173-175 and 177. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used to detect prostate tumor-specific sequences in biological samples, including blood, semen, prostate tissue and/or prostate tumor tissue.<br><br>
The following Examples are offered by way of illustration and not by way of limitation.<br>
EXAMPLES<br>
Example 1 ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES<br>
This Example describes the isolation of prostate tumor polypeptides from a prostate tumor cDNA library.<br>
A human prostate tumor cDNA expression library was constructed from prostate tumor poly A' RNA using a Superscript Plasmid System for cDNA Synthesis and PJasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A+ RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, CA) and digested with Notl. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA 94303), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax E. coli DHIOB cells (BRL Life Technologies) by electroporation.<br>
Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis. The prostate tumor library contained 1.64 x 107 independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained 3.3 x 10' independent colonies, with 69% of clones having inserts and the average insert size<br><br>
being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.<br>
cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara et al. (Blood, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70 u.g) was digested with EcoRI, NotI, and Sful, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 \i\ of H,0, heat-denatured and mixed with 100 (il (100 jag) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 (j,l) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 fjj H2O to form the driver DNA.<br>
To form the tracer DNA, 10 jag prostate tumor cDNA library was digested with BamHl and Xhol, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 ^1 H,0. Tracer DNA was mixed with 15 \i\ driver DNA and 20 u.1 of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 \\\ H2O, mixed with 8 (il driver DNA and 20 |^1 of 2 x hybridization buffer, and subjected to a hybridization at 68 °C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/Xhol site of chloramphenicol resistant pBCSlT (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax E. coll DH10B cells by electroporation to generate a prostate tumor specific subtracted cDNA library (prostate subtraction 1).<br><br>
To analyze the subtracted cDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A (Foster City, CA). Six cDNA clones, hereinafter referred to as Fl-13, Fl-12, Fl-16, Hl-1, HI-9 and Hl-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3' and 5' cDNA sequences for Fl-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3' cDNA sequences for Fl-13, Fl-16, Hl-1, Hl-9 and Hl-4 being provided in SEQ ID NO: 1 and 4-7, respectively.<br>
The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, Fl-13, Fl-16, Hl-1, and Hl-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA), human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. Hl-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for Fl-12 were found.<br>
Subsequent studies led to the isolation of a full-length cDNA sequence for Fl-12. This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108.<br>
To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described above with the normal pancreas cDNA library and with the three most abundant genes in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1 jag each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNAS.l were added to the driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the "subtracted prostate tumor specific cDNA library with spike".<br><br>
Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3' and 5' cDNA sequences for the clones referred to as .11-17, LI-12, Nl-1862, Jl-13, Jl-19, Jl-25, Jl-24, Kl-58, Kl-63, Ll-4 and Ll-14 are provided in SEQ ID NOS: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-2.7 and 28-29, respectively. The determined 3' cDNA sequences for the clones referred to as Jl-12, Jl-16, Jl-21, Kl-48, Kl-55, Ll-2, Ll-6, Nl-1858, Nl-1860, Nl-1861, Nl-1864 are provided in SEQ ID NOS: 30-40, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (Jl-17, Ll-12 and Nl-1862; SEQ ID NOS: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (Jl-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein, and the other (Kl-48; SEQ ID NO:33) was determined to have some homology to R. non&gt;egicus mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (Jl-16, Kl-55, Ll-6 and Nl-1864; SEQ ID NOS:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (Jl-21 and Nl-1860; SEQ ID NOS: 32 and 38, respectively) were found to show some homology to non-hurnan sequences, and two (Ll-2 and Nl-1861; SEQ ID NOS: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides Jl-13, JM9, Jl-24, Jl-25, Kl-58, Kl-63, Ll-4, Ll-14 (SEQ ID NOS: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29, respectively).<br>
Subsequent studies led to the isolation of full length cDNA sequences for Jl-17, Ll-12 and Nl-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114.<br>
In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (prostate subtraction 2). The determined cDNA sequences for these clones, hereinafter referred to as Ul-3064, Ul-3065, Vl-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively. Comparison of the determined sequences with those in the gene bank revealed no significant homologies to Ul-3065.<br><br>
A second subtraction with spike (prostate subtraction spike 2) was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, Jl-17, pulmonary surfactant-associated protein, mitochondria! DNA, cytochronie c oxidase subunit II, Nl-1862, autonomously replicating sequence, LI-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as Vl-3686, Rl-2330, 1B-3976 and Vl-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO:73-76, respectively. Comparison of these sequences with those in the gene bank revealed no significant homologies to VI-3686 and Rl-2330.<br>
Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones, referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 11-4810, 11-4811, 1J-4876, 1K-4884 and 1K-4896. The determinedcDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 11-4807, 1J-4876 and 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 11-4807, 1J-4876, 1K-4884 and 1K-4896, provided in SEQ ID NOS: 179-188 and 191-193, respectively, and to the determination of additional partial cDNA sequences for 11-4810 and 11-4811, provided in SEQ ID NOS: 189 and 190, respectively.<br>
An additional subtraction was performed by subtracting a normal prostate cDNA library with normal pancreas cDNA (prostate subtraction 3). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1G-4761, 1G-4762, 1H-4766 and 1H-4772 provided in SEQ<br><br>
ID NOS: 194-196 and 199, respectively, and to the determination of additional partial cDNA sequences for 1H-4770 and 1H-4771, provided in SEQ ID NOS:  197 and 198, respectively.<br>
Subtraction of a prostate tumor cDNA library, prepared from a pool of polyA+ RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D.1-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS: 103 and 104, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1D-4309, ID. 1-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280, provided in SEQ ID NOS: 200-206, respectively.cDNA clones isolated in prostate subtraction 1 and prostate subtraction 2, described above, were colony PCR amplified and their mRNA expression levels in prostate tumor, normal prostate and in various other normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted onto slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested, reverse transcribed, and fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity. Two novel clones (referred to as P509S and P510S) were found to be over-expressed in prostate tumor and normal prostate and expressed at low levels in all other normal tissues tested (liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon). The determined cDNA sequences for P509S and P510S are provided in SEQ ID NO: 207 and 208, respectively. Comparison of these sequences with those in the gene bank as described above, revealed some homology to previously identified ESTs.<br><br>
Example 2<br>
DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE TUMOR<br>
POLYPEPTIDES<br>
Using gene specific primers, mRNA expression levels for the representative prostate tumor polypeptides Fl-16, Hl-1, Jl-17, Ll-12, Fl-12 and Nl-1862 were examined in a variety of normal and tumor tissues using RT-PCR.<br>
Briefly, total RNA was extracted from a variety of normal and tumor tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 ug of total RNA with Superscript II reverse transcriptase (BRL Life Technologies) at 42 °C for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, p-actin was used as an internal control for each of the tissues examined. First, serial dilutions of the first strand cDNAs were prepared and RT-PCR assays were performed using P-actin specific primers. A dilution was then chosen that enabled the linear range amplification of the P-actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the P-actin levels were determined lor each reverse transcription reaction from each tissue. DNA contamination was minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.<br>
mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. Fl-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. Hl-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin, small intestine, bone marrow, and was not detected in the other tissues tested. Jl-17 and Ll-12 appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in<br><br>
prostate tumor and nonnal prostate but at low to undetectable levels in all the other tissues examined. Nl-1862 was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that Fl-16, Hl-1, Jl-17, Nl-1862 and L1 -12 are either prostate specific or are expressed at significantly elevated levels in prostate,<br>
Further RT-PCR studies showed that Fl-12 is over-expressed in 60% of prostate tumors, detectable in nonnal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. Ul-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not delectable in normal tissues.<br>
RT-PCR characterization of Rl-2330, Ul-3064 and 1D-4279 showed that these three antigens are overexpressed in prostate and/or prostate tumors.<br>
Northern analysis with four prostate tumor samples, two normal prostates, two BPH prostate samples, and nonnal colon, kidney, liver, lung, pancreas, skeletal muscle, brain, stomach, testes, small intestine and bone marrow showed that LI-12 is over-expressed in prostate tumor and nonnal prostate, while being undetectable in other normal tissues tested. Jl-17 was detected in two prostate tumors and not in the other tissues tested. Nl-1862 was found to be over-expressed in three prostate tumors and also expressed in normal prostate, colon and kidney, but not in the other tissues tested. Fl-12 was found to be highly expressed in two prostate tumors and was not detected in all other tissues tested.<br>
The micro-array technology described above was used to detennine the expression levels of representative antigens described herein in prostate tumor, breast tumor and the following normal tissues: prostate, liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon. Ll-12 was found to be over-exrpessed in normal prostate and prostate tumor, with some expression being detected in normal skeletal muscle. Both Jl-12 and Fl-12 were found to be over-expressed in prostate tumor, with expression being lower or undetectable in all other tissues tested. N1-1862 was found to be expressed at high levels in prostate tumor and normal prostate, and at low levels in normal large intestine and nonnal<br><br>
colon, with expression being undetectable in all other tissues tested. Rl-2330 was found to be over-expressed in prostate tumor, breast tumor and the following normal tissues: prostate, bladder, skin, testes, lung, spinal cord, skeletal muscle and colon. 1D-4279 was found to be expressed in prostate tumor and normal prostate, in addition to normal spinal cord.<br>
Example 3<br>
ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES<br>
BY PCR-BASED SUBTRACTION<br>
A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, WI) and transformed into XL-1 Blue MRP E. coli (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.<br>
Fifty-nine positive clones were sequenced. Comparison of the DNA sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, PI 8, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79 and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO:41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID NO:46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate.<br>
Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant homologies to known sequences. The determined cDNA sequences for these<br><br>
clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145, 147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. An additional clone, referred to as P703, was found to have five splice variants. The determined DNA sequence for the variants referred to as DEI, DEI3 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.<br>
mRNA Expression levels for representative clones in tumor tissues (prostate (n-5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n-2), ovary (n=:2), skeletal muscle, skin, stomach, small intestine and brain), and activated and non-activated PBMC was determined by RT-PCT as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.<br>
P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed comparable expression. P20 was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of PI 8 was found in normal prostate, prostate tumor and breast tumor compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal prostate and prostate tumor, compared to six of twelve other normal tissues tested. Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to the majority of normal tissues. However, substantial expression of P29<br><br>
was observed in normal colon and normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.<br>
Further studies using the above methodology resulted in the isolation of sixteen additional clones. The determined DNA sequences for those clones are provided in SEQ ID NO: 207-222.<br>
Example 4 SYNTHESIS OF POLYPEPTIDES<br>
Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems 430A peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by CIS reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.<br>
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.<br><br>
SEQUENCE LISTING<br>
(1) GENERAL INFORMATION:<br>
(i) APPLICANTS: Xu, Jiangchun<br>
Dillin, Davin C.<br>
iii) TITLE OF INVENTION: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE<br>
(iii) NUMBER OF SEQUENCES: 224<br>
(lv; CORRESPONDENCE ADDRESS:<br>
(A)	ADDRESSEE: SEED and BERRY LLP<br>
(B)	STREET: 6300 Columbia Center, 701 Fifth Avenue<br>
(C)	CITY: Seattle<br>
(D)	STATE: WA<br>
(E)	COUNTRY: USA<br>
(F)	ZIP: 98104<br>
(v) COMPUTER READABLE FORM:<br>
(A)	MEDIUM TYPE: Floppy disk<br>
(B)	COMPUTER: IBM PC compatible<br>
(C)	OPERATING SYSTEM: PC-DOS/MS-DOS<br>
(D! SOFTWARE: Patentln Release #1.0, Version #1.30<br>
(vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER:<br>
(B)	FILING DATE: 23-FEB-1998<br>
(C)	CLASSIFICATION:<br>
(viii) ATTORNEY/AGENT INFORMATION:<br>
(A)	NAME: Maki, David J.<br>
(B)	REGISTRATION NUMBER: 31,392<br>
(C)	REFERENCE/DOCKET NUMBER: 210121.427C3<br>
(ix) TELECOMMUNICATION INFORMATION:<br>
(A)	TELEPHONE: (206) 622-4900<br>
(B)	TELEFAX: (206) 682-6031<br>
(2) .INFORMATION FOR SRQ ID NO: 1 :<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 814 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:<br>
TTTTTTTTTT TTTTTCACAG TATAACAGCT CTTTATTTCT GTGAGTTCTA CTAGGAAATC	60<br>
ATCAAATCTG AGGGTTGTCT GGAGGACTTC AATACACCTC CCCCCATAGT GAATCAGCTT	120<br>
CCAGGGGGTC CAGTCCCTCT CCTTACTTCA TCCCCATCCC ATGCCAAAGG AAGACCCTCC	180<br>
CTCCTTGGCT CACAGCCTTC TCTAGGCTTC CCAGTGCCTC CAGGACAGAG TGGGTTATGT	240<br>
TTTCAGCTCC ATCCTTGCTG TGAGTGTCTG GTGCGTTGTG CCTCCAGCTT CTGCTCAGTG	300<br>
CTTCATGGAC AGTGTCCAGC ACATGTCACT CTCCACTCTC TCAGTGTGGA TCCACTAGTT	360<br>
CTAGAGCGGC CGCCACCGCG GTGGAGCTCC AGCTTTTGTT CCCTTTAGTG AGGGTTAATT	420<br><br>
GCGCGCTTGG CGTAATCATG GTCATAACTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA	480<br>
ATTCCACACA ACATACGAGC CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG	540<br>
ANCTAACTCA CATTAATTGC GTTGCGCTCA CTGNCCGCTT TCCAGTCNGG AAAACTGTCG	600<br>
TGCCAGCTGC ATTAATGAAT CGGCCAACGC NCGGGGAAAA GCGGTTTGCG TTTTGGGGGC	660<br>
TCTTCCGCTT CTCGCTCACT NANTCCTGCG CTCGGTCNTT CGGCTGCGGG GAACGGTATC	720<br>
ACTCCTCAAA GGNGGTATTA CGGTTATCCN NAAATCNGGG GATACCCNGG AAAAAANTTT	780<br>
AACAAAAGGG CANCAAAGGG CNGAAACGTA AAAA	814<br>
(2) INFORMATION FOR SEQ ID NO:2:<br>
(i) SEQUENCE, CHARACTERISTICS:<br>
(A)	LENGTH: 816 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID K'0:2 :<br>
ACAGAAATGT TGGATGGTGG AGCACCTTTC TATACGACTT ACAGGACAGC AGATGGGGAA	60<br>
TTCATGGCTG TTGGAGCAAT AGAACCCCAG TTCTACGAGC TGCTGATCAA AGGACTTGGA	120<br>
CTAAAGTCTG ATGAACTTCC CAATCAGATG AGCATGGATG ATTGGCCAGA AATGAAGAAG	180<br>
AAGTTTGCAG ATGTATTTGC AAAGAAGACG AAGGCAGAGT GGTGTCAAAT CTTTGACGGC	240<br>
ACAGATGCCT GTGTGACTCC GGTTCTGACT TTTGAGGAGG TTGTTCATCA TGATCACAAC	300<br>
AAGGAACGGG GCTCGTTTAT CACCAGTGAG GAGCAGGACG TGAGCCCCCG CCCTGCACCT	360<br>
CTGCTGTTAA ACACCCCAGC CATCCCTTCT TTCAAAAGGG ATCCACTAGT TCTAGAAGCG	420<br>
GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG TGAGGGTTAA TTGCGCGCTT	480<br>
GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCCCC	540<br>
AACATACGAG CCGGAACATA AAGTGTTAAG CCTGGGGTGC CTAATGANTG AGCTAACTCN	600<br>
CATTAATTGC GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAAACTGTCG TGCCACTGCN	660<br>
TTANTGAATC NGCCACCCCC CGGGAAAAGG CGGTTGCNTT TTGGGCCTCT TCCGCTTTCC	720<br>
TCGCTCATTG ATCCTNGCNC CCGGTCTTCG GCTGCGGNGA ACGGTTCACT CCTCAAAGGC	780<br>
GGTNTNCCGG TTATCCCCAA ACNGGGGATA CCCNGA	816<br>
(2) INFORMATION FOR SEQ ID NO:3:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 773 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE• cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 :<br>
CTTTTGAAAG AAGGGATGGC TGGGGTGTTT AACAGCAGAG GTGCAGGGCG GGGGCTCACG	60<br>
TCCTGCTCCT CACTGGTGAT AAACGAGCCC CGTTCCTTGT TGTGATCATG ATGAACAACC	120<br>
TCCTCAAAAG TCAGAACCGG AGTCACACAG GCATCTGTGC CGTCAAAGAT TTGACACCAC	180<br>
TCTGCCTTCG TCTTCTTTGC AAATACATCT GCAAACTTCT TCTTCATTTC TGGCCAATCA	240<br>
TCCATGCTCA TCTGATTGGG AAGTTCATCA GACTTTAGTC CANNTCCTTT GATCAGCAGC	300<br>
TCGTAGAACT GGGGTTCTAT TGCTCCAACA GCCATGAATT CCCCATCTGC TGTCCTGTAA	360<br>
GTCGTATAGA AAGGTGCTCC ACCATCCAAC ATGTTCTGTC CTCGAGGGGG GGCCCGGTAC	420<br>
CCAATTCGCC CTATANTGAG TCGTATTACG CGCGCTCACT GGCCGTCGTT TTACAACGTC	480<br>
GTGACTGGGA AAACCCTGGG CGTTACCAAC TTAATCGCCT TGCAGCACAT CCCCCTTTCG	540<br>
CCAGCTGGGC GTAATANCGA AAAGGCCCGC ACCGATCGCC CTTCCAACAG TTGCGCACCT	600<br>
GAATGGGNAA ATGGGACCCC CCTGTTACCG CGCATTNAAC CCCCGCNGGG TTTNGTTGTT	660<br>
AC'CCCCACNT NNACCGCTTA CACTTTGCCA GCGCC'TTANC GCCCGCTCCC TTTCNCCTTT	720<br>
CTTCCCTTCC TTTCNCNCCN CTTTCCCCCG GGGTTTCCCC CNTCAAACCC CNA	773<br><br>
(2) INFORMATION FOR SEQ ID NO:4:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 828 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:<br>
CCTCCTGAGT CCTACTGACC TGTGCTTTCT GGTGTGGAGT CCAGGGCTGC TAGGAAAAGG	60<br>
AATGGGCAGA CACAGGTGTA TGCCAATGTT TCTGAAATGG GTATAATTTC GTCCTCTCCT	120<br>
TCGGAACACT GGCTGTCTCT GAAGACTTCT CGCTCAGTTT CAGTGAGGAC ACACACAAAG	180<br>
ACGTGGGTGA CCATGTTGTT TGTGGGGTGC AGAGATGGGA GGGGTGGGGC CCACCCTGGA	240<br>
AGAGTGGACA GTGACACAAG GTGGACACTC TCTACAGATC ACTGAGGATA AGCTGGAGCC	300<br>
ACAATGCATG AGGCACACAC ACAGCAAGGA TGACNCTGTA AACATAGCCC ACGCTGTCCT	360<br>
GNGGGCACTG GGAAGCCTAN ATNAGGCCGT GAGCAWAAAG AAGGGGAGGA TCCACTAGTT	420<br>
CTANAGCGGC CGCCACCGCG GTGGANCTCC ANCTTTTGTT CCCTTTAGTG AGGGTTAATT	480<br>
GCGCGCTTGG CNTAATCATG GTCATANCTN TTTCCTGTGT GAAATTGTTA TCCGCTCACA	540<br>
ATTCCACACA ACATACGANC CGGAAACATA AANTGTAAAC CTGGGGTGCC TAATGANTGA	600<br>
CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCGCTTTC CAATCNGGAA ACCTGTCTTG	660<br>
CCNCTTGCAT TNATGAATCN GCCAACCCCC GGGGAAAAGC GTTTGCGTTT TGGGCGCTCT	720<br>
TCCGCTTCCT CNCTCANTTA NTCCCTNCNC TCGGTCATTC CGGCTGCNGC AAACCGGTTC	780<br>
ACCNCCTCCA AAGGGGGTAT TCCGGTTTCC CCNAATCCGG GGANANCC	828<br>
(2) INFORMATION FOR SEQ ID NO:5:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 834 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:<br>
XTTTTTTTTT TTTTTACTGA TAGATGGAAT TTATTAAGCT TTTCACATGT GATAGCACAT	60<br>
AGTTTTAATT GCATCCAAAG TACTAACAAA AACTCTAGCA ATCAAGAATG GCAGCATGTT	120<br>
ATTTTATAAC AATCAACACC TGTGGCTTTT AAAATTTGGT TTTCATAAGA TAATTTATAC	180<br>
TGAAGTAAAT CTAGCCATGC TTTTAAAAAA TGCTTTAGGT CACTCCAAGC TTGGCAGTTA	240<br>
ACATTTGGCA TAAACAATAA TAAAACAATC ACAATTTAAT AAATAACAAA TACAACATTG	300<br>
TAGGCCATAA TCATATACAG TATAAGGAAA AGGTGGTAGT GTTGAGTAAG CAGTTATTAG	360<br>
AATAGAATAC CTTGGCCTCT ATGCAAATAT GTCTAGACAC TTTGATTCAC TCAGCCCTGA	420<br>
CATTCAGTTT TCAAAGTAGG AGACAGGTTC TACAGTATCA TTTTACAGTT TCCAACACAT	480<br>
TGAAAACAAG TAGAAAATGA TGAGTTGATT TTTATTAATG CATTACATCC TCAAGAGTTA	540<br>
TCACCAACCC CTCAGTTATA AAAAATTTTC AAGTTATATT AGTCATATAA CTTGGTGTGC	600<br>
TTATTTTAAA TTAGTGCTAA ATGGATTAAG TGAAGACAAC AATGGTCCCC TAATGTGATT	660<br>
GATATTGGTC ATTTTTACCA GCTTCTAAAT CTNAACTTTC AGGCTTTTGA ACTGGAACAT	720<br>
TGNATNACAG TGTTCCANAG TTNCAACCTA CTGGAACATT ACAGTGTGCT TGATTCAAAA	780<br>
TGTTATTTTG TTAAAAATTA AATTTTAACC TGGTGGAAAA ATAATTTGAA ATNA	834<br>
(2) INFORMATION FOR SEQ ID NO:6:<br>
ii) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 818 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
(ii) MOLECULE TYPF, : CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:<br>
TTTTTTTTTT TTTTTTTTTT AAGACCCTCA TCAATAGATG GAGACATACA GAAATAGTCA	60<br>
AACCACATCT ACAAAATGCC AGTATCAGGC GGCGGCTTCG AAGCCAAAGT GATGTTTGGA	120<br>
TGTAAAGTGA AATATTAGTT GGCGGATGAA GCAGATAGTG AGGAAAGTTG AGCCAATAAT	180<br>
GACGTGAAGT CCGTGGAAGC CTGTGGCTAC AAAAAATGTT GAGCCGTAGA TGCCGTCGGA	240<br>
AATGGTGAAG GGAGACTCGA AGTACTCTGA GGCTTGTAGG AGGGTAAAAT AGAGACCCAG	300<br>
TAAAATTGTA ATAAGCAGTG CTTGAATTAT TTGGTTTCGG TTGTTTTCTA TTAGACTATG	360<br>
GTGAGCTCAG GTGATTGATA CTCCTGATGC GAGTAATACG GATGTGTTTA GGAGTGGGAC	420<br>
TTCTAGGGGA TTTAGCGGGG TGATGCCTGT TGGGGGCCAG TGCCCTCCTA GTTGGGGGGT	480<br>
AGGGGCTAGG CTGGAGTGGT AAAAGGCTCA GAAAAATCCT GCGAAGAAAA AAACTTCTGA	540<br>
GGTAATAAAT AGGATTATCC CGTATCGAAG GCCTTTTTGG ACAGGTGGTG TGTGGTGGCC	600<br>
TTGGTATGTG CTTTCTCGTG TTACATCGCG CCATCATTGG TATATGGTTA GTGTGTTGGG	660<br>
TTANTANGGC CTANTATGAA GAACTTTTGG ANTGGAATTA AATCAATNGC TTGGCCGGAA	720<br>
GTCATT\NGA NGGCTNAAAA GGCCCTGTTA NGGGTCTGGG CTNGGTTTTA CCCNACCCAT	780<br>
GGAATNCNCC CCCCGGACNA NTGNATCCCT ATTCTTAA	818<br>
(2) INFORMATION FOR SEQ ID NO:7:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 817 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: s ingle<br>
(D)	TOPOLOGY: linear-<br>
ill) MOLECULK TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID ND:7:<br>
TTTTTTTTTT TTTTTTTTTT	TGGCTCTAGA GGGGGTAGAG GGGGTGCTAT AGGGTAAATA	60<br>
CGGGCCCTAT TTCAAAGATT	TTTAGGGGAA TTAATTCTAG GACGATGGGT ATGAAACTGT	120<br>
GGTTTGCTCC ACAGATTTCA	GAGCATTGAC CGTAGTATAC CCCCGGTCGT GTAGCGGTGA	180<br>
AAGTGGTTTG GTTTAGACGT	CCGGGAATTG CATCTGTTTT TAAGCCTAAT GTGGGGACAG	240<br>
CTCATGAGTG CAAGACGTCT	TGTGATGTAA TTATTATACN AATGGGGGCT TCAATCGGGA	300<br>
GTACTACTCG ATTGTCAACG	TCAAGGAGTC GCAGGTCGCC TGGTTCTAGG AATAATGGGG	360<br>
GAAGTATGTA GGAATTGAAG	ATTAATCCGC CGTAGTCGGT GTTCTCCTAG GTTCAATACC	420<br>
ATTGGTGGCC AATTGATTTG	ATGGTAAGGG GAGGGATCGT TGAACTCGTC TGTTATGTAA	480<br>
AGGATNCCTT NGGGATGGGA	AGGCNATNAA GGACTANGGA TNAATGGCGG GCANGATATT	540<br>
TCAAACNGTC TCTANTTCCT	GAAACGTCTG AAATGTTAAT AANAATTAAN TTTNGTTATT	600<br>
GAATNTTNNG GAAAAGGGCT	TACAGGACTA GAAACCAAAT ANGAAAANTA ATNNTAANGG	660<br>
CNTTATCNTN AAAGGTNATA	ACCNCTCCTA TNATCCCACC CAATNGNATT CCCCACNCNN	720<br>
ACNATTGGAT NCCCCANTTC	CANAAANGGC CNCCCCCCGG TGNANNCCNC CTTTTGTTCC	780<br>
CTTNANTGAN GGTTATTCNC	CCCTNGCNTT ATCANCC	817<br>
(2) INFORMATION FOR SEQ ID NO:8:<br>
I. i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: '99 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: 1inea r<br>
(ii.) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:<br>
CATTTCCGGG TTTACTTTCT AAGGAAAGCC GAGCGGAAGC TGCTAACGTG GGAATCGGTG      60 CATAAGGAGA ACTTTCTGCT GGCACGCGCT AGGGACAAGC GGGAGAGCGA CTCCGAGCGT     120<br><br>
CTGAAGCGCA CGTCCCAGAA GGTGGACTTG GCACTGAAAC AGCTGGGACA CATCCGCGAG	180<br>
TACGAACAGC GCCTGAAAGT GCTGGAGCGG GAGGTCCAGC AGTGTAGCCG CGTCCTGGGG	240<br>
TGGGTGGCCG ANGCCTGANC CGCTCTGCCT TGCTGCCCCC ANGTGGGCCG CCACCCCCTG	300<br>
ACCTGCCTGG GTCCAAACAC TGAGCCCTGC TGGCGGACTT CAAGGANAAC CCCCACANGG	360<br>
GGATTTTGCT CCTANANTAA GGCTCATCTG GGCCTCGGCC CCCCCACCTG GTTGGCCTTG	420<br>
TCTTTGANGT GAGCCCCATG TCCATCTGGG CCACTGTCNG GACCACCTTT NGGGAGTGTT	480<br>
CTCCTTACAA CCACANNATG CCCGGCTCCT CCCGGAAACC ANTCCCANCC TGNGAAGGAT	540<br>
CAAGNCCTGN ATCCACTNNT NCTANAACCG GCCNCCNCCG CNGTGGAACC CNCCTTNTGT	600<br>
TCCTTTTCNT TNAGGGTTAA TNNCGCCTTG GCCTTNCCAN NGTCCTNCNC NTTTTCCNNT	660<br>
GTTNAAATTG TTANGCNCCC NCCNNTCCCN CNNCNHCNAN CCCGACCCNN ANNTTNNANN	720<br>
NCCTGGGGGT NCCNNCNGAT TGACCCNNCC NCCCTNTANT TGCNTTNGGG NNCNNTGCCC	780<br>
CTTTCCCTCT NGGGANNCG	799<br>
(2) INFORMATION FOR SEQ ID NO:9:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 801 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
SEQUENCE DESCRIPTION: SEQ ID NO:9:<br>
ACGCCTTGAT CCTCCCAGGC TGGGACTGGT TCTGGGAGGA GCCGGGCATG CTGTGGTTTG	60<br>
TAANGATGAC ACTCCCAAAG GTGGTCCTGA CAGTGGCCCA GATGGACATG GGGCTCACCT	120<br>
CAAGGACAAG GCCACCAGGT GCGGGGGCCG AAGCCCACAT GATCCTTACT CTATGAGCAA	180<br>
AATCCCCTGT GGGGGCTTCT CCTTGAAGTC CGCCAKCAGG GCTCAGTCTT TGGACCCANG	240<br>
CAGGTCATGG GGTTGTNGNC CAACTGGGGG CCNCAACGCA AAANGGCNCA GGGCCTCNGN	300<br>
CACCCATCCC ANGACGCGGC TACACTNCTG GACCTCCCNC TCCACCACTT TCATGCGCTG	360<br>
TTCNTACCCG CGNATNTGTC CCANCTGTTT CNGTGCCNAC TCCANCTTCT NGGACGTGCG	420<br>
CTACATACGC CCGGANTCNC NCTCCCGCTT TGTCCCTATC CACGTNCCAN CAACAAATTT	480<br>
CNCCNTANTG CACCNATTCC CACNTTTNNC AGNTTTCCNC NNCGNGCTTC CTTNTAAAAG	540<br>
GGTTGANCCC CGGAAAATNC CCCAAAGGGG GGGGGCCNGG TACCCAACTN CCCCCTNATA	600<br>
GCTGAANTCC CCATNACCNN GNCTCNATGG ANCCNTCCNT TTTAANNACN TTCTNAACTT	660<br>
GGGAANANCC CTCGNCCNTN CCCCCNTTAA TCCCNCCTTG CNANGNNCNT CCCCCNNTCC	720<br>
NCCCNNNTNG GCNTNTNANN CNAAAAAGGC CCNNNANCAA TCTCCTNNCN CCTCANTTCG	780<br>
CCANCCCTCG AAATCGGCCN C	801<br>
(2) INFORMATION FOR SEQ ID NO:10:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 789 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:<br>
CAGTCTATNT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC CGGTGCCACA TGCCTGTCCC	60<br>
ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCGG GTTCACCTTC TCAGCCCTGC	120<br>
AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA GAAGCAGGTG TTCCTGCCCA	180<br>
AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG CCTGATGACC AGCTTCCTGC	240<br>
CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT GGGTGCTGGA GGCAGTGGCC	300<br>
TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG TGATGTCTCC GTACGTGTGG	360<br>
TGGTGGGTGA GCCCACCGAN GCCAGGGTGG TTCCGGGCCG GGGCATCTGC CTGGACCTCG	420<br>
CCATCCTGGA TAGTGCTTCC TGCTGTCCCA NGTGGCCCCA TCCCTGTTTA TGGGCTCCAT	480<br>
TGTCCAGCTC AGCCAGTCTG TCACTGCCTA TATGGTGTCT GCCGCAGGCC TGGGTCTGGT	540<br><br>
CCCATTTACT TTGCTACACA GGTANTATTT GACAAGAACG ANTTGGCCAA ATACTCAGCG	600<br>
TTAAAAAATT CCAGCAACAT TGGGGGTGGA AGGCCTGCCT CACTGGGTCC AACTCCCCGC	660<br>
TCCTGTTAAC CCCATGGGGC TGCCGGCTTG GCCGCCAATT TCTGTTGCTG CCAAANTNAT	720<br>
GTGGCTCTCT GCTGCCACCT GTTGCTGGCT GAAGTGCNTA CNGCNCANCT NGGGGGGTNG	780<br>
GGNGTTCCC	7(39<br>
(2) INFORMATION FOR SEQ ID NO:11:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 772 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:<br>
CCCACCCTAC CCAAATATTA GACACCAACA CAGAAAAGCT AGCAATGGAT TCCCTTCTAC	60<br>
TTTGTTAAAT AAATAAGTTA AATATTTAAA TGCCTGTGTC TCTGTGATGG CAACAGAAGG	120<br>
ACCAACAGGC CACATCCTGA TAAAAGGTAA GAGGGGGGTG GATCAGCAAA AAGACAGTGC	180<br>
TGTGGGCTGA GGGGACCTGG TTCTTGTGTG TTGCCCCTCA GGACTCTTCC CCTACAAATA	240<br>
ACTTTCATAT GTTCAAATCC CATGGAGGAG TGTTTCATCC TAGAAACTCC CATGCAAGAG	300<br>
CTACATTAAA CGAAGCTGCA GGTTAAGGGG CTTANAGATG GGAAACCAGG TGACTGAGTT	360<br>
TATTCAGCTC CCAAAAACCC TTCTCTAGGT GTGTCTCAAC TAGGAGGCTA GCTGTTAACC	420<br>
CTGAGCCTGG GTAATCCACC TGCAGAGTCC CCGCATTCCA GTGCATGGAA CCCTTCTGGC	480<br>
CTCCCTGTAT AAGTCCAGAC TGAAACCCCC TTGGAAGGNC TCCAGTCAGG CAGCCCTANA	540<br>
AACTGGGGAA AAAAGAAAAG GACGCCCCAN CCCCCAGCTG TGCANCTACG CACCTCAACA	600<br>
GCACAGGGTG GCAGCAAAAA AACCACTTTA CTTTGGCACA AACAAAAACT NGGGGGGGCA	660<br>
ACCCCGGCAC CCCNANGGGG GTTAACAGGA ANCNGGGNAA CNTGGAACCC AATTNAGGCA	720<br>
GGGCC'NCCAC CCCNAATNTT GCTGGGAAAT TTTTCCTCCC CTAAATTNTT TC	772<br>
(2i  INFORMATION FOR SEQ ID NO:12:<br>
ii) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 751 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( 1 i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:<br>
GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA	60<br>
AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA	120<br>
TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG	180<br>
AAGTANGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC	240<br>
ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA	300<br>
GGCACTACCA GCAACGTCAG GGAAGTGCTC AGCCATTGTG GTGTACACCA AGGCGACCAC	360<br>
AGCAGCTGCN ACCTCAGCAA TGAAGATGAN GAGGANGATG AAGAAGAACG TCNCGAGGGC	420<br>
ACACTTGCTC TCAGTCTTAN CACCATANCA GCCCNTGAAA ACCAANANCA AAGACCACNA	480<br>
CNCCGGCTGC GATGAAGAAA TNACCCCNCG TTGACAAACT TGCATGGCAC TGGGANCCAC	540<br>
AGTGGCCCNA AAAATCTTCA AAAAGGATGC CCCATCNATT GACCCCCCAA ATGCCCACTG	600<br>
CCAACAGGGG CTGCCCCACN CNCNNAACGA TGANCCNATT GNACAAGATC TNCNTGGTCT	660<br>
TNATNAACNT GAACCCTGCN TNGTGGCTCC TGTTCAGGNC CNNGGCCTGA CTTCTNAANN	720<br>
AANGAACTCN GAAGNCCCCA CNGGANANNC G	751<br>
(2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 729 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:<br>
GAGCCAGGCG TCCCTCTGCC TGCCCACTCA GTGGCAACAC CCGGGAGCTG TTTTGTCCTT	60<br>
TGTGGANCCT CAGCAGTNCC CTCTTTCAGA ACTCANTGCC AAGANCCCTG AACAGGAGCC	120<br>
ACCATGCAGT GCTTCAGCTT CATTAAGACC ATGATGATCC TCTTCAATTT GCTCATCTTT	180<br>
CTGTGTGGTG CAGCCCTGTT GGCAGTGGGC ATCTGGGTGT CAATCGATGG GGCATCCTTT	240<br>
CTGAAGATCT TCGGGCCACT GTCGTCCAGT GCCATGCAGT TTGTCAACGT GGGCTACTTC	300<br>
CTCATCGCAG CCGGCGTTGT GGTCTTAGCT CTAGGTTTCC TGGGCTGCTA TGGTGCTAAG	360<br>
ACTGAGAGCA AGTGTGCCCT CGTGACGTTC TTCTTCATCC TCCTCCTCAT CTTCATTGCT	420<br>
GAGGTTGCAA TGCTGTGGTC GCCTTGGTGT ACACCACAAT GGCTGAGCAC TTCCTGACGT	480<br>
TGCTGGTAAT GCCTGCCATC AANAAAAGAT TATGGGTTCC CAGGAANACT TCACTCAAGT	540<br>
GTTGGAACAC CACCATGAAA GGGCTCAAGT GCTGTGGCTT CNNCCAACTA TACGGATTTT	600<br>
GAAGANTCAC CTACTTCAAA GAAAANAGTG CCTTTCCCCC ATTTCTGTTG CAATTGACAA	660<br>
ACGTCCCCAA CACAGCCAAT TGAAAACCTG CACCCAACCC AAANGGGTCC CCAACCANAA	720<br>
ATTNAAGGG	729<br>
(21 INFORMATION FOR SEQ ID NO:14:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 816 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:<br>
TGCTCTTCCT CAAAGTTGTT CTTGTTGCCA TAACAACCAC CATAGGTAAA GCGGGCGCAG	60<br>
TGTTCGCTGA AGGGGTTGTA GTACCAGCGC GGGATGCTCT CCTTGCAGAG TCCTGTGTCT	120<br>
GGCAGGTCCA CGCAGTGCCC TTTGTCACTG GGGAAATGGA TGCGCTGGAG CTCGTCAAAG	180<br>
CCACTCGTGT ATTTTTCACA GGCAGCCTCG TCCGACGCGT CGGGGCAGTT GGGGGTGTCT	240<br>
TCACACTCCA GGAAACTGTC NATGCAGCAG CCATTGCTGC AGCGGAACTG GGTGGGCTGA	300<br>
CANGTGCCAG AGCACACTGG ATGGCGCCTT TCCATGNNAN GGGCCCTGNG GGAAAGTCCC	360<br>
TGANCCCCAN ANCTGCCTCT CAAANGCCCC ACCTTGCACA CCCCGACAGG CTAGAATGGA	420<br>
ATCTTCTTCC CGAAAGGTAG TTNTTCTTGT TGCCCAANCC ANCCCCNTAA ACAAACTCTT	480<br>
GCANATCTGC TCCGNGGGGG TCNTANTACC ANCGTGGGAA AAGAACCCCA GGCNGCGAAC	540<br>
CAANCTTGTT TGGATNCGAA GCNATAATCT NCTNTTCTGC TTGGTGGACA GCACCANTNA	600<br>
CTGTNNANCT TTAGNCCNTG GTCCTCNTGG GTTGNNCTTG AACCTAATCN CCNNTCAACT	660<br>
GGGACAAGGT AANTNGCCNT CCTTTNAATT CCCNANCNTN CCCCCTGGTT TGGGGTTTTN	720<br>
CNCNCTCCTA CCCCAGAAAN NCCGTGTTCC CCCCCAACTA GGGGCCNAAA CCNNTTNTTC	780<br>
CACAACCCTN CCCCACCCAC GGGTTCNGNT GGTTNG	816<br>
(2) INFORMATION FOR SEQ ID NO:15:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 783 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:<br><br>
CCAAGGCCTG GGCAGGCATA NACTTGAAGG TACAACCCCA GGAACCCCTG GTGCTGAAGG	60<br>
ATGTGGAAAA CACAGATTGG CGCCTACTGC GGGGTC3ACAC GGATGTCAGG GTAGAGAGGA	120<br>
AAGACCCAAA CCAGGTGGAA CTGTGGGGAC TCAAGGAANG CACCTACCTG TTCCAGCTGA	180<br>
CAGTGACTAG CTCAGACCAC CCAGAGGACA CGGCCAACGT CACAGTCACT GTGCTGTCCA	240<br>
CCAAGCAGAC AGAAGACTAC TGCCTCGCAT CCAACAANGT GGGTCGCTGC CGGGGCTCTT	300<br>
TCCCACGCTG GTACTATGAC CCCACGGAGC AGATCTGCAA GAGTTTCGTT TATGGAGGCT	360<br>
GCTTGGGCAA CAAGAACAAC TACCTTCGGG AAGAAGAGTG CATTCTANCC TGTCNGGGTG	420<br>
TGCAAGGTGG GCCTTTGANA NGCANCTCTG GGGCTCANGC GACTTTCCCC CAGGGCCCCT	480<br>
CCATGGAAAG GCGCCATCCA NTGTTCTCTG GCACCTGTCA GCCCACCCAG TTCCGCTGCA	540<br>
NCAATGGCTG CTGCATCNAC ANTTTCCTNG AATTGTGACA ACACCCCCCA NTGCCCCCAA	600<br>
CCCTCCCAAC AAAGCTTCCC TGTTNAAAAA TACNCCANTT GGCTTTTNAC AAACNCCCGG	660<br>
CNCCTCCNTT TTCCCCNNTN AACAAAGGGC NCTNGCNTTT GAACTGCCCN AACCCNGGAA	720<br>
TCTNCCNNGG AAAAANTNCC CCCCCTGGTT CCTNNAANCC CCTCCNCNAA ANCTNCCCCC	780<br>
CCC	783<br>
(2) INFORMATION FOR SEQ ID N0:16:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 801 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:<br>
GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA	60<br>
AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA	120<br>
TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG	180<br>
AAGTAGGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC	240<br>
ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA	300<br>
GGCACTACCA GCAACGTCAG GAAGTGCTCA GCCATTGTGG TGTACACCAA GGCGACCACA	360<br>
GCAGCTGCAA CCTCAGCAAT GAAGATGAGG AGGAGGATGA AGAAGAACGT CNCGAGGGCA	420<br>
CACTTGCTCT CCGTCTTAGC ACCATAGCAG CCCANGAAAC CAAGAGCAAA GACCACAACG	480<br>
CCNGCTGCGA ATGAAAGAAA NTACCCACGT TGACAAACTG CATGGCCACT GGACGACAGT	540<br>
TGGCCCGAAN ATCTTCAGAA AAGGGATGCC CCATCGATTG AACACCCANA TGCCCACTGC	600<br>
CMACAGGGCT GCNCCNCNCN GAAAGAATGA GCCATTGAAG AAGGATCNTC NTGGTCTTAA	660<br>
TGAACTGAAA CCNTGCATGG TGGCCCCTGT TCAGGGCTCT TGGCAGTGAA TTCTGANAAA	720<br>
AAGGAACNGC NTNAGCCCCC CCAAANGANA AAACACCCCC GGGTGTTGCC CTGAATTGGC	780<br>
GGCCAAGGAN CCCTGCCCCN G	801<br>
(2) INFORMATION FOR SEQ ID NO:17:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 740 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:<br>
GTGAGAGCCA GGCGTCCCTC TGCCTGCCCA CTCAGTGGCA ACACCCGGGA GCTGTTTTGT	60<br>
CCTTTGTGGA GCCTCAGCAG TTCCCTCTTT CAGAACTCAC TGCCAAGAGC CCTGAACAGG	120<br>
AGCCACCATG CAGTGCTTCA GCTTCATTAA GACCATGATG ATCCTCTTCA ATTTGCTCAT	180<br>
CTTTCTGTGT GGTGCAGCCC TGTTGGCAGT GGGCATCTGG GTGTCAATCG ATGGGGCATC	240<br>
CTTTCTGAAG ATCTTCGGGC CACTGTCGTC CAGTGCGATG CAGTTTGTCA ACGTGGGCTA	300<br>
CTTCOTCATC GCAGC'CGGCG TTGTGGTCTT TGCTCTTGGT TTCCTGGGCT GCTATGGTGC	360<br><br>
TAAGACGGAG AGCAAGTGTG CCCTCGTGAC GTTCTTCTTC ATCCTCCTCC TCATCTTCAT	420<br>
TGCTGAAGTT GCAGCTGCTG TGGTCGCCTT GGTGTACACC ACAATGGCTG AACCATTCCT	480<br>
GACGTTGCTG GTANTGCCTG CCATCAANAA AGATTATGGG TTCCCAGGAA AAATTCACTC	540<br>
AANTNTGGAA CACCNCCATG AAAAGGGCTC CAATTTCTGN TGGCTTCCCC AACTATACCG	600<br>
GAATTTTGAA AGANTCNCCC TACTTCCAAA AAAAAANANT TGCCTTTNCC CCCNTTCTGT	660<br>
TGCAATGAAA ACNTCCCAAN ACNGCCAATN AAAACCTGCC CNNNCAAAAA GGNTCNCAAA	720<br>
CAAAAAAANT NNAAGGGTTN	740<br>
(2) INFORMATION FOR SEQ ID NO:18:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 802 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:<br>
CCGCTGGTTG CGCTGGTCCA GNGNAGCCAC GAAGCACGTC AGCATACACA GCCTCAATCA	60<br>
CAAGGTCTTC CAGCTGCCGC ACATTACGCA GGGCAAGAGC CTCCAGCAAC ACTGCATATG	120<br>
GGATACACTT TACTTTAGCA GCCAGGGTGA CAACTGAGAG GTGTCGAAGC TTATTCTTCT	180<br>
GAGCCTCTGT TAGTGGAGGA AGATTCCGGG CTTCAGCTAA GTAGTCAGCG TATGTCCCAT	240<br>
AAGCAAACAC TGTGAGCAGC CGGAAGGTAG AGGCAAAGTC ACTCTCAGCC AGCTCTCTAA	300<br>
CATTGGGCAT GTCCAGCAGT TCTCCAAACA CGTAGACACC AGNGGCCTCC AGCACCTGAT	360<br>
GGATGAGTGT GGCCAGCGCT GCCCCCTTGG CCGACTTGGC TAGGAGCAGA AATTGCTCCT	420<br>
GGTTCTGCCC TGTCACCTTC ACTTCCGCAC TCATCACTGC ACTGAGTGTG GGGGACTTGG	480<br>
GCTCAGGATG TCCAGAGACG TGGTTCCGCC CCCTCNCTTA ATGACACCGN CCANNCAACC	540<br>
GTCGGCTCCC GCCGANTGNG TTCGTCGTNC CTGGGTCAGG GTCTGCTGGC CNCTACTTGC	600<br>
AANCTTCGTC NGGCCCATGG AATTCACCNC ACCGGAACTN GTANGATCCA CTNNTTCTAT	660<br>
AACCGGNCGC CACCGCNNNT GGAACTCCAC TCTTNTTNCC TTTACTTGAG GGTTAAGGTC	720<br>
ACCCTTNNCG TTACCTTGGT CCAAACCNTN CCNTGTGTCG ANATNGTNAA TCNGGNCCNA	780<br>
TNCCANCCNC ATANGAAGCC NG	802<br>
(2) INFORMATION FOR SEQ ID NO:19:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 731 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:<br>
CNAAGCTTCC AGGTNACGGG CCGCNAANCC TGACCCNAGG TANCANAANG CAGNCNGCGG	60<br>
GAGCCCACCG TCACGNGGNG GNGTCTTTAT NGGAGGGGGC GGAGCCACAT CNCTGGACNT	120<br>
CNTGACCCCA ACTCCCCNCC NCNCANTGCA GTGATGAGTG CAGAACTGAA GGTNACGTGG	180<br>
CAGGAACCAA GANCAAANNC TGCTCCNNTC CAAGTCGGCN NAGGGGGCGG GGCTGGCCAC	240<br>
GCNCATCCNT CNAGTGCTGN AAAGCCCCNN CCTGTCTACT TGTTTGGAGA ACNGCNNNGA	300<br>
CATGCCCAGN GTTANATAAC NGGCNGAGAG TNANTTTGCC TCTCCCTTCC GGCTGCGCAN	360<br>
CGNGTNTGCT TAGNGGACAT AACCTGACTA CTTAACTGAA CCCNNGAATC TNCCNCCCCT	420<br>
CCACTAAGCT CAGAACAAAA AACTTCGACA CCACTCANTT GTCACCTGNC TGCTCAAGTA	480<br>
AAGTGTACCC CATNCCCAAT GTNTGCTNGA NGCTCTGNCC TGCNTTANGT TCGGTCCTGG	540<br>
GAAGACCTAT CAATTNAAGO TATGTTTCTG ACTGCCTCTT GCTCCCTGNA ACAANCNACC	600<br>
CNNCNNTCCA AGGGGGGGNC GGCCCCCAAT CCCCCCAACC NTNAATTNAN TTTANCCCCN	660<br>
CCCCCNGGCC CGGCCTTTTA CNANCNTCNN NNACNGGGNA AAACCNNNGC TTTNCCCAAC	720<br>
NNAATCCNCC T	731<br><br>
(2) INFORMATION FOR SEQ ID NO:20:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 754 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:<br>
TTTTTTTTTT TTTTTTTTTT TAAAAACCCC CTCCATTNAA TGNAAACTTC CGAAATTGTC	60<br>
CAACCCCCTC NTCCAAATNN CCNTTTCCGG GNGGGGGTTC CAAACCCAAN TTANNTTTGG	120<br>
ANNTTAAATT AAATNTTNHT TGGNGGNNNA ANCCNAATGT NANGAAAGTT NAACCCANTA	180<br>
TNANCTTNAA TNCCTGGAAA CC'NGTNGNTT CCAAAAATNT TTAACCCTTA ANTCCCTCCG	240<br>
AAATNGTTNA NGGAAAACCC AANTTCTCNT AAGGTTGTTT GAAGGNTNAA TNAAAANCCC	300<br>
NNCCAATTGT TTTTNGCCAC GCCTGAATTA ATTGGNTTCC GNTGTTTTCC NTTAAAANAA	360<br>
GGNNANCCCC GGTTANTNAA TCCCCCCNNC CCCAATTATA CCGANTTTTT TTNGAATTGG	420<br>
GANCCCNCGG GAATTAACGG GGNNNNTCCC TNTTGGGGGG CNGGNNCCCC CCCCNTCGGG	480<br>
GGTTNGGGNC AGGNCNNAAT TGTTTAAGGG TCCGAAAAAT CCCTCCNAGA AAAAAANCTC	540<br>
CCAGGNTGAG NNTNGGGTTT NCCCCCCCCC CANGGCCCCT CTCGNANAGT TGGGGTTTGG	600<br>
GGGGCCTGGG ATTTTNTTTC CCCTNTTNCC TCCCCCCCCC CCNGGGANAG AGGTTNGNGT	660<br>
TTTGNTCNNC GGCCCCNCCN AAGANCTTTN CCGANTTNAN TTAAATCCNT GCCTNGGCGA	720<br>
AGTCCNTTGN AGGGNTAAAN GGCCCCCTNN CGGG	754<br>
(2) INFORMATION FOR SEQ ID NO:21:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 755 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D! TOPOLOGY: linear<br>
iii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:<br>
ATCANCCCAT GACCCCNAAC	NMGGGACCNC TCANCCGGNC NNNCNACCNC CGGCCNATCA	60<br>
NNGTNAGNNC ACTNCNNTTN	NATCACNCCC CNCCNACTAC GCCCNCNANC CNACGCNCTA	120<br>
NNCANATNCC ACTGANNGCG	CGANGTNGAN NGAGAAANCT NATACCANAG NCACCANACN	180<br>
CCAGCTGTCC NANAANGCCT	NNNATACNGG NNNATCCAAT NTGNANCCTC CNAAGTATTN	240<br>
NNCNNCANAT GATTTTCCTN	ANCCGATTAC CCNTNCCCCC TANCCCCTCC CCCCCAACNA	300<br>
CGAAGGCNCT GGNCCNAAGG	NNGCGNCNCC CCGCTAGNTC CCCNNCAAGT CNCNCNCCTA	360<br>
AACTCANCCN NATTACNCGC	TTCNTGAGTA TCACTCCCCG AATCTCACCC TACTCAACTC	420<br>
AAAAANATCN GATACAAAAT	AATNCAAGCC TGNTTATNAC ACTNTGACTG GGTCTCTATT	480<br>
TTAGNGGTCC NTNAANCNTC	CTAATACTTC CAGTCTNCCT TCNCCAATTT CCNAANGGCT	540<br>
CTTTCNGACA GCATNTTTTG	GTTCCCNNTT GGGTTCTTAN NGAATTGCCC TTCNTNGAAC	600<br>
GGGCTCNTCT TTTCCTTCGG	TTANCCTGGN TTCNNCCGGC CAGTTATTAT TTCCCNTTTT	660<br>
AAATTCNTNC CNTTTANTTT	TGGCNTTCNA AACCCCCGGC CTTGAAAACG GCCCCCTGGT	720<br>
AAAAGGTTGT TTTGANAAAA	TTTTTGTTTT GTTCC	755<br>
(2) INFORMATION FOR SEQ ID NO:22:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 849 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
ill) MOLECULE TYPE: cDNA<br><br>
ixi) SEQUENCE DESCRIPTION: SEQ ID NO:22:<br>
TTTTTTTTTT TTTTTANGTG TNGTCGTGCA GGTAGAGGCT TACTACAANT GTGAANACGT	60<br>
ACGCTNGGAN TAANGCGACC CGANTTCTAG GANNCNCCCT AAAATCANAC TGTGAAGATN	120<br>
ATCCTGNNNA CGGAANGGTC ACCGGNNGAT NNTGCTAGGG TGNCCNCTCC CANNNCNTTN	180<br>
CATAACTCNG NGGCCCTGCC CACCACCTTC GGCGGCCCNG NGNCCGGGCC CGGGTCATTN	240<br>
GNNTTAACCN CACTNNGCNA NCGGTTTCCN NCCCCNNCNG ACCCNGGCGA TCCGGGGTNC	300<br>
TCTGTCTTCC CCTGNAGNCN ANAAANTGGG CCNCGGNCCC CTTTACCCCT NNACAAGCCA	360<br>
CNGCCNTCTA NCCNCNGCCC CCCCTCCANT NNGGGGGACT GCCNANNGCT CCGTTNCTNG	420<br>
NNACCCCNNN GGGTNCCTCG GTTGTCGANT CNACCGNANG CCANGGATTC CNAAGGAAGG	480<br>
TGCGTTNTTG GCCCCTACCC TTCGCTNCGG NNCACCCTTC CCGACNANGA NCCGCTCCCG	540<br>
CNCNNCGNNG CCTCNCCTCG CAACACCCGC NCTCNTCNGT NCGGNNNCCC CCCCACCCGC	600<br>
NCCCTCNCNC NGNCGNANCN CTCCNCCNCC GTCTCANNCA CCACCCCGCC CCGCCAGGCC	660<br>
NTCANCCACN GGNNGACNNG NAGCNCNNTC GCNCCGCGCN GCGNCNCCCT CGCCNCNGAA	720<br>
CTNCNTCNGG CCANTNNCGC TCAANCCNNA CNAAACGCCG CTGCGCGGCC CGNAGCGNCC	780<br>
NCCTCCNCGA GTCCTCCCGN CTTCCNACCC ANGNNTTCCN CGAGGACACN NNACCCCGCC	840<br>
NNCANGCGG	849<br>
(2) INFORMATION FOR SEQ ID NO:23:<br>
fi) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 872 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID K0:23:<br>
GCGCAAACTA TACTTCGCTC	GNACTCGTGC GCCTCGCTNC TCTTTTCCTC CGCAACCATG	60<br>
TCTGACNANC CCGATTNGGC	NGATATCNAN AAGNTCGANC AGTCCAAACT GANTAACACA	120<br>
CACACNCNAN AGANAAATCC	NCTGCCTTCC ANAGTANACN ATTGAACNNG AGAACCANGC	180<br>
NGGCGAATCG TAATNAGGCG	TGCGCCGCCA ATNTGTCNCC GTTTATTNTN CCAGCNTCNC	240<br>
CTNCCNACCC TACNTCTTCN	NAGCTGTCNN ACCCCTNGTN CGNACCCCCC NAGGTCGGGA	300<br>
TCGGGTTTNN NNTGACCGNG	CNNCCCCTCC CCCCNTCCAT NACGANCCNC CCGCACCACC	360<br>
NANNGCNCGC NCCCCGNNCT	CTTCGCCNCC CTGTCCTNTN CCCCTGTNGC CTGGCNCNGN	420<br>
ACCGCATTGA CCCTCGCCNN	CTNCNNGAAA NCGNANACGT CCGGGTTGNN ANNANCGCTG	480<br>
TGGGNNNGCG TCTGCNCCGC	GTTCCTTCCN NCNNCTTCCA CCATCTTCNT TACNGGGTCT	540<br>
CCNCGCCNTC TCNNNCACNC	CCTGGGACGC TNTCCTNTGC CCCCCTTNAC TCCCCCCCTT	600<br>
CGNCGTGNCC CGNCCCCACC	NTCATTTNCA NACGNTCTTC ACAANNNCCT GGNTNNCTCC	660<br>
CNANCNGNCN GTCANCCNAG	GGAAGGGNGG GGNNCCNNTG NTTGACGTTG NGGNGANGTC	720<br>
CGAANANTCC TCNCCNTCAN	CNCTACCCCT CGGGCGNNCT CTCNGTTNCC AACTTANCAA	780<br>
NTCTCCCCCG NGNGCNCNTC TCAGCCTCNC CCNCCCCNCT CTCTGCANTG TNCTCTGCTC	840<br>
TNACCNNTAC GANTNTTCGN	CNCCCTCTTT CC	872<br>
(2) INFORMATION FOR SEQ ID NO:24:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 815 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:<br>
GCATGCAAGC TTGAGTATTC TATAGNGTCA CCTAAATANC TTGGCNTAAT CATGGTCNTA      60 NCTGNCTTCC TGTGTCAAAT GTATACNAAN TANATATGAA TCTNATNTGA CAAGANNGTA     120<br><br>
TCNTNCATTA GTAACAANTG TNNTGTCCAT CCTGTCNGAN CANATTCCCA TNNATTNCGN	180<br>
CGCATTCNCN GCNCANTATN TAATNGGGAA NTCNNNTNNN NCACCNNCAT CTATCNTNCC	240<br>
GCNCCCTGAC TGGNAGAGAT GGATNANTTC TNNTNTGACC NACATGTTCA TCTTGGATTN	300<br>
AANANCCCCC CGCNGNCCAC CGGTTNGNNG CNAGCCNNTC CCAAGACCTC CTGTGGAGGT	360<br>
AACCTGCGTC AGANNCATCA AACNTGGGAA ACCCGCNNCC ANGTNNAAGT NGNNNCANAN	420<br>
GATCCCGTCC AGGNTTNACC ATCCCTTCNC AGCGCCCCCT TTNGTGCCTT ANAGNGNAGC	480<br>
GTGTCCNANC CNCTCAACAT GANACGCGCC AGNCCANCCG CAATTNGGCA CAATGTCGNC	540<br>
GAACCCCCTA GGGGGANTNA TNCAAANCCC CAGGATTGTC CNCNCANGAA ATCCCNCANC	600<br>
CCCNCCCTAC CCNNCTTTGG GACNGTGACC AANTCCCGGA GTNCCAGTCC GGCCNGNCTC	660<br>
CCCCACCGGT NNCCNTGGGG GGGTGAANCT CNGNNTCANC CNGNCGAGGN NTCGNAAGGA	720<br>
ACCGGNCCTN GGNCGAANNG ANCNNTCNGA AGNGCCNCNT CGTATAACCC CCCCTCNCCA	780<br>
NCCNACNGNT AGNTCCCCCC CNGGGTNCGG AANGG	815<br>
(2) INFORMATION FOR SEQ ID NO:25:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
LENGTH: 775 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: 1Lnear<br>
(ii) MOLECULE TYPK: CDNA<br>
Sxi) SEQUENCE DESCRIPTION: SEQ ID MO:25:<br>
CCGAGATGTC TCGCTCCGTG GCCTTAGCTG TGCTCGCGCT ACTCTCTCTT TCTGGCCTGG	60<br>
AGGCTATCCA GCGTACTCCA AAGATTCAGG TTTACTCACG TCATCCAGCA GAGAATGGAA	120<br>
AGTCAAATTT CCTGAATTGC TATGTGTCTG GGTTTCATCC ATCCGACATT GAANTTGACT	180<br>
TACTGAAGAA TGGANAGAGA ATTGAAAAAG TGGAGCATTC AGACTTGTCT TTCAGCAAGG	240<br>
ACTGGTCTTT CTATCTCNTG TACTACACTG AATTCACCCC CACTGAAAAA GATGAGTATG	300<br>
CCTGCCGTGT GAACCATGTG ACTTTGTCAC AGCCCAAGAT AGTTAAGTGG GATCGAGACA	360<br>
TGTAAGCAGN CNNCATGGAA GTTTGAAGAT GCCGCATTTG GATTGGATGA ATTCCAAATT	420<br>
CTGC'TTGCTT GCNTTTTAAT ANTGATATGC NTATACACCC TACCCTTTAT GNCCCCAAAT	480<br>
TGTAGGGGTT ACATNANTGT TCNCNTNGGA CATGATCTTC CTTTATAANT CCNCCNTTCG	540<br>
AATTGCCCGT CNCCCNGTTN NGAATGTTTC CNNAACCACG GTTGGCTCCC CCAGGTCNCC	600<br>
TCTTACGGAA GGGCCTGGGC CNCTTTNCAA GGTTGGGGGA ACCNAAAATT TCNCTTNTGC	660<br>
CCNCCCNCCA CNNTCTTGNG NNCNCANTTT GGAACCCTTC CNATTCCCCT TGGCCTCNNA	720<br>
NCCTTNNCTA ANAAAACTTN AAANCGTNGC NAAANNTTTN ACTTCCCCCC TTACC	775<br>
(2) INFORMATION FOR SEQ ID NO:26:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 820 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
ii i J MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:<br>
ANATTANTAC AGTGTAATCT TTTCCCAGAG GTGTGTANAG GGAACGGGGC CTAGAGGCAT	60<br>
CCCANAGATA NCTTATANCA ACAGTGCTTT GACCAAGAGC TGCTGGGCAC ATTTCCTGCA	120<br>
GAAAAGGTGG CGGTCCCCAT CACTCCTCCT CTCCCATAGC CATCCCAGAG GGGTGAGTAG	180<br>
CCATCANGCC TTCGGTGGGA GGGAGTCANG GAAACAACAN ACCACAGAGC ANACAGACCA	240<br>
NTGATGAC'CA TGGGCGGGAG CGAGCCTCTT CCCTGNACCG GGGTGGCANA NGANAGCCTA	300<br>
NCTGAGGGGT CACACTATAA ACGTTAACGA CCNAGATNAN CACCTGCTTC AAGTGCACCC	360<br>
TTCCTACCTG ACNACCAGNG ACCNNNAACT GCNGCCTGGG GACAGCNCTG GGANCAGCTA	420<br>
ACNNAGCACT CACCTGCCCC CCCATGGCCG TNCGCNTCCC TGGTCCTGNC AAGGGAAGCT	480<br>
CCCTGTTGGA ATTNCGGGGA NACCAAGGGA NCCCCCTCCT CCANCTGTGA AGGAAAAANN	540<br>
GATGGAATTT TNCCCTTCCG GCCNNTCCCC TCTTCCTTTA CACGCCCCCT NNTACTCNTC	600<br><br>
TCCCTCTNTT NTCCTGNCNC ACTTTTNACC CCNNNATTTC CCTTNATTGA TCGGANNCTN	660<br>
GANATTCCAC TNNCGCCTNC CNTCNATCNG NAANACNAAA NACTNTCTNA CCCNGGGGAT	720<br>
GGGNNCCTCG NTCATCCTCT CTTTTTCNCT ACCNCCNNTT CTTTGCCTCT CCTTNGATCA	780<br>
TCCAACCNTC GNTGGCCNTN CCCCCCCNNN TCCTTTNCCC	820<br>
(2) INFORMATION FOR SEQ ID N0:27:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 818 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY; linear<br>
(i i} MOLECULE; TYPE : CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:<br>
TCTGGGTGAT GGCCTCTTCC TCCTCAGGGA CCTCTGACTG CTCTGGGCCA AAGAATCTCT	60<br>
TGTTTCTTCT CCGAGCCCCA GGCAGCGGTG ATTCAGCCCT GCCCAACCTG ATTCTGATGA	120<br>
CTGCGGATGC TGTGACGGAC CCAAGGGGCA AATAGGGTCC CAGGGTCCAG GGAGGGGCGC	180<br>
CTGCTGAGCA CTTCCGCCCC TCACCCTGCC CAGCCCCTGC CATGAGCTCT GGGCTGGGTC	240<br>
TCCGCCTCCA GGGTTCTGCT CTTCCANGCA NGCCANCAAG TGGCGCTGGG CCACACTGGC	300<br>
TTCTTCCTGC CCCNTCCCTG GCTCTGANTC TCTGTCTTCC TGTCCTGTGC ANGCNCCTTG	360<br>
GATCTCAGTT TCCCTCNCTC ANNGAACTCT GTTTCTGANN TCTTCANTTA ACTNTGANTT	420<br>
TATNACCNAN TGGNCTGTNC TGTCNNACTT TAATGGGCCN GACCGGCTAA TCCCTCCCTC	480<br>
NCTCCCTTCC ANTTCNNNNA ACCNGCTTNC CNTCNTCTCC CCNTANCCCG CCNGGGAANC	540<br>
CTCCTTTGCC CTNACCANGG GCCNNNACCG CCCNTNNCTN GGGGGGCNNG GTNNCTNCNC	600<br>
CTGNTNNCCC CNCTCNCNNT TNCCTCGTCC CNNCNNCGCN NNGCANNTTC NCNGTCCCNN	660<br>
TNNCTCTTCN NGTNTCGNAA NGNTCNCNTN TNNNNNGNCN NGNTNNTNCN TCCCTCTCNC	720<br>
CNNNTGNANG TNNTTNNNNC NCNGNNCCCC NNNNCNNNNN NGGNNNTNNN TCTNCNCNGC	780<br>
CCCNNCCCCC NGNATTAAGG CCTCCNNTCT CCGGCCNC	818<br>
(2) INFORMATION B'OR SEQ ID N0:28:<br>
d) SEQUENCE: CHARACTERISTICS:<br>
(A)	LENGTH: 731 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY  linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:<br>
AGGAAGGGCG GAGGGATATT GTANGGGATT GAGGGATAGG AGNATAANGG GGGAGGTGTG	60<br>
TCCCAACATG ANGGTGNNGT TCTCTTTTGA ANGAGGGTTG NGTTTTTANN CCNGGTGGGT	120<br>
GATTNAACCC CATTGTATGG AGNNAAAGGN TTTNAGGGAT TTTTCGGCTC TTATCAGTAT	180<br>
NTANATTCCT GTNAATCGGA AAATNATNTT TCNNCNGGAA AATNTTGCTC CCATCCGNAA	240<br>
ATTNCTCCCG GGTAGTGCAT NTTNGGGGGN CNGCCAMGTT TCCCAGGCTG CTANAATCGT	300<br>
ACTAAAGNTT NAAGTGGGAN TNCAAATGAA AACCTNNCAC AGAGNATCCN TACCCGACTG	360<br>
TNNNTTNC'CT TCGCCCTNTG ACTCTGCNNG AGCCCAATAC CCNNGNGNAT GTCNCCCNGN	420<br>
NNNGCGNCNC TGAAANNNNC TCGNGGCTNN GANCATCANG GGGTTTCGCA TCAAAAGCNN	480<br>
CGTTTCNCAT NAAGGCACTT TNGCCTCATC CAACCNCTNG CCCTCNNCCA TTTNGCCGTC	540<br>
NGGTTCNCCT ACGCTNNTNG CNCCTNNNTN GANATTTTNC CCGCCTNGGG NAANCCTCCT	600<br>
GNAATGGGTA GGGNCTTNTC TTTTNACCNN GNGGTNTACT AATCNNCTNC ACGCNTNCTT	660<br>
TCTCNACCCC CCCCCTTTTT CAATCCCANC GGCNAATGGG GTCTCCCCNN CGANGGGGGG	720<br>
NNNCCCANNC C	'31<br>
(2) INFORMATION FOR SEQ ID NO:29: (l) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 822 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:<br>
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGNCNC TTCTATGANT ANTNTTAGAT	60<br>
CGCTCANACC TCACANCCTC CCNACNANGC CTATAANGAA NANNAATAGA NCTGTNCNNT	120<br>
ATNTNTACNC TCATANNCCT CNNNACCCAC TCCCTCTTAA CCCNTACTGT GCCTATNGCN	180<br>
TNNCTANTCT NTGCCGCCTN CNANCCACCN GTGGGCCNAC CNCNNGNATT CTCNATCTCC	240<br>
TCNCCATNTN GCCTANANTA NGTNCATACC CTATACCTAC NCCAATGCTA NNNCTAANCN	300<br>
TCCATNANTT ANNNTAACTA CCACTGACNT NGACTTTCNC ATNANCTCCT AATTTGAATC	360<br>
TACTCTGACT CCCACNGCCT ANNNATTAGC ANCNTCCCCC NACNATNTCT CAACCAAATC	420<br>
NTCAACAACC TATCTANCTG TTCNCCAACC NTTNCCTCCG ATCCCCNNAC AACCCCCCTC	480<br>
CCAAATACCC NCCACCTGAC NCCTAACCCN CACCATCCCG GCAAGCCNAN GGNCATTTAN	540<br>
CCACTGGAAT CACNATNGGA NAAAAAAAAC CCNAACTCTC TANCNCNNAT CTCCCTAANA	600<br>
AATNCTCCTN NAATTTACTN NCANTNCCAT CAANCCCACN TGAAACNNAA CCCCTGTTTT	660<br>
TANATCCCTT CTTTCGAAAA CCNACCCTTT ANNNCCCAAC CTTTNGGGCC CCCCCNCTNC	720<br>
CCNAATGAAG GNCNCCCAAT CNANGAAACG NCCNTGAAAA ANCNAGGCNA ANANNNTCCG	780<br>
CANATCCTAT CCCTTANTTN GGGGNCCCTT NCCCNGGGCC CC	822<br>
(2) INFORMATION FOR SEQ ID NO:30:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 787 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
{xi) SEQUENCE DESCRIPTION: SEQ ID MO:30:<br>
CGGCCGCCTG	CTCTGGCACA	TGCCTCCTGA ATGGCATCAA AAGTGATGGA CTGCCCATTG	60<br>
CTAGAGAAGA	CCTTCTCTCC	TACTGTCATT ATGGAGCCCT GCAGACTGAG GGCTCCCCTT	120<br>
GTCTGCAGGA	TTTGATGTCT	GAAGTCGTGG AGTGTGGCTT GGAGCTCCTC ATCTACATNA	180<br>
GCTGGAAGCC	CTGGAGGGCC	TCTCTCGCCA GCCTCCCCCT TCTCTCCACG CTCTCCANGG	240<br>
ACACCAGGGG	CTCCAGGCAG	CCCATTATTC CCAGNANGAC ATGGTGTTTC TCCACGCGGA	300<br>
CCCATGGGGC	CTGNAAGGCC	AGGGTCTCCT TTGACACCAT CTCTCCCGTC CTGCCTGGCA	360<br>
GGCCGTGGGA	TCCACTANTT	CTANAACGGN CGCCACCNCG GTGGGAGCTC CAGCTTTTGT	420<br>
TCCCNTTAAT	GAAGGTTAAT	TGCNCGCTTG GCGTAATCAT NGGTCANAAC TNTTTCCTGT	480<br>
GTGAAATTGT	TTNTCCCCTC	NCNATTCCNC NCNACATACN AACCCGGAAN CATAAAGTGT	540<br>
TAAAGCCTGG	GGGTNGCCTN	NNGAATNAAC TNAACTCAAT TAATTGCGTT GGCTCATGGC	600<br>
CCGCTTTC'CN	TTCNGGAAAA CTGTCNTCCC CTGCNTTNNT GAATCGGCCA CCCCCCNGGG	660<br>
AAAAGCGGTT	TGCNTTTTNG	GGGGNTCCTT CCNCTTCCCC CCTCNCTAAN CCCTNCGCCT	720<br>
CGGTCGTTNC NGGTNGCGGG GAANGGGNAT NNNCTCCCNC NAAGGGGGNG AGNNNGNTAT	780<br>
CCCCAAA	"787<br>
(2) INFORMATION FOR SEQ ID NO:31:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
LENGTH- 799 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br><br>
txi) SEQUENCE DESCRIPTION: SEQ ID NO:31:<br>
TTTTTTTTTT TTTTTTTGGC GATGCTACTG TTTAATTGCA GGAGGTGGGG GTGTGTGTAC	60<br>
CATGTACCAG GGCTATTAGA AGCAAGAAGG AAGGAGGGAG GGCAGAGCGC CCTGCTGAGC	120<br>
AACAAAGGAC TCCTGCAGCC TTCTCTGTCT GTCTCTTGGC GCAGGCACAT GGGGAGGCCT	180<br>
CCCGCAGGGT GGGGGCCACC AGTCCAGGGG TGGGAGCACT ACANGGGGTG GGAGTGGGTG	240<br>
GTGGCTGGTN CNAATGGCCT GNCACANATC CCTACGATTC TTGACACCTG GATTTCACCA	300<br>
GGGGACCTTC TGTTCTCCCA NGGNAACTTC NTNNATCTCN AAAGAACACA ACTGTTTCTT	360<br>
CNGCANTTCT GGCTGTTCAT GGAAAGCACA GGTGTCCNAT TTNGGCTGGG ACTTGGTACA	420<br>
TATGGTTCCG GCCCACCTCT CCCNTCNAAN AAGTAATTCA CCCCCCCCCN CCNTCTNTTG	480<br>
CCTGGGCCCT TAANTACCCA CACCGGAACT CANTTANTTA TTCATCTTNG GNTGGGCTTG	540<br>
NTNATCNCCN CCTGAANGCG CCAAGTTGAA AGGCCACGCC GTNCCCNCTC CCCATAGNAN	600<br>
NTTTTNNCNT CANCTAATGC CC'CCCCNGGC AACNATCCAA TCCCCCCCCN TGGGGGCCCC	660<br>
AGCCCANGGC CCCCGNCTCG GGNNNCCNGN CNCGNANTCC CCAGGNTCTC CCANTCNGNC	720<br>
CCNNNGCNCC CCCGCACGCA GAACANAAGG NTNGAGCCNC CGCANNNNNN NGGTNNCNAC	780<br>
CTCGCCCCCC CCNNCGNNG	799<br>
(2) INFORMATION FOR SEQ ID NO:32:<br>
(il SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 789 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(Di TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:32:<br>
TTTTNCCNAG GGCAGGTTTA TTGACAACCT CNCGGGACAC AANCAGGCTG GGGACAGGAC	120<br>
GGCAACAGGC TCCGGCGGCG GCGGCGGCGG CCCTACCTGC GGTACCAAAT NTGCAGCCTC	180<br>
CGCTCCCGCT TGATNTTCCT CTGCAGCTGC AGGATGCCNT AAAACAGGGC CTCGGCCNTN	240<br>
GGTGGGCACC CTGGGATTTN AATTTCCACG GGCACAATGC GGTCGCANCC CCTCACCACC	300<br>
NATTAGGAAT AGTGGTNTTA CCCNCCNCCG TTGGCNCACT CCCCNTGGAA ACCACTTNTC	360<br>
GCGGCTCCGG CATCTGGTCT TAAACCTTGC AAACNCTGGG GCCCTCTTTT TGGTTANTNT	420<br>
NCCNGCCACA ATCATNACTC AGACTGGCNC GGGCTGGCCC CAAAAAANCN CCCCAAAACC	480<br>
GGNCCATGTC TTNNCGGGGT TGCTGCNATN TNCATCACCT CCCGGGCNCA NCAGGNCAAC	540<br>
CCAAAAGTTC TTGNGGCCCN CAAAAAANCT CCGGGGGGNC CCAGTTTCAA CAAAGTCATC	600<br>
CCCCTTGGCC CCCAAATCCT CCCCCCGNTT NCTGGGTTTG GGAACCCACG CCTCTNNCTT	660<br>
TGGNNGGCAA GNTGGNTCCC CCTTCGGGCC CCCGGTGGGC CCNNCTCTAA NGAAAACNCC	720<br>
NTCCTNNNCA CCATCCCCCC NNGNNACGNC TANCAANGNA TCCCTTTTTT TANAAACGGG	780<br>
CCCCCCNCG	789<br>
(2) INFORMATION FOR SEQ ID N0:33:<br>
(i; SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 793 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
. (D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi; SEQUENCE DESCRIPTION: SEQ ID NO:33:<br>
GACAGAACAT GTTGGATGGT GGAGCACCTT TCTATACGAC TTACAGGACA GCAGATGGGG	60<br>
AATTCATGGC TGTTGGAGCA ATANAACCCC AGTTCTACGA GCTGCTGATC AAAGGACTTG	120<br>
GACTAAAGTC TGATGAACTT CCCAATCAGA TGAGCATGGA TGATTGGCCA GAAATGAANA	180<br>
AGAAGTTTGC AGATGTATTT GCAAAGAAGA CGAAGGCAGA GTGGTGTCAA ATCTTTGACG	240<br>
GCACAGATGC CTGTGTGACT CCGGTTCTGA CTTTTGAGGA GGTTGTTCAT CATGATCACA	300<br><br>
ACAANGAACG GGGCTCGTTT ATCACCANTG AGGAGCAGGA CGTGAGCCCC CGCCCTGCAC	360<br>
CTCTGCTGTT AAACACCCCA GCCATCCCTT CTTTCAAAAG GGATCCACTA CTTCTAGAGC	420<br>
GGNCGCCACC GCGGTGGAGC TCCAGCTTTT GTTCCCTTTA GTGAGGGTTA ATTGCGCGCT	480<br>
TGGCGTAATC ATGGTCATAN CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC	540<br>
ACAACATACG ANCCGGAAGC ATNAAATTTT AAAGCCTGGN GGTNGCCTAA TGANTGAACT	600<br>
NACTCACATT AATTGGCTTT GCGCTCACTG CCCGCTTTCC AGTCCGGAAA ACCTGTCCTT	660<br>
GCCAGCTGCC NTTAATGAAT CNGGCCACCC CCCGGGGAAA AGGCNGTTTG CTTNTTGGGG	720<br>
CGCNCTTCCC GCTTTCTCGC TTCCTGAANT CCTTCCCCCC GGTCTTTCGG CTTGCGGCNA	780<br>
ACGGTATCNA CCT	793<br>
(2) INFORMATION FOR SEQ ID NO:34:<br>
(i; SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 756 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:<br>
GCCGCGACCG GCATGTACGA 3CAACTCAAG GGCGAGTGGA ACCGTAAAAG CCCCAATCTT	60<br>
ANCAAGTGCG GGGAANAGCT 3GGTCGACTC AAGCTAGTTC TTCTGGAGCT CAACTTCTTG	120<br>
CCAACCACAG GGACCAAGCT GACCAAACAG CAGCTAATTC TGGCCCGTGA CATACTGGAG	180<br>
ATCGGGGCCC AATGGAGCAT CCTACGCAAN GACATCCCCT CCTTCGAGCG CTACATGGCC	240<br>
CAGCTCAAAT GCTACTACTT TGATTACAAN GAGCAGCTCC CCGAGTCAGC CTATATGCAC	300<br>
CAGCTCTTGG GCCTCAACCT CCTCTTCCTG CTGTCCCAGA ACCGGGTGGC TGANTNCCAC	360<br>
ACGGANTTGG ANCGGCTGCC TGCCCAANGA CATACANACC AATGTCTACA TCNACCACCA	420<br>
GTGTCCTGGA GCAATACTGA TGGANGGCAG CTACCNCAAA GTNTTCCTGG CCNAGGGTAA	480<br>
CATCCCCCGC CGAGAGCTAC ACCTTCTTCA TTGACATCCT GCTCGACACT ATCAGGGATG	540<br>
AAAATCGCNG GGTTGCTCCA GAAAGGCTNC AANAANATCC TTTTCNCTGA AGGCCCCCGG	600<br>
ATNCNCTAGT NCTAGAATCG GCCCGCCATC GCGGTGGANC CTCCAACCTT TCGTTNCCCT	660<br>
TTACTGAGGG TTNATTGCCG CCCTTGGCGT TATCATGGTC ACNCCNGTTM CCTGTGTTGA	720<br>
AATTNTTAAC CCCCCACAAT TCCACGCCNA CATTNG	756<br>
(2) INFORMATION FOR SEQ ID NO:35:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 834 base pairs (Bj TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
!ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:<br>
GGGGATCTCT ANATCNACCT GNATGCATGG TTGTCGGTGT GGTCGCTGTC GATGAANATG	60<br>
AACAGGATCT TGCCCTTGAA GCTCTCGGCT GCTGTNTTTA AGTTGCTCAG TCTGCCGTCA	120<br>
TAGTCAGACA CNCTCTTGGG CAAAAAACAN CAGGATNTGA GTCTTGATTT CACCTCCAAT	180<br>
AATCTTCNGG GCTGTCTGCT CGGTGAACTC GATGACNANG GGCAGCTGGT TGTGTNTGAT	240<br>
AAANTCCANC ANGTTCTCCT TGGTGACCTC CCCTTCAAAG TTGTTCCGGC CTTCATCAAA	300<br>
CTTCTNNAAN ANGANNANCC CANCTTTGTC GAGCTGGNAT TTGGANAACA CGTCACTGTT	360<br>
GGAAACTGAT CCCAAATGGT ATGTCATCCA TCGCCTCTGC TGCCTGCAAA AAACTTGCTT	420<br>
GGCNCAAATC CGACTCCCCN TCCTTGAAAG AAGCCNATCA CACCCCCCTC CCTGGACTCC	480<br>
NNCAANGACT CTNCCGCTNC CCCNTCCNNG CAGGGTTGGT GGCANNCCGG GCCCNTGCGC	540<br>
TTCTTCAGCC AGTTCACNAT NTTCATCAGC CCCTCTGCCA GCTGTTNTAT TCCTTGGGGG	600<br>
GGAANCCGTC TCTCCCTTCC TGAANNAACT TTGACCGTNG GAATAGCCGC GCNTCNCCNT	660<br>
ACNTNCTGGG CCGGGTTCAA ANTCCCTCCN TTGNCNNTCN CCTCGGGCCA TTCTGGATTT	720<br>
NCCNAACTTT TTCCTTCCCC CNCCCCNCGG NGTTTGGNTT TTTCATNGGG CCCCAACTCT	780<br><br>
GCTNTTGGCC ANTCC'CCTGG GGGCNTNTAN CNCCCCCTNT GGTCCCNTNG GGCC	834<br>
(2) INFORMATION FOR SEQ ID NO:36:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 814 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:36:<br>
CGGNCGCTTT CCNGCCGCGC CCCGTTTCCA TGACNAAGGC TCCCTTCANG TTAAATACNN	60<br>
CCTAGNAAAC ATTAATGGGT TGCTCTACTA ATACATCATA CNAACCAGTA AGCCTGCCCA	120<br>
NAACGCCAAC TCAGGCCATT CCTACCAAAG GAAGAAAGGC TGGTCTCTCC ACCCCCTGTA	180<br>
GGAAAGGCCT GCCTTGTAAG ACACCACAAT NCGGCTGAAT CTNAAGTCTT GTGTTTTACT	240<br>
AATGGAAAAA AAAAATAAAC AANAGGTTTT GTTCTCATGG CTGCCCACCG CAGCCTGGCA	300<br>
CTAAAACANC CCAGCGCTCA CTTCTGCTTG GANAAATATT CTTTGCTCTT TTGGACATCA	360<br>
GGCTTGATGG TATCACTGCC ACNTTTCCAC CCAGCTGGGC NCCCTTCCCC CATNTTTGTC	420<br>
ANTGANCTGG AAGGCCTGAA NCTTAGTCTC CAAAAGTCTC NGCCCACAAG ACCGGCCACC	480<br>
AGGGGANGTC NTTTNCAGTG GATCTGCCAA ANANTACCCN TATCATCNNT GAATAAAAAG	540<br>
GCCCCTGAAC GANATGCTTC CANCANCCTT TAAGACCCAT AATCCTNGAA CCATGGTGCC	600<br>
CTTCCGGTCT GATCCNAAAG GAATGTTCCT GGGTCCCANT CCCTCCTTTG TTNCTTACGT	660<br>
TGTNTTGGAC CCNTGCTNGN ATNACCCAAN TGANATCCCC NGAAGCACCC TNCCCCTGGC	720<br>
ATTTGANTTT CNTAAATTCT CTGCCCTACN NCTGAAAGCA CNATTCCCTN GGCNCCNAAN	780<br>
GGNGAACTCA AGAAGGTCTN NGAAAAACCA CMCN	814<br>
(2) INFORMATION FOR SEQ ID NO:37:<br>
(ii SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH; 760 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii; MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:<br>
GCATGCTGCT CTTCCTCAAA GTTGTTCTTG TTGCCATAAC AACCACCATA GGTAAAGCGG	60<br>
GCGCAGTGTT CGCTGAAGGG GTTGTAGTAC CAGCGCGGGA TGCTCTCCTT GCAGAGTCCT	120<br>
GTGTCTGGCA GGTCCACGCA ATGCCCTTTG TCACTGGGGA AATGGATGCG CTGGAGCTCG	180<br>
TCNAANCCAC TCGTGTATTT TTCACANGCA GCCTCCTCCG AAGCNTCCGG GCAGTTGGGG	240<br>
GTGTCGTCAC ACTCCACTAA ACTGTCGATN CANCAGCCCA TTGCTGCAGC GGAACTGGGT	300<br>
GGGCTGACAG GTGCCAGAAC ACACTGGATN GGCCTTTCCA TGGAAGGGCC TGGGGGAAAT	360<br>
CNCCTNANCC CAAACTGCCT CTCAAAGGCC ACCTTGCACA CCCCGACAGG CTAGAAATGC	420<br>
ACTCTTCTTC CCAAAGGTAG TTGTTCTTGT TGCCCAAGCA NCCTCCANCA AACCAAAANC	480<br>
TTGCAAAATC TGCTCCGTGG GGGTCATNNN TACCANGGTT GGGGAAANAA ACCCGGCNGN	540<br>
GANCCNCCTT GTTTGAATGC NAAGGNAATA ATCCTCCTGT CTTGCTTGGG TGGAANAGCA	600<br>
CAATTGAACT GTTAACNTTG GGCCGNGTTC CNCTNGGGTG GTCTGAAACT AATCACCGTC	660<br>
ACTGGAAAAA GGTANGTGCC TTCCTTGAAT TCCCAAANTT CCCCTNGNTT TGGGTNNTTT	720<br>
CTCCTCTNCC CTAAAAATCG TNTTCCCCCC CCNTANGGCG	760<br>
(2) INFORMATION FOR SEQ ID NO:38:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 724 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
(D) TOPOLOGY: linear (li) MOLECULE TYPE: cDNA (xi.) SEQUENCE DESCRIPTION: SEQ ID NO:38:<br>
TTTTTTTTTT TTTTTTTTT'J' TTTTTTTTTT TTTTTAAAAA CCCCCTCCAT TGAATGAAAA	60<br>
CTTCCNAAAT TGTCCAACCO CCTCNNCCAA ATNNCCATTT CCGGGGGGGG GTTCCAAACC	120<br>
CAAATTAATT TTGGANTTTA AATTAAATNT TNATTNGGGG AANAANCCAA ATGTNAAGAA	180<br>
AATTTAACCC ATTATNAACT TAAATNCCTN GAAACCCNTG GNTTCCAAAA ATTTTTAACC	240<br>
CTTAAATCCC TCCGAAATTG NTAANGGAAA ACCAAATTCN CCTAAGGCTN TTTGAAGGTT	300<br>
NGATTTAAAC CCCCTTNANT TNTTTTNACC CNNGNCTNAA NTATTTNGNT TCCGGTGTTT	360<br>
TCCTNTTAAN CNTNGGTAAC TCCCGNTAAT GAANNNCCCT AANCCAATTA AACCGAATTT	420<br>
TTTTTGAATT GGAAATTCC'N NGGGAATTNA CCGGGGTTTT TCCCNTTTGG GGGCCATNCC	480<br>
CCCNCTTTCG GGGTTTGGGN NTAGGTTGAA TTTTTNTCANG NCCCAAAAAA NCCCCCAANA	540<br>
AAAAAACTCC CAAGNNTTAA TTNGAATNTC CCCCTTCCCA GGCCTTTTGG GAAAGGNGGG	600<br>
TTTNTGGGGG CCNGGGANTT CNTTCCCCCN TTNCCNCCCC CCCCCCNGGT AAANGGTTAT	660<br>
NGNNTTTGGT TTTTGGGCCC CTTNANGGAC CTTCCGGATN GAAATTAAAT CCCCGGGNCG	720<br>
GCCG	724<br>
(2) .INFORMATION FOR SEQ ID NO: 39:<br>
Si) SEQUENCE CHARACTERISTICS:<br>
LENGTH: 751 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear<br>
ili! MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:<br>
TTTTTTTTTT TTTTTOTTTG	CTCACATTTA ATTTTTATTT TGATTTTTTT TAATGCTGCA	60<br>
CAACACAATA TTTATTTCAT	TTGTTTCTTT TATTTCATTT TATTTGTTTG CTGCTGCTGT	120<br>
TTTATTTATT TTTACTGAAA	GTGAGAGGGA ACTTTTGTGG CCTTTTTTCC TTTTTCTGTA	180<br>
GGCCGCCTTA AGCTTTCTAA	ATTTGGAACA TCTAAGCAAG CTGAANGGAA AAGGGGGTTT	240<br>
CGCAAAATCA CTCGGGGGAA	NGGAAAGGTT GCTTTGTTAA TCATGCCCTA TGGTGGGTGA	300<br>
TTAACTGCTT GTACAATTAC	NTTTCACTTT TAATTAATTG TGCTNAANGC TTTAATTANA	360<br>
CTTGGGGGTT CCCTCCCCAN	ACCAACCCCN CTGACAAAAA GTGCCNGCCC TCAAATNATG	420<br>
TCCCGGCNNT CNTTGAAACA	CACNGCNGAA NGTTCTCATT NTCCCCNCNC CAGGTNAAAA	480<br>
TGAAGGGTTA CCATNTTTAA	CNCCACCTCC ACNTGGCNNN GCCTGAATCC TCNAAAANCN	540<br>
CCCTCAANCN AATTNCTNNG	CCCCGGTCNC GCNTNNGTCC CNCCCGGGCT CCGGGAANTN	600<br>
CACCCCCNGA ANNCNNTNNC	NAACNAAATT CCGAAAATAT TCCCNNTCNC TCAATTCCCC	660<br>
CNNAGACTNT CCTCNNCNAN	CNCAATTTTC TTTTNNTCAC GAACNCGNNC CNNAAAATGN	720<br>
NNNNCNCCTC CNCTNGTCCN	NAATCNCCAN C	751<br>
(2) INFORMATION FOR SEQ ID NO:40:<br>
(i! SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 753 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:<br>
GTGGTATTTT CTGTAAGATC AGGTGTTCCT CCCTCGTAGG TTTAGAGGAA ACACCCTCAT 60 AGATGAAAAC CCCCCCGAGA CAGCAGCACT GCAACTGCCA AGCAGCCGGG GTAGGAGGGG 120 CGCCCTATGC ACAGCTGGGC CCTTGAGACA GCAGGGCTTC GATGTCAGGC TCGATGTCAA 180<br><br>
TGGTCTGGAA GCGGCGGCTG TACCTGCGTA GGGGCACACC GTCAGGGCCC ACCAGGAACT	240<br>
TCTCAAAGTT CCAGGCAACN TCGTTGCGAC ACACCGGAGA CCAGGTGATN AGCTTGGGGT	300<br>
CGGTCATAAN CGCGGTGGCG TCGTCGCTGG GAGCTGGCAG GGCCTCCCGC AGGAAGGCNA	360<br>
ATAAAAGGTG CGCCCCCGCA CCGTTCANCT CGCACTTCTC NAANACCATG ANGTTGGGCT	420<br>
CNAACCCACC ACCANNCCGG ACTTCCTTGA NGGAATTCCC AAATCTCTTC GNTCTTGGGC	480<br>
TTCTNCTGAT GCCCTANCTG GTTGCCCNGN ATGCCAANCA NCCCCAANCC CCGGGGTCCT	540<br>
AAANCACCCN CCTCCTCNTT TCATCTGGGT TNTTNTCCCC GGACCNTGGT TCCTCTCAAG	600<br>
GGANCCCATA TCTCNACCAN TACTCACCNT NCCCCCCCNT GNNACCCANC CTTCTANNGN	660<br>
TTCCCNCCCG NCCTCTGGCC CNTCAAANAN GCTTNCACNA CCTGGGTCTG CCTTCCCCCC	720<br>
TNCCCTATCT GNACCCCNCN TTTGTCTCAN TNT	753<br>
(2) INFORMATION FOR SEQ ID NO:41:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH. 341 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i} MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:<br>
ACTATATCCA TCACAACAGA	CATGCTTCAT CCCATAGACT TCTTGACATA GCTTCAAATG	60<br>
AGTGAACCCA TCCTTGATTT	ATATACATAT ATGTTCTCAG TATTTTGGGA GCCTTTCCAC	120<br>
TTCTTTAAAC CTTGTTCATT	ATGAACACTG AAAATAGGAA TTTGTGAAGA GTTAAAAAGT	180<br>
TATAGCTTGT TTACGTAGTA	AGTTTTTGAA GTCTAC'ATTC AATCCAGACA CTTAGTTGAG	240<br>
TGTTAAACTG TGATTTTTAA	AAAATATCAT TTGAGAATAT TCTTTCAGAG GTATTTTCAT	300<br>
TTTTACTTTT TGATTAATTG	TGTTTTATAT ATTAGGGTAG T	341<br>
(2) INFORMATION FOR SEQ ID NO:42:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1.01 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
ixi) SEQUENCE DESCRIPTION: SEQ ID NO:42:<br>
ACTTACTGAA TTTAGTTCTG TGCTCTTCCT TATTTAGTGT TGTATCATAA ATACTTTGAT      60<br>
GTTTCAAACA TTCTAAATAA ATAATTTTCA GTGGCTTCAT A	101<br>
(2) INFORMATION FOR SEQ ID N0:43:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 305 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
Ui) MOLECULE TYPE: cDNA<br><br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo spiens<br>
(xi.l SEQUENCE DESCRIPTION: SEQ ID N0:43:<br>
ACATCTTTGT TACAGTCTAA GATGTGTTCT TAAATCACCA TTCCTTCCTG GTCCTCACCC	60<br>
TCCAGGGTGG TCTCACACTG TAATTAGAGC TATTGAGGAG TCTTTACAGC AAATTAAGAT	120<br>
TCAGATGCCT TGCTAAGTCT AGAGTTCTAG AGTTATGTTT CAGAAAGTCT AAGAAACCCA	180<br>
CCTCTTGAGA GGTCAGTAAA GAGGACTTAA TATTTCATAT CTACAAAATG ACCACAGGAT	240<br>
TGGATACAGA ACGAGAGTTA TCCTGGATAA CTCAGAGCTG AGTACCTGCC CGGGGGCCGC	300<br>
TCGAA	305<br>
(2) INFORMATION FOR SEQ ID NO:44:<br>
iij SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 852 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: Single<br>
(D)	TOPOLOGY: Idnear<br>
(ii) MOLECULE TYPE: CDNA (vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens (yd) SEQUENCE DESCRIPTION: SEQ ID NO:44:<br>
ACATAAATAT CAGAGAAAAG 1'AGTCTTTGA	AATATTTACG TCCAGGAGTT CTTTGTTTCT	60<br>
GATTATTTGG TGTGTGTTTT GGTTTGTGTC	CAAAGTATTG GCAGCTTCAG TTTTCATTTT	120<br>
CTCTCCATCC TC'GGGCATTC TTCCCAAATT	TATATACCAG TCTTCGTCCA TCCACACGCT	180<br>
CCAGAATTTC TCTTTTGTAG TAATATCTCA	TAGCTCGGCT GAGCTTTTCA TAGGTCATGC	240<br>
TGCTGTTGTT CTTCTTTTTA CCCCATAGCT	GAGCCACTGC CTCTGATTTC AAGAACCTGA	300<br>
AGACGCCCTC AGATCGGTC'l TCCCATTTTA	TTAATCCTGG GTTCTTGTCT GGGTTCAAGA	360<br>
GGATGTCGCG GATGAATTCC CATAAGTGAG	TCCCTCTCGG GTTGTGCTTT TTGGTGTGGC	420<br>
ACTTGGCAGG GGGGI'CTTGC TCCTTTTTCA	TATCAGGTGA CTCTGCAACA GGAAGGTGAC	480<br>
TGGTGGTTGT CATGGAGATC TGAGCCCGGC	AGAAAGTTTT GCTGTCCAAC AAATCTACTG	540<br>
TGCTACCATA GTTGGTGTCA TATAAATAGT	TCTNGTCTTT CCAGGTGTTC ATGATGGAAG	600<br>
GCTCAGTTTG TTCAGTCTTG ACAATGACAT	TGTGTGTGGA CTGGAACAGG TCACTACTGC	660<br>
ACTGGCCGTT CCACTTCAGA TGCTGCAAGT	TGCTGTAGAG GAGNTGCCCC GCCGTCCCTG	720<br>
CCGCCCGGGT GAACTOCTGC AAACTCATGC	TGCAAAGGTG CTCGCCGTTG ATGTCGAACT	780<br>
CNTGGAAAGG GATACAATTG GCATCCAGCT	GGTTGGTGTC CAGGAGGTGA TGGAGCCACT	840<br>
CC'CACACCTG GT	852<br>
(2) INFORMATION FOR SEQ ID NO:45:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 234 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D! TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:<br>
ACAACAGACC CTTGCTCGCT AACGACCTCA TGCTCATCAA GTTGGACGAA TCCGTGTCCG 60 AGTCTGACAC CATCCGGAGC ATCAGCATTG CTTCGCAGTG CCCTACCGCG GGGAACTCTT 120 GCCTCGTTTC TGGCTGGGGT CTGCTGGCGA ACGGCAGAAT GCCTACCGTG CTGCAGTGCG 180<br><br>
TGAACGTGTC GGTGGTGTCT GAGGAGGTCT GCAGTAAGCT CTATGACCCG CTGT	234<br>
(2) INFORMATION FOR SEQ ID NO:46:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 590 base pairs<br>
(B)	TYPE; nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:<br>
ACTTTTTATT TAAATGTTTA TAAGGCAGAT CTATGAGAAT GATAGAAAAC ATGGTGTGTA	60<br>
ATTTGATAGC AATATTTTGG AGATTACAGA GTTTTAGTAA TTACCAATTA CACAGTTAAA	120<br>
AAGAAGATAA TATATTCCAA GCANATACAA AATATCTAAT GAAAGATCAA GGCAGGAAAA	180<br>
TGANTATAAC TAATTGACAA TGGAAAATCA ATTTTAATGT GAATTGCACA TTATCCTTTA	240<br>
AAAGCTTTCA AAANAAANAA TTATTGCAGT CTANTTAATT CAAACAGTGT TAAATGGTAT	300<br>
CAGGATAAAN AACTGAAGGG CANAAAGAAT TAATTTTCAC TTCATGTAAC NCACCCANAT	360<br>
TTACAATGGC TTAAATGCAN (3GAAAAAGCA GTGGAAGTAG GGAAGTANTC AAGGTCTTTC	420<br>
TGGTCTCTAA TCTGCCTTAC TCTTTGGGTG TGGCTTTGAT CCTCTGGAGA CAGCTGCCAG	480<br>
GGCTCCTGTT ATATCCACAA TCCCAGCAGC AAGATGAAGG GATGAAAAAG GACACATGCT	540<br>
GCCTTCCTTT GAGGAGACTT CATCTCACTG GCCAACACTC AGTCACATGT	590<br>
(2) INFORMATION FOR SEQ. ID NO: 47:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 774 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:<br>
ACAAGGGGGC ATAATGAAGG AGTGGGGANA GATTTTAAAG AAGGAAAAAA AACGAGGCCC	60<br>
TGAACAGAAT TTTCCTGNAC AACGGGGCTT CAAAATAATT TTCTTGGGGA GGTTCAAGAC	120<br>
GCTTCACTGC TTGAAACTTA AATGGATGTG GGACANAATT TTCTGTAATG ACCCTGAGGG	180<br>
CATTACAGAC GGGACTCTGG GAGGAAGGAT AAACAGAAAG GGGACAAAGG CTAATCCCAA	240<br>
AACATCAAAG AAAGGAAGGT GGCGTCATAC CTCCCAGCCT ACACAGTTCT CCAGGGCTCT	300<br>
CCTCATCCCT GGAGGACGAC AGTGGAGGAA CAACTGACCA TGTCCCCAGG CTCCTGTGTG	360<br>
CTGGCTCCTG GTCTTCAGCC CCCAGCTCTG GAAGCCCACC CTCTGCTGAT CCTGCGTGGC	420<br>
CCACACTCCT TGAACACACA TCCCCAGGTT ATATTCCTGG ACATGGCTGA ACCTCCTATT	480<br>
CCTACTTCCG AGATGCCTTG CTCCCTGCAG CCTGTCAAAA TCCCACTCAC CCTCCAAACC	540<br>
ACGGCATGGG AAGCCTTTCT GACTTGCCTG ATTACTCCAG CATCTTGGAA CAATCCCTGA	600<br>
TTCCCCACTC CTTAGAGGCA AGATAGGGTG GTTAAGAGTA GGGCTGGACC ACTTGGAGCC	660<br>
AGGCTGCTGG CTTCAAATTN TGGCTCATTT ACGAGCTATG GGACCTTGGG CAAGTNATCT	720<br>
TCACTTCTAT GGGCNTCATT TTGTTCTACC TGCAAAATGG 'GGGATAATAA TAGT	774<br>
(2) INFORMATION FOR SEQ ID N0:48:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 124 base pairs<br><br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:<br>
CANAAATTGA AATTTTATAA AAAGGCATTT TTCTCTTATA TCCATAAAAT GATATAATTT 60<br>
TTGCAANTAT ANAAATGTGT CATAAATTAT AATGTTCCTT AATTACAGCT CAACGCAACT 120<br>
TGGT	124<br>
(2) INFORMATION FOR SEQ ID NO:49:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1.47 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE; cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:49:<br>
GCCGATGCTA CTATTTTATT GCAGGAGGTG GGGGTGTTTT TATTATTCTC TCAACAGCTT 60<br>
TGTGGCTACA GGTGGTGTC'T GACTGCATNA AAAANTTTTT TACGGGTGAT TGCAAAAATT 120<br>
TTAGGGCACC CATATCCCAA GCANTGT	147<br>
*<br>
(2) INFORMATION FOR SEQ ID NO:50:<br>
(i) SEQUENCE CHARACTER ISTICS:<br>
(A) LENGTH: 107 base pairs SB) TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:<br>
ACATTAAATT AATAAAAGGA CTGTTGGGGT TCTGCTAAAA CACATGGCTT GATATATTGC 60<br>
ATGGTTTGAG GTTAGGAGGA GTTAGGCATA TGTTTTGGGA GAGGGGT	107<br>
(2) INFORMATION FOR SEQ ID N0:51:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 204 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i. i) MOLECULE TYPE: cDNA<br><br>
ivi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
i.xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:<br>
GTCCTAGGAA GTCTAGGGGA CACACGACTC TGGGGTCACG GGGCCGACAC ACTTGCACGG	60<br>
CGGGAAGGAA AGGCAGAGAA GTGACACCGT CAGGGGGAAA TGACAGAAAG GAAAATCAAG	120<br>
GCCTTGCAAG GTCAGAAAGG GGACTCAGGG CTTCCACCAC AGCCCTGCCC CACTTGGCCA	180<br>
CCTCCCTTTT GGGACCAGCA ATGT	204<br>
(2) INFORMATION FOR SEQ ID NO:52:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH; 491 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:52:<br>
ACAAAGATAA CATTTATCTT ATAACAAAAA TTTGATAGTT TTAAAGGTTA GTATTGTGTA	60<br>
GGGTATTTTC CAAAAGACTA AAGAGATAAC TCAGGTAAAA AGTTAGAAAT GTATAAAACA	120<br>
CCATCAGACA GGTTTTTAAA AAACAACATA TTACAAAATT AGACAATCAT CCTTAAAAAA	180<br>
AAAACTTCTT GTATCAATTT CTTTTGTTCA AAATGACTGA CTTAANTATT TTTAAATATT	240<br>
TCANAAACAC TTCCTCAAAA ATTTTCAANA TGGTAGCTTT CANATGTNCC CTCAGTCCCA	300<br>
ATGTTGCTCA GATAAATAAA TCTCGTGAGA ACTTACCACC CACCACAAGC TTTCTGGGGC	360<br>
ATGCAACAGT GTCTTTTCTT TNCTTTTTCT TTTTTTTTTT TTACAGGCAC AGAAACTCAT	420<br>
CAATTTTATT TGGATAACAA AGGGTCTCCA AATTATATTG AAAAATAAAT CCAAGTTAAT	480<br>
ATCACTCTTG T	491<br>
(2) INFORMATION FOR SEQ ID NO:53:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 484 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:53:<br>
ACATAATTTA GCAGGGCTAA TTACCATAAG ATGCTATTTA TTAANAGGTN TATGATCTGA	60<br>
GTATTAACAG TTGCTGAAGT TTGGTATTTT TATGCAGCAT TTTCTTTTTG CTTTGATAAC	120<br>
ACTACAGAAC CCTTAAGGAC ACTGAAAATT AGTAAGTAAA GTTCAGAAAC ATTAGCTGCT	180<br>
CAATCAAATC TCTACATAAC ACTATAGTAA TTAAAACGTT AAAAAAAAGT GTTGAAATCT	240<br>
GCACTAGTAT ANACCGCTCC TGTCAGGATA ANACTGCTTT GGAACAGAAA GGGAAAAANC	300<br>
AGCTTTGANT TTCTTTGTGC TGATANGAGG AAAGGCTGAA TTACCTTGTT GCCTCTCCCT	360<br>
AATGATTGGC AGGTCNGGTA AATNCCAAAA CATATTCCAA CTCAACACTT CTTTTCCNCG	420<br>
TANCTTGANT CTGTGTATTC CAGGANCAGG CGGATGGAAT GGGCCAGCCC NCGGATGTTC	480<br>
CANT	484<br><br>
(2) INFORMATION FOR SBQ ID NO:54:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 151 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:<br>
ACTAAACCTC GTGCTTGTGA ACTCCATACA GAAAACGGTG CCATCCCTGA ACACGGCTGG 60 CCACTGGGTA TACTGCTGAC AACCGCAACA ACAAAAACAC AAATCCTTGG CACTGGCTAG 120<br>
TCTATGTCCT CTCAAGTGCC TTTTTGTTTG T	151<br>
(2) INFORMATION FOR SEQ ID NO:55:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 91 base pairs<br>
(B)	TYPE: nucleic acid<br>
(Cj STRANDEDNESS: single<br>
(D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:<br>
ACCTGGCTTG TCTCCGGGTG 3TTCCCGGCG CCCCCCACGG TCCCCAGAAC GGACACTTTC 60<br>
GCCCTCCAGT GGATAGTCGA 3CCAAAGTGG T	» 91<br>
(2) INFORMATION FOR SEQ ID NO:56:<br>
ii) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 133 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:<br>
GGCGGATGTG CGTTGGTTAT ATACAAATAT GTCATTTTAT GTAAGGGACT TGAGTATACT 60<br>
TGGATTTTTG GTATCTGTGG GTTGGGGGGA CGGTCCAGGA ACCAATACCC CATGGATACC 120<br>
AAGGGACAAC TGT	133<br>
(2) INFORMATION FOR SEQ ID NO:57:<br>
(i; SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 147 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:<br>
ACTCTGGAGA ACCTGAGCCG CTGCTCCGCC TCTGGGATGA GGTGATGCAN GCNGTGGCGC 60<br>
GACTGGGAGC TGAGCCCTTC CCTTTGCGCC TGCCTCAGAG GATTGTTGCC GACNTGCANA 120<br>
TCTCANTGGG CTGGATNCAT GCAGGGT	147<br>
(2) INFORMATION FOR SEQ ID NO:58:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 198 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE;: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:<br>
ACAGGGATAT AGGTTTNAAG TTATTGTNAT TGTAAAATAC ATTGAATTTT	CTGTATACTC	60<br>
TGATTACATA CATTTATCCT TTAAAAAAGA TGTAAATCTT AATTTTTATG	CCATCTATTA	120<br>
ATTTACCAAT GAGTTACCTT GTAAATGAGA AGTCATGATA GCACTGAATT	TTAACTAGTT	180<br>
TTGACTTCTA AGTTTGGT	198<br>
(2! INFORMATION FOR SEQ ID NO:59:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 330 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:<br>
ACAACAAATG GGTTGTGAGG AAGTCTTATC AGCAAAACTG GTGATGGCTA	CTGAAAAGAT	60<br>
CCATTGAAAA TTATCATTAA TGATTTTAAA TGACAAGTTA TCAAAAACTC	ACTCAATTTT	120<br>
CACCTGTGCT AGCTTGCTAA AATGGGAGTT AACTCTAGAG CAAATATAGT	ATCTTCTGAA	180<br>
TACAGTCAAT AAATGACAAA GCCAGGGCCT ACAGGTGGTT TCCAGACTTT	CCAGACCCAG	240<br>
CAGAAGGAAT CTATTTTATC ACATGGATCT CCGTCTGTGC TCAAAATACC	TAATGATATT	300<br>
TTTCGTCTTT ATTGGACTTC TTTGAAGAGT	330<br>
(2) INFORMATION FOR SEO. ID NO: 60:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 175 base, pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
Hi] MOLECULE TYPE: cDNA<br>
ivi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
txi) SEQUENCE DESCRIPTION: SEQ ID HO:60:<br>
ACCGTGGGTG CCTTCTACAT TCCTGACGGC TCCTTCACCA ACATCTGGTT CTACTTCGGC 60<br>
GTCGTGGGCT CCTTCCTCTT CATCCTCATC CAGCTGGTGC TGCTCATCGA CTTTGCGCAC 120<br>
TCCTGGAACC AGCGGTGGCT GGGCAAGGCC GAGGAGTGCG ATTCCCGTGC CTGGT	175<br>
(2) INFORMATION FOR SEQ ID NO:61:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1S4 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
! 1i i MOLECULE TYPE: cDNA<br>
ivi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(XI) SEQUENCE DESCRIPTION: SEQ ID NO:61:<br>
ACCCCACTTT TCCTCCTGTG AGCAGTCTGG ACTTCTCACT GCTACATGAT GAGGGTGAGT 60<br>
GGTTCTTGCT CTTCAACAGT ATCCTCCCCT TTCCGGATCT GCTGAGCCGG ACAGCAGTGC 120<br>
TC3GACTGCAC AGCCCCGGGG CTCCACATTG CTGT	154<br>
C.'.) INFORMATION FOR SEQ ID NO: 62:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 30 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
ivi) ORIGINAL SOURCE:<br>
(A! ORGANISM: Homo sapiens<br>
ixi) SEQUENCE DESCRIPTION: SEQ ID NO:62:<br>
CGCTCGAGCC CTATAGTGAG TCGTATTAGA	30<br>
(2) INFORMATION FOR SEQ ID NO:63:<br>
(i! SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH' 89 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
iii) MOLECULE TYPE: cDNA Ivi) ORIGINAL SOURCE:<br><br>
(A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:<br>
A'CAAGTCATT TCAGCACCCT TTGCTCTTCA AAACTGACCA TCTTTTATAT TTAATGCTTC      60<br>
CTGTATGAAT AAAAATGGTT ATGTCAAGT	89<br>
(2) INFORMATION FOR SEQ ID NO:64:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 97 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
{i i ) MOLECULE TYPE: cDNA<br>
(v i) ORIGINAL SOUR CE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:<br>
ACCGGAGTAA CTGAGTCGGG ACGCTGAATC TGAATCCACC AATAAATAAA GGTTCTGCAG      60<br>
AATCAGTGCA TCCAGGATTG GTCCTTGGAT CTGGGGT	97<br>
(2) INFORMATION FOR SEQ ID NO:65:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 377 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDMA<br>
i.vi) ORIGINAL, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:<br>
ACAACAANAA NTCCCTTCTT	TAGGCCACTG ATGGAAACCT	GGAACCCCCT TTTGATGGCA	60<br>
GCATGGCGTC CTAGGCCTTG	A.CACAGCGGC TGGGGTTTGG	GCTNTCCCAA ACCGCACACC	120<br>
CCAACCCTGG TCTACCCACA	NTTCTGGCTA TGGGCTGTCT	CTGCCACTGA ACATCAGGGT	180<br>
TCGGTCATAA NATGAAATCC	CAANGGGGAC AGAGGTCAGT	AGAGGAAGCT CAATGAGAAA	240<br>
GGTGCTGTTT GCTCAGCCAG	AAAACAGCTG CCTGGCATTC	GCCGCTGAAC TATGAACCCG	300<br>
TGGGGGTGAA CTACCCCCAN	GAGGAATCAT GCCTGGGCGA	TGCAANGGTG CCAACAGGAG	360<br>
GGGCGGGAGG AGCATGT	377<br>
(2) INFORMATION FOR SEQ ID N0:66:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 305 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:<br>
ACGCCTTTCC CTCAGAATTC AGGGAAGAGA CTGTCGCCTG CCTTCCTCCG TTGTTGCGTG	60<br>
AGAACCCGTG TGCCCCTTCC CACCATATCC ACCCTCGCTC CATCTTTGAA CTCAAACACG	120<br>
AGGAACTAAC TGCACCCTGG TCCTCTCCCC AGTCCCCAGT TCACCCTCCA TCCCTCACCT	180<br>
TCCTCCACTC TAAGGGATAT CAACACTGCC CAGCACAGGG GCCCTGAATT TATGTGGTTT	240<br>
TTATATATTT TTTAATAAGA TGCACTTTAT GTCATTTTTT AATAAAGTCT GAAGAATTAC	300<br>
TGTTT	305<br>
(2) INFORMATION FOR SEQ ID NO:67:<br>
(i; SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 385 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
ixil SEQUENCE DESCRIPTION: SEQ ID N0:67:<br>
ACTACACACA CTCCACTTGC CCTTGTGAGA CACTTTGTCC CAGCACTTTA GGAATGCTGA	60<br>
GGTCGGAC'CA GCCACATCTC ATGTGCAAGA TTGCCCAGCA GACATCAGGT CTGAGAGTTC	120<br>
CCCTTTTAAA AAAGGGGACT TGCTTAAAAA AGAAGTCTAG CCACGATTGT GTAGAGCAGC	180<br>
TGTGCTGTGC TGGAGATTCA CTTTTGAGAG AGTTCTCCTC TGAGACCTGA TCTTTAGAGG	240<br>
CTGGGCAGTC TTGCACATGA GATGGGGCTG GTCTGATCTC AGCACTCCTT AGTCTGCTTG	300<br>
CCTCTCCCAG GGCCfCAGCC TGGCCACACC TGCTTACAGG GCACTCTCAG ATGCCCATAC	360<br>
CATAGTTTCT GTGCTAGTGG ACCGT	385<br>
(2) INFORMATION FOR SEQ ID N0:68: (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 73 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: 1inear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:68:<br>
ACTTAACCAG ATATATTTTT ACCCCAGATG GGGATATTCT TTGTAAAAAA TGAAAATAAA      60<br>
GTTTTTTTAA TGG	73<br>
(2) INFORMATION FOR SEQ ID N0:69:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 536 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE:<br><br>
(A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:<br>
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGGCTC TCACCCTCCT CTCCTGCAGC	60<br>
TCCAGCTTTG TGCTCTGCCT CTGAGGAGAC CATGGCCCAG CATCTGAGTA CCCTGCTGCT	120<br>
CCTGCTGGCC ACCCTAGCTG TGGCCCTGGC CTGGAGCCCC AAGGAGGAGG ATAGGATAAT	180<br>
CCCGGGTGGC ATCTATAACG CAGACCTCAA TGATGAGTGG GTACAGCGTG CCCTTCACTT	240<br>
CGCCATCAGC GAGTATAACA AGGCCACCAA AGATGACTAC TACAGACGTC CGCTGCGGGT	300<br>
ACTAAGAGCC AGGCAACAGA CCGTTGGGGG GGTGAATTAC TTCTTCGACG TAGAGGTGGG	360<br>
CCGAACCATA TGTACCAAGT CCCAGCCCAA CTTGGACACC TGTGCCTTCC ATGAACAGCC	420<br>
AGAACTGCAG AAGAAACAGT TGTGCTCTTT CGAGATCTAC GAAGTTCCCT GGGGAGAACA	480<br>
GAANGTCCCT GGGTGAAATC CAGGTGTCAA GAAATCCTAN GGATCTGTTG CCAGGC	536<br>
(2) INFORMATION FOR SEQ ID NO:70:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 477 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
!li! MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:<br>
ATGACCCCTA ACAGGGGCCC TCTCAGCCCT CCTAATGACC TCCGGCCTAG CCATGTGATT	60<br>
TCACTTCCAC TCCATAACGC TCCTCATACT AGGCCTACTA ACCAACACAC TAACCATATA	120<br>
CCAATGATGG CGCGATGTAA CACGAGAAAG CACATACCAA GGCCACCACA CACCACCTGT	180<br>
CCAAAAAGGC CTTCGATACG GGATAATCCT ATTTATTACC TCAGAAGTTT TTTTCTTCGC	240<br>
AGGGATTTTT CTGAGCCTTT TACCACTCCA GCCTAGCCCC TACCCCCCAA CTAGGAGGGC	300<br>
ACTGGCCCCC AACAGGCATC ACCCCGCTAA ATCCCCTAGA AGTCCCACTC CTAAACACAT	360<br>
CCGTATTACT CGCATCAGGA GTATCAATCA CCTGAGCTCA CCATAGTCTA ATAGAAAACA	420<br>
ACCGAAACCA AATTATTCAA AGCACTGCTT ATTACAATTT TACTGGGTCT CTATTTT	477<br>
C!) INFORMATION FOR SEQ ID NO.-71:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 533 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:<br>
AGAGCTATAG GTACAGTGTG ATCTCAGCTT TGCAAACACA TTTTCTACAT AGATAGTACT	60<br>
AGGTATTAAT AGATATGTAA AGAAAGAAAT CACACCATTA ATAATGGTAA GATTGGTTTA	120<br>
TGTGATTTTA GTGGTATTTT TGGCACCCTT ATATATGTTT TCCAAACTTT CAGCAGTGAT	180<br>
ATTATTTCCA TAACTTAAAA AGTGAGTTTG AAAAAGAAAA TCTCCAGCAA GCATCTCATT	240<br>
TAAATAAAGG TTTGTCATCT TTAAAAATAC AGCAATATGT GACTTTTTAA AAAAGCTGTC	300<br>
AAATAGGTGT GACCCTACTA ATAATTATTA GAAATACATT TAAAAACATC GAGTACCTCA	360<br>
AGTCAGTTTG CCTTGAAAAA TATCAAATAT AACTCTTAGA GAAATGTACA TAAAAGAATG	420<br>
CTTCGTAATT TTGGAGTANG AGGTTCCCTC CTCAATTTTG TATTTTTAAA AAGTACATGG	480<br><br>
TAAAAAAAAA AATTCACAAC AGTATATAAG GCTGTAAAAT GAAGAATTCT GCC	533<br>
(2) INFORMATION FOR SEQ ID NO:72:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 511 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:<br>
TATTACGGAA AAACACACCA CATAATTCAA CTANCAAAGA ANACTGCTTC AGGGCGTGTA	60<br>
AAATGAAAGG CTTCCAGGCA GTTATCTGAT TAAAGAACAC TAAAAGAGGG ACAAGGCTAA	120<br>
AAGCCGCAGG ATGTCTACAC TATANCAGGC GCTATTTGGG TTGGCTGGAG GAGCTGTGGA	180<br>
AAACATGGAN AGATTGGTGC TGGANATCGC CGTGGCTATT CCTCATTGTT ATTACANAGT	240<br>
GAGGTTCTCT GTGTGCCCAC TGGTTTGAAA ACCGTTCTNC AATAATGATA GAATAGTACA	300<br>
CACATGAGAA CTGAAATGGC CCAAACCCAG AAAGAAAGCC CAACTAGATC CTCAGAANAC	360<br>
GCTTCTAGGG ACAATAACCG ATGAAGAAAA GATGGCCTCC TTGTGCCCCC GTCTGTTATG	420<br>
ATTTCTCTCC ATTGCAGCNA NAAACCCGTT CTTCTAAGCA AACNCAGGTG ATGATGGCNA	480<br>
AAATACACCC CCTCTTGAAG NACCNGGAGG A	511<br>
(2) INFORMATION FOR SEQ ID NO:73:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 499 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:<br>
CAGTGCCAGC ACTGGTGCCA GTACCAGTAC CAATAACAGT GCCAGTGCCA	GTGCCAGCAC	60<br>
CAGTGGTGGC TTCAGTGCTG GTGCCAGCCT GACCGCCACT CTCACATTTG	GGCTCTTCGC	120<br>
TGGCCTTGGT GGAGCTGGTG CCAGCACCAG TGGCAGCTCT GGTGCCTGTG	GTTTCTCCTA	180<br>
CAAGTGAGAT TTTAGATATT GTTAATCCTG CCAGTCTTTC TCTTCAAGCC	AGGGTGCATC	240<br>
CTCAGAAACC TACTCAACAC AGCACTCTAG GCAGCCACTA TCAATCAATT	GAAGTTGACA	300<br>
CTCTGCATTA AATCTATTTG CCATTTCTGA AAAAAAAAAA AAAAAAAGGG	CGGCCGCTCG	360<br>
ANTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT	ANTTGCCAGC	420<br>
CATCTGTTGT TTGCCCCTCC CCCGNTGCCT TCCTTGACCC TGGAAAGTGC	CACTCCCACT	480<br>
GTCCTTTCCT AANTAAAAT	499<br>
(2) INFORMATION FOR SEQ ID NO:74:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: r,37 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
MOLECULE TYPE. cDNA<br><br>
ivi) ORIGINAL SOURCE:<br>
(A)	ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:<br>
TTTCATAGGA GAACACACTG AGGAGATACT TGAAGAATTT GGATTCAGCC GCGAAGAGAT	60<br>
TTATCAGCTT AACTCAGATA AAATCATTGA AAGTAATAAG GTAAAAGCTA GTCTCTAACT	120<br>
TCCAGGCCCA CGGCTCAAGT GAATTTGAAT ACTGCATTTA CAGTGTAGAG TAACACATAA	180<br>
CATTGTATGC ATGGAAACAT GGAGGAACAG TATTACAGTG TCCTACCACT CTAATCAAGA	240<br>
AAAGAATTAC AGACTCTGAT TCTACAGTGA TGATTGAATT CTAAAAATGG TAATCATTAG	300<br>
GGCTTTTGAT TTATAANACT TTGGGTACTT ATACTAAATT ATGGTAGTTA TACTGCCTTC	360<br>
CAGTTTGCTT GATATATTTG TTGATATTAA GATTCTTGAC TTATATTTTG AATGGGTTCT	420<br>
ACTGAAAAAN GAATGATATA TTCTTGAAGA CATCGATATA CATTTATTTA CACTCTTGAT	480<br>
TCTACAATGT AGAAAATGAA GGAAATGCCC CAAATTGTAT GGTGATAAAA GTCCCGT	537<br>
(2) INFORMATION FOR SEQ ID NO:75:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A! LENGTH: 467 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ill MOLECULE TYPE: cDNA<br>
fvi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi} SEQUENCE DESCRIPTION: SEQ ID NO:75:<br>
CAAANACAAT TGTTCAAAAG ATGCAAATGA TACACTACTG CTGCAGCTCA CAAACACCTC	60<br>
TGCATATTAC ACGTACCTCC TCCTGCTCCT CAAGTAGTGT GGTCTATTTT GCCATCATCA	120<br>
CCTGCTGTCT GCTTAGAAGA ACGGCTTTCT GCTGCAANGG AGAGAAATCA TAACAGACGG	180<br>
TGGCACAAGG AGGCCATCTT TTCCTCATCG GTTATTGTCC CTAGAAGCGT CTTCTGAGGA	240<br>
TCTAGTTGGG CTTTCTTTCT GGGTTTGGGC CATTTCANTT CTCATGTGTG TACTATTCTA	300<br>
TCATTATTGT ATAACGGTTT TCAAACCNGT GGGCACNCAG AGAACCTCAC TCTGTAATAA	360<br>
CAATGAGGAA TAGCCACGGT GATCTCCAGC ACCAAATCTC TCCATGTTNT TCCAGAGCTC	420<br>
CTCCAGCCAA CCCAAATAGC CGCTGCTATN GTGTAGAACA TCCCTGN	467<br>
(2) INFORMATION FOR SEQ ID NO:76:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 400 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii ; MOLECULE TYPE: cDNA<br>
(vi; ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi! SEQUENCE DESCRIPTION: SEQ ID NO:76:<br>
AAGCTGACAG CATTCGGGCC GAGATGTCTC GCTCCGTGGC CTTAGCTGTG CTCGCGCTAC	60<br>
TCTCTCTTTC TGGCCTGGAG GCTATCCAGC GTACTCCAAA GATTCAGGTT TACTCACGTC	120<br>
ATCCAGCAGA GAATGGAAAG TCAAATTTCC TGAATTGCTA TGTGTCTGGG TTTCATCCAT	180<br>
CCGACATTGA AGTTGACTTA CTGAAGAATG GAGAGAGAAT TGAAAAAGTG GAGCATTCAG	240<br>
ACTTGTCTTT CAGCAAGGAC TGGTCTTTCT ATCTCTTGTA CTACACTGAA TTCACCCCCA	300<br>
CTGAAAAAGA TGAGTATGCC TGCCGTGTGA ACCATGTGAC TTTGTCACAG CCCAAGATNG	360<br><br>
TTNAGTGGGA TCGANACATG TAAGCAGCAN CATGGGAGGT	400<br>
(2) INFORMATION FOR SEQ ID N0:77:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 248 base pairs<br>
(B)	TYPE: nucleic acid<br>
(Cj STRANDED-NESS: single<br>
(D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo Sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID MO:77:<br>
CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT	60<br>
CCAGCTGC'CC CGGCGGGGGA TGCGAGGCTC GGAGCACCCT TGCCCGGCTG TGATTGCTGC	120<br>
CAGGCACTGT TCATCTCAGC TTTTCTGTCC CTTTGCTCCC GGCAAGCGCT TCTGCTGAAA	180<br>
GTTCATATCT GGAGCCTGAT GTCTTAACGA ATAAACiGTCC CATGCTCCAC CCGAAAAAAA	240<br>
AAAAAAAA	248<br>
(2) INFORMATION FOR SEQ ID NO:78:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 201 base pairs (Bi TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
!ii) MOLECULE TYPE: cDNA<br>
(vi; ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:<br>
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT	ACCTTTAACA	60<br>
TCACCCAGAC CCCGCCCTGC CCGTGCCCCA CGCTGCTGCT AACGACAGTA	TGATGCTTAC	120<br>
TCTGCTACTC GGAAACTATT TTTATGTAAT TAATGTATGC TTTCTTGTTT	ATAAATGCCT	180<br>
GATTTAAAAA AAAAAAAAAA A	201<br>
(2) INFORMATION FOR SEQ II) NO: 79:<br>
(ii SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 552 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(Al ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:<br>
TCCTTTTGTT AGGTTTTTGA GACAACCCTA GACCTAAACT GTGTCACAGA CTTCTGAATG 60 TTTAGGCAGT GCTAGTAATT TCCTCGTAAT GATTCTGTTA TTACTTTCCT ATTCTTTATT 120 CCTCTTTCTT CTGAAGATTA ATGAAGTTGA AAATTGAGGT GGATAAATAC AAAAAGGTAG 180<br><br>
TGTGATAGTA  TAAGTATCTA  AGTGCAGATG  AAAGTGTGTT  ATATATATCC  ATTCAAAATT	240<br>
ATGCAAGTTA  GTAATTACTC  AGGGTTAACT  AAATTACTTT  AATATGCTGT  TGAACCTACT	300<br>
CTGTTCCTTG  GCTAGAAAAA ATTATAAACA  GGACTTTGTT  AGTTTGGGAA  GCCAAATTGA	360<br>
TAATATTCTA  TGTTCTAAAA  GTTGGGCTAT  ACATAAANTA  TNAAGAAATA  TGGAATTTTA	420<br>
TTCCCAGGAA  TATGGGGTTC  ATTTATGAAT ANTACCCGGG  ANAGAAGTTT  TGANTNAAAC	480<br>
CNGTTTTGGT  TAATACGTTA ATATGTCCTN AATNAACAAG  GCNTGACTTA  TTTCCAAAAA	540<br>
AAAAAAAAAA AA	552<br>
(2)    INFORMATION   FOR  SEQ   ID  NO:80:<br>
(i)    SEQUENCE   CHARACTERISTICS:<br>
(A)	LENGTH:   476   base  pairs<br>
(B)	TYPE:   nucleic  acid<br>
(C)	STRANDEDNESS:   single<br>
(D)	TOPOLOGY:   linear<br>
(ii)    MOLECULE   TYPE:    cDNA<br>
(vi)    ORIGINAL   SOURCE:<br>
(A)   ORGANISM:   Homo   sapiens<br>
(xi)    SEQUENCE   DESCRIPTION:    SEQ   ID   NO:80:<br>
ACAGGGATTT  GAGATGCTAA  GGCCCCAGAG  ATCGTTTGAT	CCAACCCTCT  TATTTTCAGA	60<br>
GGGGAAAATG  GGGCCTAGAA  GTTACAGAGC  ATCTAGCTGG	TGCGCTGGCA  CCCCTGGCCT	120<br>
CACACAGACT   CCCGA3TAGC  TGGGACTACA GGCACACAGT	CACTGAAGCA  GGCCCTGTTT	180<br>
GCAATTCACG  TTGCCACCTC   CAACTTAAAC  ATTCTTCATA	TGTGATGTCC  TTAGTCACTA	240<br>
AGGTTAAACT  TTCCCACCCA  GAAAAGGCAA  CTTAGATAAA	ATCTTAGAGT  ACTTTCATAC	300<br>
TCTTCTAAGT   CCTCTTCCAG   CCTCACTTTG  AGTCCTCCTT	GGGGGTTGAT  AGGAANTNTC	360<br>
TCTTGGCTTT   CTCAATAAAA  TCTCTATCCA  TCTCATGTTT	AATTTGGTAC  GCNTAAAAAT	420<br>
GCTGAAAAAA  TTAAAATGTT   CTGGTTTCNC  TTTAAAAAAA	AAAAAAAAAA AAAAAA	476<br>
(2)    INFORMATION   FOR   SEQ   ID   NO:81:<br>
(i)    SEQUENCE   CHARACTERISTICS:<br>
(A)   LENGTH:   232   base  pairs IB)   TYPE:   nucleic acid !C)    STRANDEDNESS:   single (D)   TOPOLOGY:   linear<br>
(ii)    MOLECULE   TYPE:   cDNA<br>
(vi)    ORIGINAL  SOURCE:<br>
(A)   ORGANISM:   Homo   sapiens<br>
(xi)    SEQUENC3   DESCRIPTION:    SEQ   ID   NO:81:<br>
TTTTTTTTTG  TATGCCNTCN   CTGTGGNGTT  ATTGTTGCTG   CCACCCTGGA GGAGCCCAGT	60<br>
TTCTTCTGTA  TCTTTCTTTT   CTGGGGGATC  TTCCTGGCTC   TGCCCCTCCA  TTCCCAGCCT	120<br>
CTCATCCCCA  TCTTGCACTT   TTGCTAGGGT  TGGAGGCGCT   TTCCTGGTAG  CCCCTCAGAG	180<br>
ACTCAGTCAG   CGGGAATAAG   TCCTAGGGGT   GGGGGGTGTG   GCAAGCCGGC   CT	232<br>
(2)    INFORMATION   FOR  SEQ   ID  NO:82:<br>
(i)    SEQUENCE   CHARACTERISTICS:<br>
(A)	LENGTH:   383   base  pairs<br>
(B)	TYPE:   nucleic  acid<br>
(C)	STRANDEDNESS:   single<br>
(D)	TOPOLOGY:   linear<br>
(ii)    MOLECULE  TYPE:   CDNA<br><br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:<br>
AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC	60<br>
AGTACCAGTA CCAATAACAT GCCAGTGCCA GTGCCAGCAC CAGTGGTGGC TTCAGTGCTG	120<br>
GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC TGGCCTTGGT GGAGCTGGTG	180<br>
CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA CAAGTGAGAT TTTAGATATT	240<br>
GTTAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC CTCAGAAACC TACTCAACAC	300<br>
AGCACTCTNG GCAGCCACTA TCAATCAATT GAAGTTGACA CTCTGCATTA AATCTATTTG	360<br>
CCATTTCAAA AAAAAAAAAA AAA	383<br>
(21 INFORMATION FOR SEQ ID NO:83:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 494 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(Li) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:<br>
ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTCCTC CAGTATTACC TCAACGAGCA	60<br>
GGGAGATCGA GTCTATACGC TGAAGAAATT TGACCCGATG GGACAACAGA CCTGCTCAGC	120<br>
CCATCCTGCT CGGTTCTCCC CAGATGACAA ATACTCTCGA CACCGAATCA CCATCAAGAA	180<br>
ACGCTTCAAG GTGCTCATGA CCCAGCAACC GCGCCCTGTC CTCTGAGGGT CCTTAAACTG	240<br>
ATGTCTTTTC TGCCAC'CTGT TACCCCTCGG AGACTCCGTA ACCAAACTCT TCGGACTGTG	300<br>
AGCCCTGATG CCTTTTTGCC AGCCATACTC TTTGGCNTCC AGTCTCTCGT GGCGATTGAT	360<br>
TATGCTTGTG TGAGGCAATC ATGGTGGCAT CACCCATNAA GGGAACACAT TTGANTTTTT	420<br>
TTTCNCATAT TTTAAA.TTAC NACCAGAATA NTTCAGAATA AATGAATTGA AAAACTCTTA	480<br>
AAAAAAAAAA AAAA	494<br>
(2) INFORMATION FOR SEQ ID NO:84:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 380 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(11) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:<br>
GCTGGTAGCC TATGGCGTGG	CCACGGANGG GCTCCTGAGG CACGGGACAG TGACTTCCCA	60<br>
AGTATCCTGC GCCGCGTCTT	CTACCGTCCC TACCTGCAGA TCTTCGGGCA GATTCCCCAG	120<br>
GAGGACATGG ACGTGGCCCT	CATGGAGCAC AGCAACTGCT CGTCGGAGCC CGGCTTCTGG	180<br>
GCACACCCTC CTGGGGCCCA	GGCGGGCACC TGCGTCTCCC AGTATGCCAA CTGGCTGGTG	240<br>
GTGCTGCTCC TCGTCATCTT	CCTGCTCGTG GCCAACATCC TGCTGGTCAC TTGCTCATTG	300<br>
CCATGTTCAG TTACACATTC	GGCAAAGTAC AGGGCAACAG CNATCTCTAC TGGGAAGGCC	360<br>
AGCGTTNCCG CCTCATCCGG                     '    -	380<br><br>
(2) INFORMATION FOR SEQ ID NO:85:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 481 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
fvi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:<br>
GAGTTAGCTC CTCCACAACC TTGATGAGGT CGTCTGCAGT GGCCTCTCGC TTCATACCGC	60<br>
TNCCATCGTC ATACTGTAGG TTTGCCACCA CCTCCTGCAT CTTGGGGCGG CTAATATCCA	120<br>
GGAAACTCTC AATCAAGTCA CCGTCNATNA AACCTGTGGC TGGTTCTGTC TTCCGCTCGG	180<br>
TGTGAAAGGA TCTCCAGAAG GAGTGCTCGA TCTTCCCCAC ACTTTTGATG ACTTTATTGA	240<br>
GTCGATTCTG CATGTCCAGC AGGAGGTTGT ACCAGCTCTC TGACAGTGAG GTCACCAGCC	300<br>
CTATCATGCC NTTGAACGTG CCGAAGAACA CCGAGCCTTG TGTGGGGGGT GNAGTCTCAC	360<br>
CCAGATTCTG CATTACCAGA NAGCCGTGGC AAAAGANATT GACAACTCGC CCAGGNNGAA	420<br>
AAAGAACACC TCCTGGAAGT GCTNGCCGCT CCTCGTCCNT TGGTGGNNGC GCNTNCCTTT	480<br>
T	481<br>
(2) INFORMATION FOR SEQ ID NO:86:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 472 base pairs<br>
(B)	TYPE: nucleic acid<br>
1C) STRANDEDNESS: single<br>
CD) TOPOLOGY: linear<br>
(iii MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:<br>
AACATCTTCC TGTATAATGC TGTGTAATAT	CGATCCGATN TTGTCTGCTG AGAATTCATT	60<br>
ACTTGGAAAA GCAACTTNAA GCCTGGACAC	TGGTATTAAA ATTCACAATA TGCAACACTT	120<br>
TAAACAGTGT GTCAATCTGC TCCCTTACTT	TGTCATCACC AGTCTGGGAA TAAGGGTATG	180<br>
CCCTATTCAC ACCTGTTAAA AGGGCGCTAA	GCATTTTTGA TTCAACATCT TTTTTTTTGA	240<br>
CACAAGTCCG AAAAAAGCAA AAGTAAACAG	TTNTTAATTT GTTAGCCAAT TCACTTTCTT	300<br>
CATGGGACAG AGCCATTTGA TTTAAAAAGC	AAATTGCATA ATATTGAGCT TTGGGAGCTG	360<br>
ATATNTGAGC GGAAGANTAG CCTTTCTACT	TCACCAGACA CAACTCCTTT CATATTGGGA	420<br>
TGTTNACNAA AGTTATGTCT CTTACAGATG GGATGCTTTT GTGGCAATTC TG	472<br>
(2; INFORMATION FOR SEQ ID NO:87:<br>
(i) SEQUENCE; CHARACTERISTICS:<br>
(A)	LENGTH: 413 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE:<br><br>
(A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:<br>
AGAAACCAGT ATCTCTNAAA ACAACCTCTC ATACCTTGTG GACCTAATTT TGTGTGCGTG	60<br>
TGTGTGTGCG CGCATATTAT ATAGACAGGC ACATCTTTTT TACTTTTGTA AAAGCTTATG	120<br>
CCTCTTTGGT ATCTATATCT GTGAAAGTTT TAATGATCTG CCATAATGTC TTGGGGACCT	180<br>
TTGTCTTCTG TGTAAATGGT ACTAGAGAAA ACACCTATNT TATGAGTCAA TCTAGTTNGT	240<br>
TTTATTCGAC ATGAAGGAAA TTTCCAGATN ACAACACTNA CAAACTCTCC CTTGACTAGG	300<br>
GGGGACAAAG AAAAGCANAA CTGAACATNA GAAACAATTN CCTGGTGAGA AATTNCATAA	360<br>
ACAGAAATTG GGTNGTATAT TGAAANANNG CATCATTNAA ACGTTTTTTT TTT	413<br>
(2) INFORMATION FOR SEQ ID NO:88:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 448 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE; DESCRIPTION: SEQ ID NO:88:<br>
CGCAGCGGGT CCTCTCTATC TAGCTCCAGC CTCTCGCCTG CCCCACTCCC CGCGTCCCGC	60<br>
GTCCTAGCCN ACCATGGCCG GGCCCCTGCG CGCCCCGCTG CTCCTGCTGG CCATCCTGGC	120<br>
CGTGGCCCTG GCCGTGAGCC CCGCGGCCGG CTCCAGTCCC GGCAAGCCGC CGCGCCTGGT	180<br>
GGGAGGCCCA TGGACCCCGC GTGGAAGAAG AAGGTGTGCG GCGTGCACTG GACTTTGCCG	240<br>
TCGGCNANTA CAACAAACCC GCAACNACTT TTACCNAGCN CGCGCTGCAG GTTGTGCCGC	300<br>
CCCAANCAAA TTGTTACTNG GGGTAANTAA TTCTTGGAAG TTGAACCTGG GCCAAACNNG	360<br>
TTTACCAGAA CCNAGCCAAT TNGAACAATT NCCCCTCCAT AACAGCCCCT TTTAAAAAGG	420<br>
GAANCANTCC TGNTCTTTTC CAAATTTT	448<br>
(2) INFORMATION FOR SEQ ID NO:89:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 463 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:<br>
GAATTTTGTG CACTGGCCAC TGTGATGGAA CCATTGGGCC AGGATGCTTT GAGTTTATCA	60<br>
GTAGTGATTC TGCCAAAGTT GGTGTTGTAA CATGAGTATG TAAAATGTCA AAAAATTAGC	120<br>
AGAGGTCTAG GTCTGCATAT CAGCAGACAG TTTGTCCGTG TATTTTGTAG CCTTGAAGTT	180<br>
CTCAGTGACA AGTTNNTTCT GATGCGAAGT TCTNATTCCA GTGTTTTAGT CCTTTGCATC	240<br>
TTTNATGTTN AGACTTGCCT CTNTNAAATT GCTTTTGTNT TCTGCAGGTA CTATCTGTGG	300<br>
TTTAACAAAA TAGAANNACT TCTCTGCTTN GAANATTTGA ATATCTTACA TCTNAAAATN	360<br>
AATTCTCTCC CCATANNAAA ACCCANGCCC TTGGGANAAT TTGAAAAANG GNTCCTTCNN	420<br>
AATTCNNANA ANTTCAGNTN TCATACAACA NAACNGGANC CCC	463<br>
(2) INFORMATION FOR SEQ ID NO:90:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 400 base pairs !B) TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:<br>
AGGGATTGAA GGTCTNTTNT ACTGTCGGAC TGTTCANCCA CCAACTCTAC AAGTTGCTGT	60<br>
CTTCCACTCA CTGTCTGTAA GCNTNTTAAC CCAGACTGTA TCTTCATAAA TAGAACAAAT	120<br>
TCTTCACCAG TCACATCTTC TAGGACCTTT TTGGATTCAG TTAGTATAAG CTCTTCCACT	180<br>
TCCTTTGTTA AGACTTCATC TGGTAAAGTC TTAAGTTTTG TAGAAAGGAA TTTAATTGCT	240<br>
CGTTCTCTAA CAATGTCCTC TCCTTGAAGT ATTTGGCTGA ACAACCCACC TNAAGTCCCT	300<br>
TTGTGCATCC ATTTTAAATA TACTTAATAG GGCATTGGTN CACTAGGTTA AATTCTGCAA	360<br>
GAGTCATCTG TCTGCAAAAG TTGCGTTAGT ATATCTGCCA	400<br>
(2) INFORMATION FOR SEQ ID NO:91:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 480 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE; TYPE: CDNA<br>
(vi) ORIGINAL, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:<br>
GAGCTCGGAT CCAATAATCT TTGTCTGAGG	GCAGCACACA TATNCAGTGC	CATGGNAACT	60<br>
GGTCTACCCC ACATGGGAGC AGCATGCCGT	AGNTATATAA GGTCATTCCC	TGAGTCAGAC	120<br>
ATGCCTCTTT GACTACCGTG TGCCAGTGCT	GGTGATTCTC ACACACCTCC	NNCCGCTCTT	180<br>
TGTGG.AAAAA CTGGCACTTG NCTGGAACTA	GCAAGACATC ACTTACAAAT	TCACCCACGA	240<br>
GACACTTGAA AGGTGTAACA AAGCGACTCT	TGCATTGCTT TTTGTCCCTC	CGGCACCAGT	300<br>
TGTCAATACT AACCCGCTGG TTTGCCTCCA	TCACATTTGT GATCTGTAGC	TCTGGATACA	360<br>
TCTCCTGACA GTACTGAAGA ACTTCTTCTT	TTGTTTCAAA AGCAACTCTT	GGTGCCTGTT	420<br>
NGATCAGGTT CCCATTTCCC AGTCCGAATG	TTCACATGGC ATATNTTACT	TCCCACAAAA	480<br>
(2) INFORMATION FOR SEQ ID NO.-92:<br>
(i) SEQUENCE CHARACTERISTICS;<br>
(A)	LENGTH: 477 base pa:.rs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vii ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:<br><br>
ATACAGCCCA NATCCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT	60<br>
GGTCCCGCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCCTT	120<br>
CCCACGCAGG CAGCAGCGGG GCCGGTCAAT GAACTCCACT CGTGGCTTGG GGTTGACGGT	180<br>
TAANTGCAGG AAGAG3CTGA CCACCTCGCG GTCCACCAGG ATGCCCGACT GTGCGGGACC	240<br>
TGCAGCGAAA CTCCTCGATG GTCATGAGCG GGAAGCGAAT GANGCCCAGG GCCTTGCCCA	300<br>
GAACCTTCCG CCTGTTCTCT GGCGTCACCT GCAGCTGCTG CCGCTNACAC TCGGCCTCGG	360<br>
ACCAGCGGAC AAACGGCGTT GAACAGCCGC ACCTCACGGA TGCCCANTGT GTCGCGCTCC	420<br>
AG;GAACGGCN CCAGCGTGTC CAGGTCAATG TCGGTGAANC CTCCGCGGGT AATGGCG	477<br>
(2) INFORMATION FOR SEQ ID NO:93: (I) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 377 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i} MOLECULE; TYPE : CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(XI) SEQUENCE DESCRIPTION: SEQ ID NO:93:<br>
GAACGGCTGG ACCTTGCCTC	GCATTGTGCT GCTGGCAGGA ATACCTTGGC AAGCAGCTCC	60<br>
AGTCCGAGCA GCCCCAGACC	GCTGCCGCCC GAAGCTAAGC CTGCCTCTGG CCTTCCCCTC	120<br>
CGCCTCAATG CAGAACCANT	AGTGGGAGCA CTGTGTTTAG AGTTAAGAGT GAACACTGTN	180<br>
TGATTTTACT TGGGAATTTC	CTCTGTTATA TAGCTTTTCC CAATGCTAAT TTCCAAACAA	240<br>
CAACAACAAA ATAACATGTT	TGCCTGTTNA GTTGTATAAA AGTANGTGAT TCTGTATNTA	300<br>
AAGAAAATAT TACTGn'TACA TATACTGCTT GCAANTTCTG TATTTATTGG TNCTCTGGAA	360<br>
ATAAATATAT TATTAAA	377<br>
(21 INFORMATION FOR SEQ ID NO:94:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A) LENGTH: 495 base pairs IB) TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ll) MOLECULE: TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
Ui) SEQUENCE DESCRIPTION: SEQ ID NO:94:<br>
CCCTTTGAGG GGTTAGGGTC CAGTTCCCAG TGGAAGAAAC AGGCCAGGAG AANTGCGTGC	60<br>
CGAGCTGANG CAGATTTCCC ACAGTGACCC CAGAGCCCTG GGCTATAGTC TCTGACCCCT	120<br>
CCAAGGAAAG ACCACCTTCT GGGGACATGG GCTGGAGGGC AGGACCTAGA GGCACCAAGG	180<br>
GAAGGCCCCA TTCCGGGGCT GTTCCCCGAG GAGGAAGGGA AGGGGCTCTG TGTGCCCCCC	240<br>
ACGAGGAANA GGCCCT'GANT CCTGGGATCA NACACCCCTT CACGTGTATC CCCACACAAA	300<br>
TGCAAGCTCA CCAAGC-TCCC CTCTCAGTCC CTTCCCTACA CCCTGAACGG NCACTGGCCC	360<br>
ACACCCACCC AGANCANCCA CCCGCCATGG GGAATGTNCT CAAGGAATCG CNGGGCAACG	420<br>
TGGACTCTNG TCCCNNAAGG GGGCAGAATC TCCAATAGAN GGANNGAACC CTTGCTNANA	480<br>
AAAAAAAANA AAAAA	495<br>
(2! INFORMATION FOR SEQ ID NO:95: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 472 base pairs<br>
(B)	TYPE: nucleic acid<br>
!C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(VI) ORIGINAL, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:<br>
GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT TTGTCTGCTC	60<br>
CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT GCTGAATTTT	120<br>
TAGCTGTTTT GAGTTGATTC GCACCACTGC ACCACAACTC AATATGAAAA CTATTTNACT	180<br>
TATTTATTAT CTTGTGAAAA GTATACAATG AAAATTTTGT TCATACTGTA TTTATCAAGT	240<br>
ATGATGAAAA GCAATAGATA TATATTCTTT TATTATGTTN AATTATGATT GCCATTATTA	300<br>
ATCGGCAAAA TGTGGAGTGT ATGTTCTTTT CACAGTAATA TATGCCTTTT GTAACTTCAC	360<br>
TTGGTTATTT TATTGTAAAT GAATTACAAA ATTCTTAATT TAAGAAAATG GTANGTTATA	420<br>
TTTANTTCAN TAATTTCTTT CCTTGTTTAC GTTAATTTTG AAAAGAATGC AT	472<br>
(2) INFORMATION FOR SEQ ID NO:96:<br>
d) SEQUENCE: CHARACTERISTICS:<br>
(A)	LENGTH: 476 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: 1inear<br>
fli) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:<br>
CTGAAGCATT TCTTCAAACT TMTCTACTTT TGTCATTGAT ACCTGTAGTA AGTTGACAAT	60<br>
GTGGTGAAAT TTCAAAATTA TATGTAACTT CTACTAGTTT TACTTTCTCC CCCAAGTCTT	120<br>
TTTTAACTCA TGATTTTTAC ACACACAATC CAGAACTTAT TATATAGCCT CTAAGTCTTT	180<br>
ATTCTTCACA GTAGATGATG AAAGAGTCCT CCAGTGTCTT GNGCANAATG TTCTAGNTAT	240<br>
AGCTGGATAC ATACNGTGGG AGTTCTATAA ACTCATACCT CAGTGGGACT NAACCAAAAT	300<br>
TGTGTTAGTC TCAATTCCTA CCACACTGAG GGAGCCTCCC AAATCACTAT ATTCTTATCT	360<br>
GCAGGTACTC CTCCAGAAAA ACNGACAGGG CAGGCTTGCA TGAAAAAGTN ACATCTGCGT	420<br>
TACAAAGTCT ATCTTCCTCA NANGTCTGTN AAGGAACAAT TTAATCTTCT AGCTTT	476<br>
(2) INFORMATION FOR SEQ ID NO:97:<br>
(i; SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 479 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(0) TOPOLOGY: linear<br>
(ill MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><xi sequence description: seq id no:97: actctttcta atgctgatat gatcttgagt ataagaatgc atatgtcact agaatggata></xi><br>
AAATAATGCT GCAAACTTAA TGTTCTTATG CAAAATGGAA CGCTAATGAA ACACAGCTTA	120<br>
CAATCGCAAA TCAAAACTCA CAAGTGCTCA TCTGTTGTAG ATTTAGTGTA ATAAGACTTA	180<br>
GATTGTGCTC CTTCGGATAT GATTGTTTCT CANATCTTGG GCAATNTTCC TTAGTCAAAT	240<br>
CAGGCTACTA GAATTCTGTT ATTGGATATN TGAGAGCATG AAATTTTTAA NAATACACTT	300<br>
GTGATTATNA AATTAATCAC AAATTTCACT TATACCTGCT ATCAGCAGCT AGAAAAACAT	360<br>
NTNNTTTTTA NATCAAAGTA TTTTGTGTTT GGAANTGTNN AAATGAAATC TGAATGTGGG	420<br>
TTCNATCTTA TTTTTTCCCN GACNACTANT TNCTTTTTTA GGGNCTATTC TGANCCATC	479<br>
(2) INFORMATION FOR SEQ ID NO:98:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 461 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE: DESCRIPTION: SEQ ID NO:98:<br>
AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCACTGACA ATCAGACCTA	60<br>
TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA	120<br>
TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA	180<br>
AGTGATTCAG TTTCCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA	240<br>
TGAAGCCACT CTGAACACGC TGGTTATCTA GATGAGAACA GAGAAATAAA GTCAGAAAAT	300<br>
TTACCTGGAG AAAAGAGGCT TTGGCTGGGG ACCATCCCAT TGAACCTTCT CTTAAGGACT	360<br>
TTAAGAAAAA CTACCACATG TTGTGTATCC TGGTGCCGGC CGTTTATGAA CTGACCACCC	420<br>
TTTGGAATAA TCTTGACGCT CCTGAACTTG CTCCTCTGCG A	461<br>
(2) INFORMATION FOR SEQ ID NO:99:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 171 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(il) MOLECULE TYPE: CDNA<br>
(v1) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:<br>
GTGGCCGCGC GCAGGTGTTT CCTCGTACCG CAGGGCCCCC TCCCTTCCCC AGGCGTCCCT 60<br>
CGGCGCCTCT GCGGGCCCGA GGAGGAGCGG CTGGCGGGTG GGGGGAGTGT GACCCACCCT 120<br>
CGGTGAGAAA AGCCTTCTCT AGCGATCTGA GAGGCGTGCC TTGGGGGTAC C	171<br>
(2)  INFORMATION FOR SEQ ID NO:100:<br>
(l) SEQUENCE CHAPJVCTERISTICS:<br>
(A)	LENGTH: 269 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br><br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:<br>
CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC	60<br>
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC	120<br>
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA	180<br>
CAGCCGGAAC AGAGCCCGGT GAAGCGGGAG GCCTCGGGGA GCCCCTCGGG AAGGGCGGCC	240<br>
CGAGAGATAC GCAGGTGCAG GTGGCCGCC	269<br>
(2) INFORMATION FOR SEQ ID NO:101:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 405 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:<br>
TTTTTTTTTT TTTTGGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA	60<br>
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTCAG GTCAACTTCC TTTGTCGTGG	120<br>
TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAACGAAGCA AATAACATGG	180<br>
AGTGGGTGCA CCCTCCCTGT AGAACCTGGT TACAAAGCTT GGGGCAGTTC ACCTGGTCTG	240<br>
TGACCGTCAT TTTCTTGACA TCAATGTTAT TAGAAGTCAG GATATCTTTT AGAGAGTCCA	300<br>
CTGTTCTGGA GGGAGATTAG GGTTTCTTGC CAAATCCAAC AAAATCCACT GAAAAAGTTG	360<br>
GATGATCAGT ACGAATACCG AGGCATATTC TCATATCGGT GGCCA	405<br>
(2) INFORMATION FOR SEQ ID NO:102:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 470 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) OPIGINA1, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:<br>
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT	60<br>
GGCACTTAAT CCATTTTTAT TTCAAAATGT CTACAAATTT AATCCCATTA TACGGTATTT	120<br>
TCAAAATCTA AATTATTCAA ATTAGCCAAA TCCTTACCAA ATAATACCCA AAAATCAAAA	180<br>
ATATACTTCT TTCAGCAAAC TTGTTACATA AATTAAAAAA ATATATACGG CTGGTGTTTT	240<br>
CAAAGTACAA TTATCTTAAC ACTGCAAACA TTTTAAGGAA CTAAAATAAA AAAAAACACT	300<br>
CCGCAAAGGT TAAAGGGAAC AACAAATTCT TTTACAACAC CATTATAAAA ATCATATCTC	360<br>
AAATCTTAGG GGAATATATA CTTCACACGG GATCTTAACT TTTACTCACT TTGTTTATTT	420<br>
TTTTAAACCA TTGTTTGGGC CCAACACAAT GGAATCCCCC CTGGACTAGT	470<br>
(2) INFORMATION FOR SEQ ID N0:103: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 581 base pairs<br>
iB)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:<br>
TTTTTTTTTT TTTTTTTTGA CCCCCCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT	60<br>
TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC	120<br>
TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT	180<br>
GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTTGACT CTTGTAAAAC ATCCAAATTC	240<br>
ATTTTTCTTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT	300<br>
GCTTCTCTAG CCTCATTTCC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA	360<br>
AGGGAAAACA GGAAGAGAAA TGGCACACAA AACAAACATT TTATATTCAT ATTTCTACCT	420<br>
ACGTTAATAA AATAGCATTT TGTGAAGCCA GCTCAAAAGA AGGCTTAGAT CCTTTTATGT	480<br>
CCATTTTAGT CACTAAACGA TATCAAAGTG CCAGAATGCA AAAGGTTTGT GAACATTTAT	540<br>
TCAAAAGCTA ATATAAGATA TTTCACATAC TCATCTTTCT G	581<br>
(2) INFORMATION FOR SEQ ID NO:104:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 578 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:<br>
TTTTTTTTTT TTTTTTTTTT TTTTTCTCTT CTTTTTTTTT GAAATGAGGA TCGAGTTTTT	60<br>
CACTCTCTAG ATAGGGCATG AAGAAAACTC ATCTTTCCAG CTTTAAAATA ACAATCAAAT	120<br>
CTCTTATGCT ATATCATATT TTAAGTTAAA CTAATGAGTC ACTGGCTTAT CTTCTCCTGA	180<br>
AGGAAATCTG TTCATTCTTC TCATTCATAT AGTTATATCA AGTACTACCT TGCATATTGA	240<br>
GAGGTTTTTC TTCTCTATTT ACACATATAT TTCCATGTGA ATTTGTATCA AACCTTTATT	300<br>
TTCATGCAAA CTAGAAAATA ATGTTTCTTT TGCATAAGAG AAGAGAACAA TATAGCATTA	360<br>
CAAAACTGCT CAAATTGTTT GTTAAGTTAT CCATTATAAT TAGTTGGCAG GAGCTAATAC	420<br>
AAATCACATT TACGACAGCA ATAATAAAAC TGAAGTACCA GTTAAATATC CAAAATAATT	480<br>
AAAGGAACAT TTTTAGCCTG GGTATAATTA GCTAATTCAC TTTACAAGCA TTTATTAGAA	540<br>
TGAATTCACA TGTTATTATT CCTAGCCCAA CACAATGG	578<br>
(2) INFORMATION FOR SEQ ID NO:105:<br>
(ii SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 538 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(il) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:<br>
TTTTTTTTTT TTTTTCAGTA ATAATCAGAA CAATATTTAT TTTTATATTT AAAATTCATA	60<br>
GAAAAGTGCC TTACATTTAA TAAAAGTTTG TTTCTCAAAG TGATCAGAGG AATTAGATAT	120<br>
GTCTTGAACA CCAATATTAA TTTGAGGAAA ATACACCAAA ATACATTAAG TAAATTATTT	180<br>
AAGATCATAG AGCTTGTAAG TGAAAAGATA AAATTTGACC TCAGAAACTC TGAGCATTAA	240<br>
AAATCCACTA TTAGCAAATA AATTACTATG GACTTCTTGC TTTAATTTTG TGATGAATAT	300<br>
GGGGTGTCAC TGGTAAACCA ACACATTCTG AAGGATACAT TACTTAGTGA TAGATTCTTA	360<br>
TGTACTTTGC TAATACGTGG ATATGAGTTG ACAAGTTTCT CTTTCTTCAA TCTTTTAAGG	420<br>
GGCGAGAAAT GAGGAAGAAA AGAAAAGGAT TACGCATACT GTTCTTTCTA TGGAAGGATT	480<br>
AGATATGTTT CCTTTGCCAA TATTAAAAAA ATAATAATGT TTACTACTAG TGAAACCC	538<br>
(2) INFORMATION FOR SEQ ID NO:106:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 473 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE: DESCRIPTION.- SEQ ID NO:io6:<br>
TTTTTTTTTT TTTTTTAGTC AAGTTTCTAT TTTTATTATA ATTAAAGTCT TGGTCATTTC	60<br>
ATTTATTAGC TCTGCAACTT ACATATTTAA ATTAAAGAAA CGTTTTAGAC AACTGTACAA	120<br>
TTTATAAATG TAAGGTGCCA TTATTGAGTA ATATATTCCT CCAAGAGTGG ATGTGTCCCT	180<br>
TCTCCCACCA ACTAATGAAC AGCAACATTA GTTTAATTTT ATTAGTAGAT ATACACTGCT	240<br>
GCAAACGCTA ATTCTCTTCT CCATCCCCAT GTGATATTGT GTATATGTGT GAGTTGGTAG	300<br>
AATGCATCAC AATCTACAAT CAACAGCAAG ATGAAGCTAG GCTGGGCTTT CGGTGAAAAT	360<br>
AGACTGTGTC TGTCTGAATC AAATGATCTG ACCTATCCTC GGTGGCAAGA ACTCTTCGAA	420<br>
CCGCTTCCTC AAAGGCGCTG CCACATTTGT GGCTCTTTGC ACTTGTTTCA AAA	473<br>
(2) INFORMATION FOR SEQ ID NO:107:<br>
(i) SEQUENCE CHARACTERISTICS;<br>
(A)	LENGTH: 1621 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vii ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE: DESCRIPTION: SEQ ID NO:io7:<br>
CGCCATGGCA CTGCAGGGCA TCTCGGTCAT GGAGCTGTCC GGCCTGGCCC CGGGCCCGTT	60<br>
CTGTGCTATG GTCCTGGCTG ACTTCGGGGC GCGTGTGGTA CGCGTGGACC GGCCCGGCTC	120<br>
CCGCTACGAC GTGAGCCGCT TGGGCCGGGG CAAGCGCTCG CTAGTGCTGG ACCTGAAGCA	180<br>
GCCGCGGGGA GCCGCCGTGC TGCGGCGTCT GTGCAAGCGG TCGGATGTGC TGCTGGAGCC	240<br>
CTTCCGCCGC GGTGTCATGG AGAAACTCCA GCTGGGCCCA GAGATTCTGC AGCGGGAAAA	300<br>
TCCAAGGCTT ATTTATGCCA GGCTGAGTGG ATTTGGCCAG TCAGGAAGCT TCTGCCGGTT	360<br>
AGCTGGCCAC GATATCAACT ATTTGGCTTT GTCAGGTGTT CTCTCAAAAA TTGGCAGAAG	420<br>
TGGTGAGAAT CCGTATGCCC CGCTGAATCT CCTGGCTGAC TTTGCTGGTG GTGGCCTTAT	480<br>
GTGTGCACTG GGCATTATAA TGGCTCTTTT TGACCGCACA CGCACTGACA AGGGTCAGGT	540<br><br>
CATTGATGCA AATATGGTGG AAGGAACAGC ATATTTAAGT TCTTTTCTGT GGAAAACTCA	600<br>
GAAATCGAGT CTGTGGGAAG CACCTCGAGG ACAGAACATG TTGGATGGTG GAGCACCTTT	660<br>
CTATACGACT TACAGGACAG CAGATGGGGA ATTCATGGCT GTTGGAGCAA TAGAACCCCA	720<br>
GTTCTACGAG CTGCTGATCA AAGGACTTGG ACTAAAGTCT GATGAACTTC CCAATCAGAT	780<br>
GAGCATGGAT GATTGGCCAG AAATGAAGAA GAAGTTTGCA GATGTATTTG CAAAGAAGAC	840<br>
GAAGGCAGAG TGGTGTCAAA TCTTTGACGG CACAGATGCC TGTGTGACTC CGGTTCTGAC	900<br>
TTTTGAGGAG GTTGTTCATC ATGATCACAA CAAGGAACGG GGCTCGTTTA TCACCAGTGA	960<br>
GGAGCAGGAC GTGAGCCCCC GCCCTGCACC TCTGCTGTTA AACACCCCAG CCATCCCTTC	1020<br>
TTTCAAAAGG GATCCTTTCA TAGGAGAACA CACTGAGGAG ATACTTGAAG AATTTGGATT	1080<br>
CAGCCGCGAA GAGATTTATC AGCTTAACTC AGATAAAATC ATTGAAAGTA ATAAGGTAAA	1140<br>
AGCTAGTCTC TAACTTCCAG GCCCACGGCT CAAGTGAATT TGAATACTGC ATTTACAGTG	1200<br>
TAGAGTAACA CATAACATTG TATGCATGGA AACATGGAGG AACAGTATTA CAGTGTCCTA	1260<br>
CCACTCTAAT CAAGAAAAGA ATTACAGACT CTGATTCTAC AGTGATGATT GAATTCTAAA	1320<br>
AATGGTTATC ATTAGGGCTT TTGATTTATA AAACTTTGGG TACTTATACT AAATTATGGT	1380<br>
AGTTATTCTG CCTTCCAGTT TGCTTGATAT ATTTGTTGAT ATTAAGATTC TTGACTTATA	1440<br>
TTTTGAATGG GTTCTAGTGA AAAAGGAATG ATATATTCTT GAAGACATCG ATATACATTT	1500<br>
ATTTACACTC TTGATTCTAC AATGTAGAAA ATGAGGAAAT GCCACAAATT GTATGGTGAT	1560<br>
AAAAGTCACG TGAAACAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1620<br>
A	1621<br>
(2) INFORMATION FOR SEQ ID NO:108:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 382 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:<br>
Met Ala Leu Gin Gly lie Ser Val Met Glu Leu Ser Gly Leu Ala Pro<br>
15	10	15<br>
Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val<br>
20	25	30<br>
Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg<br>
35	40	45<br>
Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gin Pro Arg Gly Ala Ala<br>
50	55	60<br>
Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe<br>
65	70	75	80<br>
Arg Arg Gly Val Met Glu Lys Leu Gin Leu Gly Pro Glu lie Leu Gin<br>
85	90	95<br>
Arg Glu Asn Pro Arg Leu lie Tyr Ala Arg Leu Ser Gly Phe Gly Gin<br>
100	105	110<br>
Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp lie Asn Tyr Leu Ala<br>
115	120	125<br>
Leu Ser Gly Val Leu Ser Lys lie Gly Arg Ser Gly Glu Asn Pro Tyr<br>
130	135	140<br>
Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Gly Leu Met Cys<br>
145	150	155	160<br>
Ala Leu Gly lie lie Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys<br>
165	170	175<br>
Gly Gin Val lie Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser<br>
180	185	190<br>
Ser Phe Leu Trp Lys Thr Gin Lys Ser Ser Leu Trp Glu Ala Pro Arg<br>
195	200	205<br><br>
Gly Gin Asn Met: Leu Asp Gly Gly Ala Pro Phe Tyr Thr Thr Tyr Arg<br>
210	215	220<br>
Thr Ala Asp Gly Glu Phe Met Ala Val Gly Ala He Glu Pro Gin Phe<br>
225	230	235	240<br>
Tyr Glu Leu Leu lie Lys Gly Leu Gly Leu Lys Ser Asp Glu Leu Pro<br>
245	250	255<br>
Asn Gin Met: Ser Met Asp Asp Trp Pro Glu Met Lys Lys Lys Phe Ala<br>
260	265	270<br>
Asp Val Phe Ala Lys Lys Thr Lys Ala Glu Trp Cys Gin He Phe Asp<br>
275	280	285<br>
Gly Thr Asp Ala Cys Val Thr Pro Val Leu Thr Phe Glu Glu Val Val<br>
290	295	300<br>
His   His   Asp  His  Asn  Lys  Glu  Arg  Gly  Ser  Phe   lie   Thr   Ser  Glu  Glu<br>
305	310	315	320<br>
Gin   Asp  Val   Ser   Pro Arg   Pro  Ala  Pro  Leu  Leu  Leu Asn  Thr  Pro Ala<br>
325	330	335<br>
He   Pro   Ser   Phe   Lys  Arg  Asp  Pro   Phe   He  Gly  Glu  His   Thr  Glu  Glu<br>
340	345	350<br>
He   Leu   Glu   Glu   Phe  Gly  Phe   Ser Arg  Glu  Glu   He   Tyr  Gin  Leu  Asn<br>
355	360	365<br>
Ser  Asp   Lys   He   lie  Glu  Ser  Asn  Lys  Val   Lys  Ala   Ser  Leu<br>
370	375	380<br>
(2)    INFORMATION   FOR   SEQ   ID   N0:109:<br>
(i)    SEQUENCE   CHARACTERISTICS:<br>
(A)    LENGTH:    1524   base  pairs IB)   TYPE:   nucleic  acid (C)    STRANDEDNESS:   single !D)    TOPOLOGY:   linear<br>
(1i!    MOLECULE   TYPE:    CDNA<br>
!vi)    ORIGINAL   SOURCE:<br>
(A)    ORGANISM:   Homo   sapiens<br>
(xi)    SEQUENCE   DESCRIPTION:    SEQ   ID  NO:109:<br>
GGCACGAGGC  TGCGCCAGGG   CCTGAGCGGA  GGCGGGGGCA  GCCTCGCCAG  CGGGGGCCCC	60<br>
GGGCCTGGCC  ATGCCTCACT  GAGCCAGCGC  CTGCGCCTCT  ACCTCGCCGA  CAGCTGGAAC	120<br>
CAGTGCGACC   TAGTGGCTCT   CACCTGCTTC   CTCCTGGGCG   TGGGCTGCCG  GCTGACCCCG	180<br>
GGTTTGTACC  ACCTGGGCCG   CACTGTCCTC  TGCATCGACT   TCATGGTTTT  CACGGTGCGG	240<br>
CTGCTTCACA  TCTTCACGGT   CAACAAACAG  CTGGGGCCCA  AGATCGTCAT  CGTGAGCAAG	300<br>
ATGATGAAGG  ACGTGTTCTT   CTTCCTCTTC  TTCCTCGGCG  TGTGGCTGGT AGCCTATGGC	360<br>
GTGGCCACGG   AGGGGCTCCT   GAGGCCACGG   GACAGTGACT   TCCCAAGTAT   CCTGCGCCGC	420<br>
GTCTTCTACC  GTCCCTACCT  GCAGATCTTC  GGGCAGATTC   CCCAGGAGGA  CATGGACGTG	480<br>
GCCCTCATGG  AGCACAGCAA  CTGCTCGTCG  GAGCCCGGCT   TCTGGGCACA  CCCTCCTGGG	540<br>
GCCCAGGCGG  GCACCTGCGT   CTCCCAGTAT  GCCAACTGGC  TGGTGGTGCT  GCTCCTCGTC	600<br>
ATCTTCCTGC  TCGTGGCCAA  CATCCTGCTG  GTCAACTTGC   TCATTGCCAT  GTTCAGTTAC	660<br>
ACATTCGGCA  AAGTACAGGG  CAACAGCGAT  CTCTACTGGA AGGCGCAGCG  TTACCGCCTC	720<br>
ATCCGGGAAT  TCCACTCTCG  GCCCGCGCTG  GCCCCGCCCT  TTATCGTCAT  CTCCCACTTG	780<br>
CGCCTCCTGC  TCAGGCAATT  GTGCAGGCGA  CCCCGGAGCC   CCCAGCCGTC  CTCCCCGGCC	840<br>
CTCGAGCATT  TCCGGGTTTA  CCTTTCTAAG  GAAGCCGAGC  GGAAGCTGCT  AACGTGGGAA	900<br>
TCGGTGCATA AGGAGAACTT   TCTGCTGGCA  CGCGCTAGGG  ACAAGCGGGA  GAGCGACTCC	960<br>
GAGCGTCTGA  AGCGCACGTC   CCAGAAGGTG  GACTTGGCAC   TGAAACAGCT  GGGACACATC	1020<br>
CGCGAGTACG AACAGCGCCT  GAAAGTGCTG  GAGCGGGAGG  TCCAGCAGTG  TAGCCGCGTC	1080<br>
CTGGGGTGGG  TGGCCGAGGC   CCTGAGCCGC  TCTGCCTTGC   TGCCCCCAGG  TGGGCCGCCA	1140<br>
CCCCCTGACC  TGCCTGGGTC   CAAAGACTGA GCCCTGCTGG   CGGACTTCAA  GGAGAAGCCC	1200<br>
CCACAGGGGA TTTTGCTCCT  AGAGTAAGGC  TCATCTGGGC  CTCGGCCCCC  GCACCTGGTG	1260<br>
GCCTTGTCCT  TGAGGTGAGC   CCCATGTCCA  TCTGGGCCAC   TGTCAGGACC  ACCTTTGGGA	1320<br>
GTGTCATCCT  TACAAACCAC  AGCATGCCCG  GCTCCTCCCA  GAACCAGTCC  CAGCCTGGGA	1380<br><br>
GGATCAAGGC CTGGATCCCG GGCCGTTATC CATCTGGAGG CTGCAGGGTC CTTGGGGTAA	1440<br>
CAGGGACCAC AGACCCCTCA CCACTCACAG ATTCCTCACA CTGGGGAAAT AAAGCCATTT	1500<br>
CAGAGGAAAA AAAAAAAAAA AAAA	1524<br>
(2) INFORMATION FOR SEQ ID NO:110:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 3410 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi)    SEQUENCE   DESCRIPTION:    SEQ   ID   NO:110:<br>
GGGAACCAGC  CTGCACGCGC  TGGCTCCGGG  TGACAGCCGC  GCGCCTCGGC  CAGGATCTGA	60<br>
GTGATGAGAC  GTGTCCCCAC   TGAGGTGCCC   CACAGCAGCA  GGTGTTGAGC ATGGGCTGAG	120<br>
AAGCTGGACC  GGCACCAAAG  GGCTGGCAGA AATGGGCGCC  TGGCTGATTC  CTAGGCAGTT	180<br>
GGCGGCAGCA AGGAGGAGAG  GCCGCAGCTT   CTGGAGCAGA  GCCGAGACGA AGCAGTTCTG	240<br>
GAGTGCCTGA ACGGCCCCCT  GAGCCCTACC  CGCCTGGCCC  ACTATGGTCC AGAGGCTGTG	300<br>
GGTGAGCCGC   CTGCTGCGGC  ACCGGAAAGC  CCAGCTCTTG   CTGGTCAACC  TGCTAACCTT	360<br>
TGGCCTGGAG  GTGTGTTTGG  CCGCAGGCAT  CACCTATGTG   CCGCCTCTGC  TGCTGGAAGT	420<br>
GGGGGTAGAG  GAGAAGTTCA  TGACCATGGT  GCTGGGCATT  GGTCCAGTGC  TGGGCCTGGT	480<br>
CTGTGTCCCG  CTCCTAGGCT  CAGCCAGTGA  CCACTGGCGT  GGACGCTATG GCCGCCGCCG	540<br>
GCCCTTCATC  TGGGCACTGT   CCTTGGGCAT  CCTGCTGAGC   CTCTTTCTCA TCCCAAGGGC	600<br>
CGGCTGGCTA  GCAGGGCTGC  TGTGCCCGGA  TCCCAGGCCC   CTGGAGCTGG  CACTGCTCAT	660<br>
CCTGGGCGTG  GGGCTGCTGG  ACTTCTGTGG  CCAGGTGTGC  TTCACTCCAC  TGGAGGCCCT	720<br>
GCTCTCTGAC  CTCTTCCGGG  ACCCGGACCA  CTGTCGCCAG   GCCTACTCTG  TCTATGCCTT	780<br>
CATGATCAGT  CTTGGGGGCT  GCCTGGGCTA CCTCCTGCCT  GCCATTGACT  GGGACACCAG	840<br>
TGCCCTGGCC  CCCTACCTGG  GCACCCAGGA GGAGTGCCTC  TTTGGCCTGC  TCACCCTCAT	900<br>
CTTCCTCACC  TGCGTAGCAG  CCACACTGCT  GGTGGCTGAG  GAGGCAGCGC  TGGGCCCCAC	960<br>
CGAGCCAGCA GAAGGGCTGT   CGGCCCCCTC   CTTGTCGCCC   CACTGCTGTC  CATGCCGGGC	1020<br>
CCGCTTGGCT  TTCCGGAACC  TGGGCGCCCT  GCTTCCCCGG   CTGCACCAGC  TGTGCTGCCG	1080<br>
CATGCCCCGC  ACCCTGCGCC  GGCTCTTCGT  GGCTGAGCTG  TGCAGCTGGA  TGGCACTCAT	1140<br>
GACCTTCACG  CTGTTTTACA  CGGATTTCGT  GGGCGAGGGG  CTGTACCAGG  GCGTGCCCAG	1200<br>
AGCTGAGCCG  GGCACCGAGG   CCCGGAGACA  CTATGATGAA  GGCGTTCGGA  TGGGCAGCCT	1260<br>
GGGGCTGTTC  CTGCAGTGCG  CCATCTCCCT  GGTCTTCTCT   CTGGTCATGG ACCGGCTGGT	1320<br>
GCAGCGATTC  GGCACTCGAG  CAGTCTATTT  GGCCAGTGTG  GCAGCTTTCC  CTGTGGCTGC	1380<br>
CGGTGCCACA  TGCCTGTCCC  ACAGTGTGGC  CGTGGTGACA  GCTTCAGCCG  CCCTCACCGG	1440<br>
GTTCACCTTC  TCAGCCCTGC  AGATCCTGCC  CTACACACTG  GCCTCCCTCT ACCACCGGGA	1500<br>
GAAGCAGGTG  TTCCTGCCCA  AATACCGAGG  GGACACTGGA  GGTGCTAGCA GTGAGGACAG	1560<br>
CCTGATGACC AGCTTCCTGC  CAGGCCCTAA GCCTGGAGCT  CCCTTCCCTA ATGGACACGT	1620<br>
GGGTGCTGGA  GGCAGTGGCC  TGCTCCCACC  TCCACCCGCG   CTCTGCGGGG  CCTCTGCCTG	1680<br>
TGATGTCTCC  GTACGTGTGG  TGGTGGGTGA  GCCCACCGAG  GCCAGGGTGG  TTCCGGGCCG	1740<br>
GGGCATCTGC  CTGGACCTCG   CCATCCTGGA  TAGTGCCTTC   CTGCTGTCCC  AGGTGGCCCC	1800<br>
ATCCCTGTTT ATGGGCTCCA  TTGTCCAGCT  CAGCCAGTCT   GTCACTGCCT  ATATGGTGTC	1860<br>
TGCCGCAGGC  CTGGGTCTGG   TCGCCATTTA  CTTTGCTACA  CAGGTAGTAT  TTGACAAGAG	1920<br>
CGACTTGGCC  AAATACTCAG   CGTAGAAAAC  TTCCAGCACA  TTGGGGTGGA  GGGCCTGCCT	1980<br>
CACTGGGTCC  CAGCTCCCCG  CTCCTGTTAG  CCCCATGGGG  CTGCCGGGCT  GGCCGCCAGT	2040<br>
TTCTGTTGCT  GCCAAAGTAA  TGTGGCTCTC  TGCTGCCACC   CTGTGCTGCT  GAGGTGCGTA	2100<br>
GCTGCACAGC TGGGGGCTGG  GGCGTCCCTC  TCCTCTCTCC   CCAGTCTCTA GGGCTGCCTG	2160<br>
ACTGGAGGCC  TTCCAAGGGG  GTTTCAGTCT  GGACTTATAC  AGGGAGGCCA GAAGGGCTCC	2220<br>
ATGCACTGGA ATGCGGGGAC  TCTGCAGGTG  GATTACCCAG  GCTCAGGGTT AACAGCTAGC	2280<br>
CTCCTAGTTG AGACACACCT  AGAGAAGGGT  TTTTGGGAGC  TGAATAAACT  CAGTCACCTG	2340<br>
GTTTCCCATC  TCTAAGCCCC  TTAACCTGCA GCTTCGTTTA ATGTAGCTCT  TGCATGGGAG	2400<br>
TTTCTAGGAT  GAAACACTCC   TCCATGGGAT  TTGAACATAT  GACTTATTTG  TAGGGGAAGA	2460<br>
GTCCTGAGGG  GCAACACACA  AGAACCAGGT  CCCCTCAGCC  CACAGCACTG  TCTTTTTGCT	2520<br><br>
GATCCACCCC  CCTCTTACCT  TTTATCAGGA  TGTGGCCTGT  TGGTCCTTCT  GTTGCCATCA	2580<br>
CAGAGACACA  GGCATTTAAA  TATTTAACTT  ATTTATTTAA  CAAAGTAGAA  GGGAATCCAT	2640<br>
TGCTAGCTTT   TCTGTGTTGG   TGTCTAATAT   TTGGGTAGGG   TGGGGGATCC   CCAACAATCA	2700<br>
GGTCCCCTGA  GATAGCTGGT   CATTGGGCTG  ATCATTGCCA  GAATCTTCTT  CTCCTGGGGT	2760<br>
CTGGCCCCCC  AAAATGCCTA  ACCCAGGACC  TTGGAAATTC   TACTCATCCC  AAATGATAAT	2820<br>
TCCAAATGCT  GTTACCCAAG  GTTAGGGTGT  TGAAGGAAGG  TAGAGGGTGG GGCTTCAGGT	2880<br>
CTCAACGGCT  TCCCTAACCA  CCCCTCTTCT   CTTGGCCCAG   CCTGGTTCCC  CCCACTTCCA	2940<br>
CTCCCCTCTA  CTCTCTCTAG  GACTGGGCTG  ATGAAGGCAC   TGCCCAAAAT  TTCCCCTACC	3000<br>
CCCAACTTTC  CCCTACCCCC  AACTTTCCCC  ACCAGCTCCA  CAACCCTGTT  TGGAGCTACT	3060<br>
GCAGGACCAG  AAGCACAAAG   TGCGGTTTCC   CAAGCCTTTG  TCCATCTCAG  CCCCCAGAGT	3120<br>
ATATCTGTGC  TTGGGGAATC  TCACACAGAA  ACTCAGGAGC  ACCCCCTGCC  TGAGCTAAGG	3180<br>
GAGGTCTTAT  CTCTCAGGGG   GGGTTTAAGT   3CCGTTTGCA ATAATGTCGT  CTTATTTATT	3240<br>
TAGCGGGGTG  AATATTTTAT  ACTGTAAGTG   AGCAATCAGA  GTATAATGTT  TATGGTGACA	3300<br>
AAATTAAAGG   CTTTCTTATA   TGTTTAAAAA  AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	3360<br>
AAAAAAAARA  AAAAAAAAAA   AAAAAAAAAA  AAAAAAATAA  AAAAAAAAAA	3410<br>
(2)    INFORMATION   FOR   SEQ   ID  NO:111:<br>
(l)    SEQUENCE   CliARACTERISTICS :<br>
(A)	LENGTH:   1289  base  pairs<br>
(B)	TYPE:   nucleic   acid<br>
(C)	STRANDEDNESS:   single<br>
(D)	TOPOLOGY:   lineai-<br>
di)    MOLECULK   TYPE:    cDNA<br>
(vi)    ORIGINAL   SOURCE:<br>
(A)   ORGANISM:   Homo  sapiens<br>
(xi)    SEQUENCE   DESCRIPTION:    SEQ   ID   NO:111:<br>
AGCCAGGCGT   CCCTCTGCCT   GCCCACTCAG   TGGCAACACC   CGGGAGCTGT  TTTGTCCTTT	60<br>
GTC3GAGCCTC  AGCAGTTCCC   TCTTTCAGAA  CTCACTGCCA AGAGCCCTGA ACAGGAGCCA	120<br>
CCATGCAGTG   CTTCAGCTTC  ATTAAGACCA  TGATGATCCT   CTTCAATTTG  CTCATCTTTC	180<br>
TGTGTGGTGC  AGCCCTGTTG  GCAGTGGGCA  TCTGGGTGTC  AATCGATGGG  GCATCCTTTC	240<br>
TGAAGATCTT  CGGGCCACTG  TCGTCCAGTG  CCATGCAGTT  TGTCAACGTG  GGCTACTTCC	300<br>
TCATCGCAGC   CGGCGTTGTG  GTCTTTGCTC  TTGGTTTCCT  GGGCTGCTAT  GGTGCTAAGA	360<br>
CTGAGAGCAA  GTGTGCCCTC  GTGACGTTCT  TCTTCATCCT   CCTCCTCATC  TTCATTGCTG	420<br>
AGGTTGCAGC  TGCTGTGGTC  GCCTTGGTGT  ACACCACAAT  GGCTGAGCAC  TTCCTGACGT      ,      480<br>
TGCTGGTAGT   GCCTGCCATC   AAGAAAGATT   ATGGTTCCCA   GGAAGACTTC  ACTCAAGTGT	540<br>
GGAACACCAC   CATGAAAGGG   CTCAAGTGCT   GTGGCTTCAC   CAACTATACG   GATTTTGAGG	600<br>
ACTCACCCTA  CTTCAAAGAG  AACAGTGCCT   TTCCCCCATT   CTGTTGCAAT  GACAACGTCA	660<br>
CCAACACAGC   CAATGAAACC   TGCACCAAGC  AAAAGGCTCA  CGACCAAAAA GTAGAGGGTT	720<br>
GCTTCAATCA  GCTTTTGTAT  GACATCCGAA  CTAATGCAGT   CACCGTGGGT  GGTGTGGCAG	780<br>
CTGGAATTGG  GGGCCTCGAG   CTGGCTGCCA  TGATTGTGTC   CATGTATCTG  TACTGCAATC	840<br>
TACAATAAGT   CCACTTCTGC   CTCTGCCACT  ACTGCTGCCA  CATGGGAACT  GTGAAGAGGC	900<br>
ACCCTGGCAA  GCAGCAGTGA  TTGGGGGAGG  GGACAGGATC  TAACAATGTC ACTTGGGCCA	960<br>
GAATGGACCT  GCCCTTTCTG   CTCCAGACTT  GGGGCTAGAT  AGGGACCACT  CCTTTTAGCG	1020<br>
ATGCCTGACT  TTCCTTCCAT   TGGTGGGTGG  ATGGGTGGGG  GGCATTCCAG  AGCCTCTAAG	1080<br>
GTAGCCAGTT  CTGTTGCCCA  TTCCCCCAGT  CTATTAAACC   CTTGATATGC  CCCCTAGGCC	1140<br>
TAGTGGTGAT   CCCAGTGCTC   TACTGGGGGA   TGAGAGAAAG   GCATTTTATA  GCCTGGGCAT	1200<br>
AAGTGAAATC  AGCAGAGCCT   CTGGGTGGAT  GTGTAGAAGG  CACTTCAAAA  TGCATAAACC	1260<br>
TGTTACAATG   TTAAAAAAAA   AAAAAAAAA	1289<br>
(2)    INFORMATION   FOR   SEQ   ID   NO:112:<br>
(ii    SEQUENCE   CHARACTERISTICS:<br>
(A)	LENGTH: 315 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(0) TOPOLOGY: linear<br><br>
(ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:<br>
Met. Val Phe Thr Val Arg Leu Leu His He Phe Thr Val Asn Lys Gin<br>
15	10	15<br>
Leu Gly Pro Lys lie Val He Val Ser Lys Met Met Lys Asp Val Phe<br>
20	25	30<br>
Plie; Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr Gly Val Ala<br>
35	40	45<br>
Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro Ser He Leu<br>
50	55	60<br>
Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gin He Phe Gly Gin He Pro<br>
65	70	75	80<br>
Gin GJu Asp Met Asp Val Ala Leu Met Glu His Ser Asn Cys Ser Ser<br>
85	90	95<br>
Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gin Ala Gly Thr Cys<br>
100	105	110<br>
Va] Ser Gin Tyr Ala Asn Trp Leu Val Val Leu Leu Leu Val He Phe<br>
115	120	125<br>
Leu Leu Va L Ala Asn He Leu Leu Val Asn Leu Leu He Ala Met Phe<br>
130	135	140<br>
Ser Tyr Thr Phe Gly Lys Val Gin Gly Asn Ser Asp Leu Tyr Trp Lys<br>
145	150	155	160<br>
Ala Gin Arg Tyr Arg Leu lie Arg Glu Phe His Ser Arg Pro Ala Leu<br>
365	170	175<br>
Ala Pro Pro Phe He Val He Ser His Leu Arg Leu Leu Leu Arg Gin<br>
180	185	190<br>
Leu Cys Arg Arg Pro Arg Ser Pro Gin Pro Ser Ser Pro Ala Leu Glu<br>
195	200	205<br>
His Phe Ary Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr<br>
210	215	220<br>
Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp<br>
225	230	235	240<br>
Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gin Lys Val<br>
245	250	255<br>
Asp Leu Ala Leu Lys Gin Leu Gly His He Arg Glu Tyr Glu Gin Arg<br>
260	265	270<br>
Leu Lys Val Leu Glu Arg Glu Val Gin Gin Cys Ser Arg Val Leu Gly<br>
275	280	285<br><br>
Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly<br>
290	295	300<br>
Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp<br>
305	310	315<br>
(2) INFORMATION FOR SEQ ID NO:113:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 553 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
!D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(vij ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:<br>
Met Val Gin Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala<br>
.1	5	10	15<br>
Gin Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu<br>
20	25	30<br>
Ala Ala Gly lie Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val<br>
35	40	45<br>
Glu Glu Lys Phe Met Thr Met Val Leu Gly lie Gly Pro Val Leu Gly<br>
50	55	60<br>
Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly<br>
65	70	75	80<br>
Arg Tyr Gly Arg Arg Arg Pro Phe lie Trp Ala Leu Ser Leu Gly lie<br>
85	90	95<br>
lieu Leu Ser Leu Phe Leu lie Pro Arg Ala Gly Trp Leu Ala Gly Leu<br>
100	105	110<br>
Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu lie Leu Gly<br>
115	120	125<br>
Val Gly Leu Leu Asp Phe Cys Gly Gin Val Cys Phe Thr Pro Leu Glu<br>
130	135	140<br>
Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gin Ala<br>
145	150	155	160<br>
Tyr Ser Val Tyr Ala Phe Met lie Ser Leu Gly Gly Cys Leu Gly Tyr<br>
165	170	175<br>
Leu Leu Pro Ala He Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu<br>
180	185	190<br>
G]y Thr Gin Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu lie Phe Leu<br>
19 f i	200	205<br><br>
Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly<br>
210	215	220<br>
Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His<br>
225	230	235	240<br>
Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu<br>
245	250	255<br>
Leu Pro Arg Leu His Gin Leu Cys Cys Arg Met Pro Arg Thr Leu Arg<br>
260	265	270<br>
Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe<br>
275	280	285<br>
Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gin Gly Val<br>
290	295	300<br>
Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly<br>
305	310	315	320<br>
Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gin Cys Ala lie Ser Leu<br>
325	330	335<br>
Val Phe Ser Leu Val Met Asp Arg Leu Val Gin Arg Phe Gly Thr Arg<br>
3 40	345	350<br>
Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala<br>
355	360	365<br>
Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu<br>
370	375	380<br>
Thr Gly Phe Thr Phe Ser Ala Leu Gin lie Leu Pro Tyr Thr Leu Ala<br>
385	390	395	400<br>
Ser Leu Tyr His Arg Glu Lys Gin Val Phe Leu Pro Lys Tyr Arg Gly<br>
405	410	415<br>
Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu<br>
420	425	430<br>
Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala<br>
435	440	445<br>
Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser<br>
450	455	460<br>
Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala<br>
465	470	475	480<br>
Arg Val Val Pro Gly Arg Gly He Cys Leu Asp Leu Ala lie Leu Asp<br>
485	490	495<br>
Ser Ala Phe Leu Leu Ser Gin Val Ala Pro Ser Leu Phe Met Gly Ser<br>
500	505	510<br>
lie Val Gin Leu Ser Gin Ser Val Thr Ala Tyr Met Val Ser Ala Ala<br>
515	520	525<br>
Gly Leu Gly Leu Val Ala He Tyr Phe Ala Thr Gin Val Val Phe Asp<br><br>
530	535	540<br>
Lys Ser Asp Leu Ala Lys Tyr Ser Ala<br>
545	550<br>
(2) INFORMATION FOR SEQ ID N0:114:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 241 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
iD) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:<br>
Met Gin Cys Phe Ser Phe lie Lys Thr Met Met lie Leu Phe Asn Leu<br>
15	10	15<br>
Leu lie Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly lie Trp Val<br>
20	25	30<br>
Ser lie Asp Gly Ala Ser Phe Leu Lys lie Phe Gly Pro Leu Ser Ser<br>
35	40	45<br>
Ser Ala Met Gin Phe Val Asn Val Gly Tyr Phe Leu He Ala Ala Gly<br>
50	55	60<br>
Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr<br>
65	70	75	80<br>
Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe He Leu Leu Leu He<br>
85	90	95<br>
Phe He Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr<br>
100	105	110<br>
Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala He Lys Lys<br>
135	120	125<br>
Asp Tyr Gly Ser Gin Glu Asp Phe Thr Gin Val Trp Asn Thr Thr Met<br>
130	135	140<br>
Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp<br>
145	150	155	160<br>
Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn<br>
165	170	175<br>
Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gin Lys Ala<br>
180	185	190<br>
His Asp Gin Lys Val Glu Gly Cys Phe Asn Gin Leu Leu Tyr Asp lie<br>
195	200	205<br>
Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly He Gly Gly<br>
210	215	220<br><br>
Leu G]u Leu Ala Ala Met lie Val Ser Met Tyr Leu Tyr Cys Asn Leu<br>
225	230	235	240<br>
Gin<br>
(2) INFORMATION FOR SEQ ID NO:115:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 366 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (VIi ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo Sapiens<br>
SEQUENCE DESCRIPTION: SEQ ID NO:115:<br>
GCTCTTTCTC TCCCCTCCTC TGAATTTAAT TCTTTCAACT TGCAATTTGC AAGGATTACA	60<br>
CATTTCACTG TGATGTATAT TGTGTTGCAA AAAAAAAAAA GTGTCTTTGT TTAAAATTAC	120<br>
TTGGTTTGTG AATCCATCTT GCTTTTTCCC CATTGGAACT AGTCATTAAC CCATCTCTGA	180<br>
ACTGGTAGAA AAACATCTGA AGAGCTAGTC TATCAGCATC TGACAGGTGA ATTGGATGGT	240<br>
TCTCAGAACC ATTTCACCCA GACAGCCTGT TTCTATCCTG TTTAATAAAT TAGTTTGGGT	300<br>
TCTCTACATG CATAACAAAC CCTGCTCCAA TCTGTCACAT AAAAGTCTGT GACTTGAAGT	360<br>
TTAGTC	366<br>
(2) INFORMATION FOR SEQ ID NO:116:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 282 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:<br>
ACAAAGATGA ACCATTTCCT ATATTATAGC AAAATTAAAA	TCTACCCGTA TTCTAATATT	60<br>
GAGAAATGAG ATNAAACACA ATNTTATAAA .GTCTACTTAG	AGAAGATCAA GTGACCTCAA	120<br>
AGACTTTACT ATTTTCATAT TTTAAGACAC ATGATTTATC	CTATTTTAGT AACCTGGTTC	180<br>
ATACGTTAAA CAAAGGATAA TGTGAACAGC AGAGAGGATT	TGTTGGCAGA AAATCTATGT	240<br>
TCAATCTNGA ACTATCTANA TCACAGACAT TTCTATTCCT	TT	282<br>
(2) INFORMATION FOR SEQ ID NO:117:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 305 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
'(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:<br>
ACACATGTCG CTTCACTGCC TTCTTAGATG CTTCTGGTCA ACATANAGGA ACAGGGACCA	60<br>
TATTTATCCT CCCTCCTGAA ACAATTGCAA AATAANACAA AATATATGAA ACAATTGCAA	120<br>
AATAAGGCAA AATATATGAA ACAACAGGTC TCGAGATATT GGAAATCAGT CAATGAAGGA	180<br>
TACTGATCCC TGATCACTGT CCTAATGCAG GATGTGGGAA ACAGATGAGG TCACCTCTGT	240<br>
GACTGCCCCA GCTTACTGCC TGTAGAGAGT TTCTANGCTG CAGTTCAGAC AGGGAGAAAT	300<br>
TGGGT	305<br>
(2) INFORMATION FOR SEQ ID NO:118:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 71 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:<br>
ACCAAGGTGT NTGAATCTCT GACGTGGGGA TCTCTGATTC CCGCACAATC TGAGTGGAAA      60<br>
AA.NTCCTGGG T	71<br>
(2) INFORMATION FOR SEQ ID NO:119:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 212 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.-119:<br>
ACTCCGGTTG GTGTCAGCAG CACGTGGCAT TGAACATNGC AATGTGGAGC CCAAACCACA	60<br>
GAAAATGGGG TGAAATTGGC CAACTTTCTA TNAACTTATG TTGGCAANTT TGCCACCAAC	120<br>
AGTAAGCTGG CCCTTCTAAT AAAAGAAAAT TGAAAGGTTT CTCACTAANC GGAATTAANT	180<br>
AATGGANTCA AGANACTCCC AGGCCTCAGC GT	212<br>
(2) INFORMATION FOR SEQ ID NO:120:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 90 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii.) MOLECULE TYPE: cDNA<br><br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:<br>
ACTCGTTGCA NATCAGGGGC CCCCCAGAGT CACCGTTGCA GGAGTCCTTC TGGTCTTGCC 60<br>
CTCCGCCGGC GCAGAACATG CTGGGGTGGT	90<br>
(2) INFORMATION FOR SEQ ID N0:121:<br>
(i) SEQUENCE; CHARACTERISTICS:<br>
(A)	LENGTH: 218 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(il) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE; DESCRIPTION: SEQ ID NO:i2i:<br>
TGTANCGTGA ANACGACAGA NAGGGTTGTC AAAAATGGAG AANCCTTGAA GTCATTTTGA	60<br>
GAATAAGATT TGCTAAAAGA TTTGGGGCTA AAACATGGTT ATTGGGAGAC ATTTCTGAAG	120<br>
ATATNCANGT AAATTANGGA ATGAATTCAT GGTTCTTTTG GGAATTCCTT TACGATNGCC	180<br>
AGCATANACT TCATGTGGGG ATANCAGCTA CCCTTGTA	218<br>
(2) INFORMATION FOR SEQ ID NO:122:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 171 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ill MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:<br>
TAGGGGTGTA TGCAACTGTA AGGACAAAAA TTGAGACTCA ACTGGCTTAA CCAATAAAGG 60<br>
CATTTGTTAG CTCATGGAAC AGGAAGTCGG ATGGTGGGGC ATCTTCAGTG CTGCATGAGT 120<br>
CACCACCCCG GCGGGGTCAT CTGTGCCACA GGTCCCTGTT GACAGTGCGG T	171<br>
(2) INFORMATION FOR SEQ ID NO:123:<br>
(i.) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 76 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single:<br>
(D)	TOPOLOGY: linear<br>
(iJi MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:<br>
TGTAGCGTGA AGACNACAGA ATGGTGTGTG CTGTGCTATC CAGGAACACA TTTATTATCA 60<br>
TTATCAANTA TTGTGT	76<br>
(2) INFORMATION FOR SEQ ID NO:124:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 131 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:<br>
ACCTTTCCCC AAGGCCAATG TCCTGTGTGC TAACTGGCCG GCTGCAGGAC AGCTGCAATT 60<br>
CAATGTGCTG GGTCATATGG AGGGGAGGAG ACTCTAAAAT AGCCAATTTT ATTCTCTTGG 120<br>
TTAAGATTTG T	131<br>
(2) INFORMATION FOR SEQ ID NO:125;<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 432 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:<br>
ACTTTATCTA CTGGC'TATGA	AATAGATGGT GGAAAATTGC GTTACCAACT ATACCACTGG	60<br>
CTTGAAAAAG AGGTGATAGC	TCTTCAGAGG ACTTGTGACT TTTGCTCAGA TGCTGAAGAA	120<br>
CTACAGTCTG CATTTGGCAG	AAATGAAGAT GAATTTGGAT TAAATGAGGA TGCTGAAGAT	180<br>
TTGCCTCACC AAACAAAAGT	GAAACAACTG AGAGAAAATT TTCAGGAAAA AAGACAGTGG	240<br>
CTCTTGAAGT ATCAGTCACT	TTTGAGAATG TTTCTTAGTT ACTGCATACT TCATGGATCC	300<br>
CATGGTGGGG GTCTTGCATC	TGTAAGAATG GAATTGATTT TGCTTTTGCA AGAATCTCAG	360<br>
CAGGAAACAT CAGAACCACT	ATTTTCTAGC CCTCTGTCAG AGCAAACCTC AGTGCCTCTC	420<br>
CTCTTTGCTT GT	432<br>
(2) INFORMATION FOR SEQ ID NO:126:<br>
(i) SEQUENCt CHARACTERISTICS:<br>
(A)	LENGTH: 112 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:<br>
ACACAACTTG AATAGTAAAA TAGAAACTGA GCTGAAATTT CTAATTCACT TTCTAACCAT      60<br>
AGTAAGAATG ATATTTCCCC CCAGGGATCA CCAAATATTT ATAAAAATTT GT	112<br>
(2) INFORMATION FOR SEQ ID NO:127:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 54 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
f i l s MOLECULE: TYPE : CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:<br>
ACCACGAAAC GACAAACAAG ATGGAAGCAT CAATCCACTT GCCAAGCACA GCAG	54<br>
(2) INFORMATION FOR SEQ ID NO:128:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 323 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS:. single<br>
(D)	TOPOLOGY: linear<br>
(d i. ) MOLECULE TYPE: cDNA<br>
(vi S ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:<br>
ACCTCATTAG TAATTGTTTT GTTGTTTCAT TTTTTTCTAA TGTCTCCCCT CTACCAGCTC	60<br>
ACCTGAGATA ACAGAATGAA AATGGAAGGA CAGCCAGATT TCTCCTTTGC TCTCTGCTCA	120<br>
TTCTCTCTGA AGTCTAGGTT ACCCATTTTG GGGACCCATT ATAGGCAATA AACACAGTTC	180<br>
CCAAAGCATT TGGACAGTTT CTTGTTGTGT TTTAGAATGG TTTTCCTTTT TCTTAGCCTT	240<br>
TTCCTGCAAA AGGCTCACTC AGTCCCTTGC TTGCTCAGTG GACTGGGCTC CCCAGGGCCT	300<br>
AGGCTGCCTT CTTTTC'CATG TCC	323<br>
(2) INFORMATION F'OR SEQ ID NO: 129:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 192 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:<br>
ACATACATGT GTGTATATTT TTAAATATCA CTTTTGTATC ACTCTGACTT TTTAGCATAC      60 TGAAAACACA CTAACATAAT TTNTGTGAAC CATGATCAGA TACAACCCAA ATCATTCATC     120<br><br>
TAGCACATTC ATCTGTGATA NAAAGATAGG TGAGTTTCAT TTCCTTCACG TTGGCCAATG     180<br>
GATAAACAAA GT	192<br>
(2) INFORMATION FOR SEQ ID N0:130;<br>
(1) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 362 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE : CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130;<br>
CCCTTTTTTA TGGAATGAGT AGACTGTATG TTTGAANATT TANCCACAAC CTCTTTGACA	60<br>
TATAATGACG CAACAAAAAG GTGCTGTTTA GTCCTATGGT TCAGTTTATG CCCCTGACAA	120<br>
GTTTCCATTG TGTTTTGCCG ATCTTCTGGC TAATCGTGGT ATCCTCCATG TTATTAGTAA	180<br>
TTCTGTATTC CATTTTGTTA ACGCCTGGTA GATGTAACCT GCTANGAGGC TAACTTTATA	240<br>
CTTATTTAAA AGCTCTTATT TTGTGGTCAT TAAAATGGCA ATTTATGTGC AGCACTTTAT	300<br>
TGCAGCAGGA AGCACGTGTG GGTTGGTTGT AAAGCTCTTT GCTAATCTTA AAAAGTAATG	360<br>
GG	362<br>
(2) INFORMATION FOR SEQ ID NO:131:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 332 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:<br>
CTTTTTGAAA GATCGTGTCC ACTCCTGTGG ACATCTTGTT TTAATGGAGT TTCCCATGCA	60<br>
GTANGACTGG TATGGTTGCA GCTGTCCAGA TAAAAACATT TGAAGAGCTC CAAAATGAGA	120<br>
GTTCTCCCAG GTTCGCCCTG CTGCTCCAAG TCTCAGCAGC AGCCTCTTTT AGGAGGCATC	180<br>
TTCTGAACTA GATTAAGGCA GCTTGTAAAT CTGATGTGAT TTGGTTTATT ATCCAACTAA	240<br>
CTTCCATCTG TTATCACTGG AGAAAGCCCA GACTCCCCAN GACNGGTACG GATTGTGGGC	300<br>
ATANAAGGAT TGGGTGAAGC TGGCGTTGTG GT	332<br>
(2) INFORMATION FOR SEQ ID NO:132:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 322 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:<br>
ACTTTTGCCA TTTTGTATAT ATAAACAATC TTGGGACATT CTCCTGAAAA CTAGGTGTCC	60<br>
AGTGGCTAAG AGAACTCGAT TTCAAGCAAT TCTGAAAGGA AAACCAGCAT GACACAGAAT	120<br>
CTCAAATTCC CAAACAGGGG CTCTGTGGGA AAAATGAGGG AGGACCTTTG TATCTCGGGT	180<br>
TTTAGCAAGT TAAAATGAAN ATGACAGGAA AGGCTTATTT ATCAACAAAG AGAAGAGTTG	240<br>
GGATGCTTCT AAAAAAAACT TTGGTAGAGA AAATAGGAAT GCTNAATCCT AGGGAAGCCT	300<br>
GTAACAATCT ACAATTGGTC CA	322<br>
(2!  INFORMATION FOR SEQ ID NO:133:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 278 base pairs<br>
(B)	TYPE; nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(v:) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:<br>
ACAAGCCTTC ACAAGTTTAA CTAAATTGGG ATTAATCTTT CTGTANTTAT CTGCATAATT	60<br>
CTTGTTTTTC TTTOCATCTG GCTCCTGGGT TGACAATTTG TGGAAACAAC TCTATTGCTA	120<br>
CTATTTAAAA AAAATCACAA ATCTTTCCCT TTAAGCTATG TTNAATTCAA ACTATTCCTG	180<br>
CTATTCCTGT TTTGTCAAAG AAATTATATT TTTCAAAATA TGTNTATTTG TTTGATGGGT	240<br>
CCCACGAAAC ACTAATAAAA ACCACAGAGA CCAGCCTG	278<br>
(2) INFORMATION FOR SEQ ID NO:134:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 121 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
I'D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:<br>
GTTTANAAAA CTTGTTTAGC TCCATAGAGG AAAGAATGTT AAACTTTGTA TTTTAAAACA 60<br>
TGATTCTCTG AGGTTAAACT TGGTTTTCAA ATGTTATTTT TACTTGTATT TTGCTTTTGG 120<br>
T	121<br>
(2) INFORMATION FOR SEQ ID NO:135:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 350 base pairs<br>
(B)	TYPE: nucleic acid<br>
1C) STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br><br>
SEQUENCE: DESCRIPTION: SEQ ID NO: 135:<br>
ACTTANAACC ATGCCTAGCA CATCAGAATC CCTCAAAGAA CATCAGTATA ATCCTATACC	60<br>
ATANCAAGTG GTGACTGGTT AAGCGTGCGA CAAAGGTCAG CTGGCACATT ACTTGTGTGC	120<br>
AAACTTGATA CTTTTGTTCT AAGTAGGAAC TAGTATACAG TNCCTAGGAN TGGTACTCCA	180<br>
GGGTGCCCCC CAACTCCTGC AGCCGCTCCT CTGTGCCAGN CCCTGNAAGG AACTTTCGCT	240<br>
CCACCTCAAT CAAGCCCTGG GCCATGCTAC CTGCAATTGG CTGAACAAAC GTTTGCTGAG	300<br>
TTCCCAAGGA TGCAAAGCCT GGTGCTCAAC TCCTGGGGCG TCAACTCAGT	350<br>
(2) INFORMATION FOR SEQ ID NO:136: (i) SEQUENCE; CHARACTERISTICS:<br>
(A)	LENGTH: 399 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:<br>
TGTACCGTGA AGACGACAGA AGTTGCATGG CAGGGACAGG GCAGGGCCGA	GGCCAGGGTT	60<br>
GCTGTGATTG TATCCGAATA NTCCTCGTGA GAAAAGATAA TGAGATGACG	TGAGCAGCCT	120<br>
GCAGACTTGT GTCTGCCTTC AANAAGCCAG ACAGGAAGGC CCTGCCTGCC	TTGGCTCTGA	180<br>
CCTGGCGGCC AGCCAGCCAG CCACAGGTGG'GCTTCTTCCT TTTGTGGTGA	CAACNCCAAG	240<br>
AAAACTGCAG AGGCCCAGGG TCAGGTGTNA GTGGGTANGT GACCATAAAA	CACCAGGTGC	300<br>
TCCCAGGAAC CCGGGCAAAG GCCATCCCCA CCTACAGCCA GCATGCCCAC	TGGCGTGATG	360<br>
GGTGCAGANG GATGAAGCAG CCAGNTGTTC TGCTGTGGT	399<br>
(2)  INFORMATION FOR SEQ ID N0:137:<br>
(i) SEQUENCE' CHARACTERISTICS:<br>
(A)	LENGTH: 165 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:<br>
ACTGGTGTGG TNGGGGGTGA TGCTGGTGGT ANAAGTTGAN GTGACTTCAN GATGGTGTGT 60<br>
GGAGGAAGTG TGTGAACGTA GGGATGTAGA NGTTTTGGCC GTGCTAAATG AGCTTCGGGA 120<br>
TTGGCTGGTC CCACTGGTGG TCACTGTCAT TGGTGGGGTT CCTGT	165<br>
(2) INFORMATION FOR SEQ ID NO:138:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH; 338 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i. i.) MOLECULE TYPE : cDNA<br><br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:138:<br>
ACTCACTGGA ATGCCACATT CACAACAGAA TCAGAGGTCT GTGAAAACAT TAATGGCTCC	60<br>
TTAACTTCTC CAGTAAGAAT CAGGGACTTG AAATGGAAAC GTTAACAGCC ACATGCCCAA	120<br>
TGCTGGGCAG TCTCCCATGC CTTCCACAGT GAAAGGGCTT GAGAAAAATC ACATCCAATG	180<br>
TCATGTGTTT CCAGCCACAC CAAAAGGTGC TTGGGGTGGA GGGCTGGGGG CATANANGGT	240<br>
CANGCCTCAG GAAGCCTCAA GTTCCATTCA GCTTTGCCAC TGTACATTCC CCATNTTTAA	300<br>
AAAAACTGAT GCCTTTTTTT TTTTTTTTTG TAAAATTC	338<br>
(2) INFORMATION FOR SEQ ID NO:139:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 382 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
iA) ORGANISM: Homo sapiens<br>
!xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:<br>
GGGAATCTTG GTTTTTGGCA TCTGGTTTGC CTATAGCCGA GGCCACTTTG ACAGAACAAA	60<br>
GAAAGGGACT TCGAGTAAGA AGGTGATTTA CAGCCAGCCT AGTGCCCGAA GTGAAGGAGA	120<br>
ATTCAAACAG ACCTCGTCAT TCCTGGTGTG AGCCTGGTCG GCTCACCGCC TATCATCTGC	180<br>
ATTTGCCTTA CTCAGGTGCT ACCGGACTCT GGCCCCTGAT GTCTGTAGTT TCACAGGATG	240<br>
CCTTATTTGT CTTCTACACC CCACAGGGCC CCCTACTTCT TCGGATGTGT TTTTAATAAT	300<br>
GTCAGCTATG TGCCCCATCC TCCTTCATGC CCTCCCTCCC TTTCCTACCA CTGCTGAGTG	360<br>
GCCTGGAACT TGTTTAAAGT GT	382<br>
(2) INFORMATION FOR SEQ ID NO:140:<br>
( i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 200 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(1 i ) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:<br>
ACCAAANCTT CTTTCTGTTG TGTTNGATTT TACTATAGGG GTTTNGCTTN TTCTAAANAT	60<br>
ACTTTTCATT TAACANCTTT TGTTAAGTGT CAGGCTGCAC TTTGCTCCAT ANAATTATTG	120<br>
TTTTCACATT TCAACTTGTA TGTGTTTGTC TCTTANAGCA TTGG.TGAAAT CACATATTTT	180<br>
ATATTCAGCA TAAAGGAGAA	200<br>
(2) INFORMATION FOR SEQ ID NO:141;<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 335 base pairs<br>
(B)	TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE: CDNA<br>
(vi.) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:<br>
ACTTTATTTT CAAAACACTC ATATGTTGCA AAAAACACAT AGAAAAATAA AGTTTGGTGG	60<br>
GGGTGCTGAC TAAACTTCAA GTCACAGACT TTTATGTGAC AGATTGGAGC AGGGTTTGTT	120<br>
ATGCATGTAG AGAACCCAAA CTAATTTATT AAACAGGATA GAAACAGGCT GTCTGGGTGA	180<br>
AATGGTTCTG AGAACCATCC AATTCACCTG TCAGATGCTG ATANACTAGC TCTTCAGATG	240<br>
TTTTTCTACC AGTTCAGAGA TNGGTTAATG ACTANTTCCA ATGGGGAAAA AGCAAGATGG	300<br>
ATTCACAAAC CAAGTAATTT TAAACAAAGA CACTT	335<br>
(2) INFORMATION FOR SEQ ID NO:142:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 459 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:<br>
ACCAGGTTAA TATTGCCACA TATATCCTTT CCAATTGCGG GCTAAACAGA CGTGTATTTA	60<br>
GGGTTGTTTA AAGACAACCC AGCTTAATAT CAAGAGAAAT TGTGACCTTT CATGGAGTAT	120<br>
CTGATGGAGA AAACACTGAG TTTTGACAAA TCTTATTTTA TTCAGATAGC AGTCTGATCA	180<br>
CACATGGTCC AACAACACTC AAATAATAAA TCAAATATNA TCAGATGTTA AAGATTGGTC	240<br>
TTCAAACATC ATAGCCAATG ATGCCCCGCT TGCCTATAAT CTCTCCGACA TAAAACCACA	300<br>
TCAACACCTC AGTGGCCACC AAACCATTCA GCACAGCTTC CTTAACTGTG AGCTGTTTGA	360<br>
AGCTACCAGT CTGAGCACTA TTGACTATNT TTTTCANGCT CTGAATAGCT CTAGGGATCT	420<br>
CAGCANGGGT GGGAGGAACC AGCTCAACCT TGGCGTANT	459<br>
(2) INFORMATION FOR SEQ ID NO:143:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 140 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:<br>
ACATTTCCTT CCACCAAGTC AGGACTCCTG GCTTCTGTGG GAGTTCTTAT CACCTGAGGG 60<br>
AAATCCAAAC AGTCTCTCCT AGAAAGGAAT AGTGTCACCA ACCCCACCCA TCTCCCTGAG 120<br>
ACCATCCGAC TTCCCTGTGT	140<br>
(2) INFORMATION FOR SEQ ID NO:144:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 164 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:<br>
ACTTCAGTAA CAACATACAA TAACAACATT AAGTGTATAT TGCCATCTTT GTCATTTTCT 60<br>
ATCTATACCA CTCTCCCTTC TGAAAACAAN AATCACTANC CAATCACTTA TACAAATTTG 120<br>
AGGCAATTAA TCCATATTTG TTTTCAATAA 3GAAAAAAAG ATGT	164<br>
(2) INFORMATION TOR SEQ ID NO:145:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 303 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single'<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULK TYPE: cDNA<br>
(vi! ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:145:<br>
ACGTAGACCA TCCAACTTTG TATTTGTAAT GGCAAACATC CAGNAGCAAT	TCCTAAACAA	60<br>
ACTGGAGGGT ATTTATACCC AATTATCCCA TTCATTAACA TGCCCTCCTC	CTCAGGCTAT	120<br>
GCAGGACAGC TATCATAAGT CGGCCCAGGC ATCCAGATAC TACCATTTGT	ATAAACTTCA	180<br>
GTAGGGGAGT CCATCCAAGT GACAGGTCTA ATCAAAGGAG GAAATGGAAC	ATAAGCCCAG	240<br>
TAGTAAAATM TTGOTTAGCT GAAACAGCCA CAAAAGACTT ACCGCCGTGG	TGATTACCAT	300<br>
CAA	303<br>
(2) INFORMATION FOR SEQ ID NO:146:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 327 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear-<br>
fii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:<br>
ACTGCAGCTC AATTAGAAGT GGTCTCTGAC TTTCATCANC TTCTCCCTGG GCTCCATGAC	60<br>
ACTGGCCTGG AGTGACTCAT TGCTCTGGTT GGTTGAGAGA GCTCCTTTGC CAACAGGCCT	120<br>
CCAAGTCAGG GCTGGGATTT GTTTCCTTTC CACATTCTAG CAACAATATG CTGGCCACTT	180<br>
CCTGAACAGG GAGGGTGGGA GGAGCCAGCA TGGAACAAGC TGCCACTTTC TAAAGTAGCC	240<br>
AGACTTGCCC CTGGGCCTGT CACACCTACT GATGACCTTC TGTGCCTGCA GGATGGAATG	300<br>
TAGGGGTGAG CTGTGTGACT CTATGGT	327<br><br>
(2) INFORMATION FOR SEQ ID NO:147:<br>
(i.) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 173 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(li) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:<br>
ACATTGTTTT TTTGAGATAA AGCATTGANA GAGCTCTCCT TAACGTGACA CAATGGAAGG 60<br>
ACTGGAACAC ATACCCACAT CTTTGTTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT 120<br>
ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTT	173<br>
(2) INFORMATION FOR SEQ ID NO:148:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 477 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(u) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE; DESCRIPTION: SEQ ID NO:i48:<br>
ACAACCACTT TATCTCATCG AATTTTTAAC CCAAACTCAC TCACTGTGCC	TTTCTATCCT	60<br>
ATGGGATATA TTATTTGATG CTCCATTTCA TCACACATAT ATGAATAATA	CACTCATACT	120<br>
GCCCTACTAC CTGCTGCAAT AATCACATTC CCTTCCTGTC CTGACCCTGA	AGCCATTGGG	180<br>
GTGGTCCTAG TGGCCATCAG TCCANGCCTG CACCTTGAGC CCTTGAGCTC	CATTGCTCAC	240<br>
NCCANCC'CAC CTCACCGACC CCATCCTCTT ACACAGCTAC CTCCTTGCTC	TCTAACCCCA	300<br>
TAGATTATNT CCAAATTCAG TCAATTAAGT TACTATTAAC ACTCTACCCG	ACATGTCCAG	360<br>
CACCACTGGT AAGCCTTCTC CAGCCAACAC ACACACACAC ACACNCACAC	ACACACATAT	420<br>
CCAGGCACAG GCTACCTCAT CTTCACAATC ACCCCTTTAA TTACCATGCT	ATGGTGG	477<br>
(2) INFORMATION FOR SEQ ID NO:149:<br>
(li SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 207 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(])) TOPOLOGY: linear<br>
(i i! MOLECULE TYPE: cDNA<br>
(vj) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:<br>
ACAGTTGTAT TATAATATCA AGAAATAAAC TTGCAATGAG AGCATTTAAG AGGGAAGAAC 60 TAACGTATTT TAGAGAGCCA AGGAAGGTTT CTGTGGGGAG TGGGATGTAA GGTGGGGCCT 120<br><br>
GATGATAAAT AAGAGTCAGC CAGGTAAGTG GGTGGTGTGG TATGGGCACA GTGAAGAACA 180<br>
TTTCAGGCAG AGGGAACAGC AGTGAAA	207<br>
(2) INFORMATION FOR SEQ ID NO.-150:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 111 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(1 i ) MOLECULE TYPE -. cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:<br>
ACCTTGATTT CATTGC'TGCT CTGATGGAAA CCCAACTATC TAATTTAGCT AAAACATGGG 60<br>
CACTTAAATG TGGTCAGTGT TTGGACTTGT TAACTANTGG CATCTTTGGG T	111<br>
(2) INFORMATION FOR SEQ ID NO:151:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 196 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:<br>
AGCGCGGCAG	GTCATATTGA ACATTCCAGA TACCTATCAT TACTCGATGC TGTTGATAAC	60<br>
AGCAAGATGG	CTTTGAACTC AGGGTCACCA CCAGCTATTG GACCTTACTA TGAAAACCAT	120<br>
GGATAC'CAAC	CGGAAAACCC CTATCCCGCA CAGCCCACTG TGGTCCCCAC TGTCTACGAG	180<br>
GTGCATCCGG	CTCAGT	196<br>
(2) INFORMATION FOR SEQ ID NO:152:<br>
(i) SEQUENCE: CHARACTERISTICS:<br>
(A)	LENGTH: 132 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi.) SEQUENCE DESCRIPTION: SEQ ID NO:152:<br>
ACAGCAC'TTT CACATG'TAAG AAGGGAGAAA TTCCTAAATG TAGGAGAAAG ATAACAGAAC 60<br>
CTTCCCCTTT TCATCTAGTG GTGGAAACCT GATGCTTTAT GTTGACAGGA ATAGAACCAG 120<br>
GAGGGAGTTT GT	132<br>
(2)  INFORMATION FOR SEQ ID NO:153:<br><br>
(:i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 285 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY; linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
iA) ORGANISM: Homo sapiens<br>
(xi&gt; SEQUENCE: DESCRIPTION: SEQ ID N0:i53:<br>
ACAANACCCA NGANAGGCCA CTGGCCGTGG TGTCATGGCC TCCAAACATG AAAGTGTCAG	60<br>
CTTCTGCTCT TATGTCCTCA TCTGACAACT CTTTACCATT TTTATCCTCG CTCAGCAGGA	120<br>
GCACATCAAT AAAGTCCAAA GTCTTGGACT TGGCCTTGGC TTGGAGGAAG TCATCAACAC	180<br>
CCTGGCTAGT GAGGGTGCGG CGCCGCTCCT GGATGACGGC ATCTGTGAAG TCGTGCACCA	240<br>
GTCTGCAGGC CCTGTGGAAG CGCCGTCCAC ACGGAGTNAG GAATT	285<br>
(2) INFORMATION FOR SEQ ID NO:154:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 333 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:<br>
ACCACAGTCC TGTTGGGCCA GGGCTTCATG ACCCTTTCTG TGAAAAGCCA TATTATCACC	60<br>
ACCCCAAATT TTTCCTTAAA TATCTTTAAC TGAAGGGGTC AGCCTCTTGA CTGCAAAGAC	120<br>
CCTAAGCCGG TTACACAGCT AACTCCCACT GGCCCTGATT TGTGAAATTG CTGCTGCCTG	180<br>
ATTGGCACAG GAGTCGAAGG TGTTCAGCTC CCCTCCTCCG TGGAACGAGA CTCTGATTTG	240<br>
AGTTTCACAA ATTCTCGGGC CACCTCGTCA TTGCTCCTCT GAAATAAAAT CCGGAGAATG	300<br>
GTCAGGCCTG TCTCATCCAT ATGGATCTTC CGG	333<br>
(2) INFORMATION FOR SEQ ID NO: 155::<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 308 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:<br>
ACTGGAAATA ATAAAACCCA CATCACAGTG TTGTGTCAAA GATCATCAGG GCATGGATGG	60<br>
GAAAGTGCTT TGGGAACTGT AAAGTGCCTA ACACATGATC GATGATTTTT GTTATAATAT	120<br>
TTGAATCACG GTGC'ATACAA ACTCTCCTGC CTGCTCCTCC TGGGCCCCAG CCCCAGCCCC	180<br>
ATCACAGCTC ACTGCTCTGT TCATCCAGGC CCAGCATGTA GTGGCTGATT CTTCTTGGCT	240<br><br>
GCTTTTAGCC TCCANAAGTT TCTCTGAAGC CAACCAAACC TCTANGTGTA AGGCATGCTG     300<br>
GCCCTGGT	308<br>
(2; INFORMATION FOR SEQ ID NO:156:<br>
(i) SEQUENCE CHARACTERISTIcs:<br>
(A)	LENGTH: 295 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i ) MOLECULE TYPE: cDNA<br>
(vi.) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(x.i) SEQUENCE DESCRIPTION: SEQ ID NO:156:<br>
ACCTTGCTCG GTGCTTGGAA CATATTAGGA ACTCAAAATA TGAGATGATA ACAGTGCCTA	60<br>
TTATTGATTA CTGAGAGAAC TGTTAGACAT TTAGTTGAAG ATTTTCTACA CAGGAACTGA	120<br>
GAATAGGAGA TTATGTTTGG CCCTCATATT CTCTCCTATC CTCCTTGCCT CATTCTATGT	180<br>
CTAATATATT CTCAATCAAA TAAGGTTAGC ATAATCAGGA AATCGACCAA ATACCAATAT	240<br>
AAAACCAGAT GTCTATCCTT AAGATTTTCA AATAGAAAAC AAATTAACAG ACTAT	295<br>
(2) INFORMATION FOR SEQ ID N0:157:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 126 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ill MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:<br>
ACAAGTTTAA ATAGTGCTGT CACTGTGCAT GTGCTGAAAT GTGAAATCCA CCACATTTCT 60<br>
GAAGAGCAAA ACAAATTCTG TCATGTAATC TCTATCTTGG GTCGTGGGTA TATCTGTCCC 120<br>
CTTAGT	126<br>
(2! INFORMATION FOR SEQ ID NO:158:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 442 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
I<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:<br>
ACCCACTGGT CTTGGAAACA CCCATCCTTA ATACGATGAT TTTTCTGTCG TGTGAAAATG 60 AANCCAGCAG GCTGCCCCTA GTCAGTCCTT CCTTCCAGAG AAAAAGAGAT TTGAGAAAGT 120 GCCTGGGTAA TTCACCATTA ATTTCCTCCC CCAAACTCTC TGAGTCTTCC CTTAATATTT 180<br><br>
CTGGTGGTTC TGACCAAAGC AGGTCATGGT TTGTTGAGCA TTTGGGATCC CAGTGAAGTA	240<br>
NATGTTTGTA GCCTTGCATA CTTAGCCCTT CCCACGCACA AACGGAGTGG CAGAGTGGTG	300<br>
CCAACCCTGT TTTCCCAGTC CACGTAGACA GATTCACAGT GCGGAATTCT GGAAGCTGGA	360<br>
NACAGACGGG CTCTTTGCAG AGCCGGGACT CTGAGANGGA CATGAGGGCC TCTGCCTCTG	420<br>
TGTTCATTCT CTGATGTCCT GT	442<br>
(2) INFORMATION FOR SEQ ID NO:159:<br>
(i) SEQUENCE; CHARACTERISTICS:<br>
(A)	LENGTH: 498 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE; TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:<br>
ACTTCCAGGT AACGTTGTTG TTTCCGTTGA GCCTGAACTG ATGGGTGACG	TTGTAGGTTC	60<br>
TCCAACAAGA ACTGAGGTTG CAGAGCGGGT AGGGAAGAGT GCTGTTCCAG	TTGCACCTGG	120<br>
GCTGCTGTGG ACTGTTGTTG ATTCCTCACT ACGGCCCAAG GTTGTGGAAC	TGGCANAAAG	180<br>
GTGTGTTGTT GGANTTGAGC TCGGGCGGCT GTGGTAGGTT GTGGGCTCTT	CAACAGGGGC	240<br>
TGCTGTGGTG CCGGGANGTG AANGTGTTGT GTCACTTGAG CTTGGCCAGC	TCTGGAAAGT	300<br>
ANTANATTCT TCCTGAAGGC CAGCGCTTGT GGAGCTGGCA NGGGTCANTG	TTGTGTGTAA	360<br>
CGAACCAGTG CTGCTGTGGG TGGGTGTANA TCCTCCACAA AGCCTGAAGT	TATGGTGTCN	420<br>
TCAGGTAANA ATGTGGTTTC AGTGTCCCTG GGCNGCTGTG GAAGGTTGTA	NATTGTCACC	480<br>
AAGGGAATAA GCTGTGGT	498<br>
(2) INFORMATION FOR SEQ ID NO:160:<br>
(:i.) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 380 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(0) TOPOLOGY: 1inear<br>
(ii! MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:<br>
ACCTGCATCC AGCTTCCCTG CCAAACTCAC AAGGAGACAT CAACCTCTAG ACAGGGAAAC	60<br>
AGCTTCAGGA TACTTCCAGG AGACAGAGCC ACCAGCAGCA AAACAAATAT TCCCATGCCT	120<br>
GGAGCATGGC ATAGAGGAAG CTGANAAATG TGGGGTCTGA GGAAGCCATT TGAGTCTGGC	180<br>
CACTAGACAT CTCATCAGCC ACTTGTGTGA AGAGATGCCC CATGACCCCA GATGCCTCTC	240<br>
CCACCCTTAC CTCCATCTCA CACACTTGAG CTTTCCACTC TGTATAATTC TAACATCCTG	300<br>
GAGAAAAATG GCAGTTTGAC CGAACCTGTT CACAACGGTA GAGGCTGATT TCTAACGAAA	360<br>
CTTGTAGAAT GAAGCCTGGA	380<br>
(2) INFORMATION FOR SEQ ID NO:161:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 114 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:<br>
ACTCCACATC CCCTCTGAGC AGGCGGTTGT CGTTCAAGGT GTATTTGGCC TTGCCTGTCA 60<br>
CACTGTCCAC TGGCCCCTTA TCCACTTGGT GCTTAATCCC TCGAAAGAGC ATGT	114<br>
(21 INFORMATION FOR SEQ ID NO:162:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 177 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vii OR fGINAL S OUR C E:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:162:<br>
ACTTTCTGAA TCGAATCAAA TGATACTTAG TGTAGTTTTA ATATCCTCAT ATATATCAAA 60 GTTTTACTAC TCTGATAATT TTGTAAACCA GGTAACCAGA ACATCCAGTC ATACAGCTTT 120 TGGTGATATA TAACTTGGCA ATAACCCAGT CTGGTGATAC ATAAAACTAC TCACTGT 177<br>
(2)  INFORMATION FOR SEQ ID NO:163:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 137 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE; DESCRIPTION: SEQ ID N0:i63:<br>
CATTTATACA GACAGGCGTG AAGACATTCA CGACAAAAAC GCGAAATTCT ATCCCGTGAC 60<br>
CANAGAAGGC AGCTACGGCT ACTCCTACAT CCTGGCGTGG GTGGCCTTCG CCTGCACCTT 120<br>
CATCAGCGGC ATGATGT	137<br>
(2) INFORMATION FOR SEQ ID NO:164:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 469 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:<br>
CTTATCACAA TGAATGTTCT CCTGGGCAGC GTTGTGATCT TTGCCACCTT CGTGACTTTA	60<br>
TGCAATGCAT CATGCTATTT CATACCTAAT GAGGGAGTTC CAGGAGATTC AACCAGGAAA	120<br>
TGCATGGATC TCAAAGGAAA CAAACACCCA ATAAACTCGG AGTGGCAGAC TGACAACTGT	180<br>
GAGACATGCA CTTGCTACGA AACAGAAATT TCATGTTGCA CCCTTGTTTC TACACCTGTG	240<br>
GGTTATGACA AAGACAACTG CCAAAGAATC TTCAAGAAGG AGGACTGCAA GTATATCGTG	300<br>
GTGGAGAAGA AGGACCCAAA AAAGACCTGT TCTGTCAGTG AATGGATAAT CTAATGTGCT	360<br>
TCTAGTAGGC ACAGGGCTCC CAGGCCAGGC CTCATTCTCC TCTGGCCTCT AATAGTCAAT	420<br>
GATTGTGTAG CCATGCCTAT CAGTAAAAAG ATNTTTGAGC AAACACTTT	469<br>
(2) INFORMATION FOR SEQ ID NO:165:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 195 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:<br>
ACAGTTTTTT ATANATATCG ACATTGCCGG CACTTGTGTT CAGTTTCATA AAGCTGGTGG	60<br>
ATCCGCTGTC ATCCACTATT CCTTGGCTAG AGTAAAAATT ATTCTTATAG CCCATGTCCC	120<br>
TGCAGGCCGC CCGCCCGTAG TTCTCGTTCC AGTCGTCTTG GCACACAGGG TGCCAGGACT	180<br>
TCCTCTGAGA TGAGT	195<br>
(2) INFORMATION FOR SEQ ID NO:166:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 383 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i} MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:<br>
ACATCTTAGT	AGTGTGGCAC ATCAGGGGGC CATCAGGGTC ACAGTCACTC ATAGCCTCGC	60<br>
CGAGGTCGGA	GTCCACACCA CCGGTGTAGG TGTGCTCAAT CTTGGGCTTG GCGCCCACCT	120<br>
TTGGAGAAGG	GATATGCTGC ACACACATGT CCACAAAGCC TGTGAACTCG CCAAAGAATT	180<br>
TTTGCAGACC	AGCCTGAGCA AGGGGCGGAT GTTCAGCTTC AGCTCCTCCT TCGTCAGGTG	240<br>
GATGCCAACC	TCGTCTANGG TCCGTGGGAA GCTGGTGTCC ACNTCACCTA CAACCTGGGC	300<br>
GANGATCTTA	TAAAGAGGCT CCNAGATAAA CTCCACGAAA CTTCTCTGGG AGCTGCTAGT	360<br>
NGGGGCCTTT	TTGGTGAACT TTO	383<br>
(2) INFORMATION FOR SEQ ID NO:167:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 247 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:<br>
ACAGAGCCAG ACCTTGGCCA TAAATGAANC AGAGATTAAG ACTAAACCCC AAGTCGANAT	60<br>
TGGAGCAGAA ACTGGAGCAA GAAGTGGGCC TGGGGCTGAA GTAGAGACCA AGGCCACTGC	120<br>
TATANCCATA CACAGAGCCA ACTCTCAGGC CAAGGCNATG GTTGGGGCAG ANCCAGAGAC	180<br>
TCAATCTGAN TCCAAAGTGG TGGCTGGAAC ACTGGTCATG ACANAGGCAG TGACTCTGAC	240<br>
TGANGTC	247<br>
(2) INFORMATION FOR SEQ ID NO:168:<br>
(i} SEQUENCE: CHARACTERISTICS :<br>
(A)	LENGTH: 273 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:<br>
ACTTCTAAGT TTTCTAGAAG	TGGAAGGATT GTANTCATCC TGAAAATGGG TTTACTTCAA	60<br>
AATCCCTCAN CCTTGTTCTT	CACNACTGTC TATACTGANA GTGTCATGTT TCCACAAAGG	120<br>
GCTGACACCT GAGCCTGNAT	TTTCACTCAT CCCTGAGAAG CCCTTTCCAG TAGGGTGGGC	180<br>
AATTCCCAAC TTCCTTGCCA	CAAGCTTCCC AGGCTTTCTC CCCTGGAAAA CTCCAGCTTG	240<br>
AGTCCCAGAT ACACTCATGG	GCTGCCCTGG CCA	273<br>
(2) INFORMATION FOR SEQ ID NO:169:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 431 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA (vj i ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID N0:169:<br>
ACAGCCTTGG CTTCC'CCAAA CTCCACAGTC TCAGTGCAGA AAGATCATCT TCCAGCAGTC	60<br>
AGCTCAGACC AGGGTCAAAG GATGTGACAT CAACAGTTTC TGGTTTCAGA ACAGGTTCTA	120<br>
CTACTGTCAA ATGACCCCCC ATACTTCCTC AAAGGCTGTG GTAAGTTTTG CACAGGTGAG	180<br>
GGCAGCAGAA AGGGGGTANT TACTGATGGA CACCATCTTC TCTGTATACT CCACACTGAC	240<br>
CTTGCCATGG GCAAAGGCCC CTACCACAAA AACAATAGGA TCACTGCTGG GCACCAGCTC	300<br>
ACGCACATCA CTGACAACCG GGATGGAAAA AGAANTGCCA ACTTTCATAC ATCCAACTGG	360<br>
AAAGTGATCT GATAC'TGGAT TCTTAATTAC CTTCAAAAGC TTCTGGGGGC CATCAGCTGC	420<br>
TCGAACACTG A	431<br>
(2) INFORMATION FOR SEQ ID NO:170:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 266 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(va ) ORIGINAL, SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:<br>
ACCTGTGGGC TGGGCTGTTA TGCCTGTGCC GGCTGCTGAA AGGGAGTTCA GAGGTGGAGC	60<br>
TCAAGGAGCT CTGCAGGCAT TTTGCCAANC CTCTCCANAG CANAGGGAGC AACCTACACT	120<br>
CCCCGCTAGA AAGACACCAG ATTGGAGTCC TGGGAGGGGG AGTTGGGGTG GGCATTTGAT	180<br>
GTATACTTGT CACCTGAATG AANGAGCCAG AGAGGAANGA GACGAANATG ANATTGGCCT	240<br>
TCAAAGCTAG GGGTCTGGCA GGTGGA	266<br>
(2) INFORMATION FOR SEQ ID NO:171:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1248 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:<br>
GGCAGCCAAA TCATAAACGG CGAGGACTGC AGCCCGCACT CGCAGCCCTG GCAGGCGGCA	60<br>
CTGGTCATGG AAAACGAATT GTTCTGCTCG GGCGTCCTGG TGCATCCGCA GTGGGTGCTG	120<br>
TCAGCCGCAC ACTGTTTCCA GAAGTGAGTG CAGAGCTCCT ACACCATCGG GCTGGGCCTG	180<br>
CACAGTCTTG AGGCCGACCA AGAGCCAGGG AGCCAGATGG TGGAGGCCAG CCTCTCCGTA	240<br>
CGGCACCCAG AGTACAACAG ACCCTTGCTC GCTAACGACC TCATGCTCAT CAAGTTGGAC	300<br>
GAATCCGTGT CCGAGTCTGA CACCATCCGG AGCATCAGCA TTGCTTCGCA GTGCCCTACC	360<br>
GCGGGGAACT CTTGCCTCGT TTCTGGCTGG GGTCTGCTGG CGAACGGCAG AATGCCTACC	420<br>
GTGCTGCAGT GCGTGAACGT GTCGGTGGTG TCTGAGGAGG TCTGCAGTAA GCTCTATGAC	480<br>
CCGCTGTACC ACCCCAGCAT GTTCTGCGCC GGCGGAGGGC AAGACCAGAA GGACTCCTGC	540<br>
AACGGTGACT CTGGGGGGCC CCTGATCTGC AACGGGTACT TGCAGGGCCT TGTGTCTTTC	600<br>
GGAAAAGCCC CGTGTGGCCA AGTTGGCGTG CCAGGTGTCT ACACCAACCT CTGCAAATTC	660<br>
ACTGAGTGGA TAGAGAAAAC CGTCCAGGCC AGTTAACTCT GGGGACTGGG AACCCATGAA	720<br>
ATTGACCCCC AAATACATCC TGCGGAAGGA ATTCAGGAAT ATCTGTTCCC AGCCCCTCCT	780<br>
CCCTCAGGCC CAGGAGTCCA GGCCCCCAGC CCCTCCTCCC TCAAACCAAG GGTACAGATC	840<br>
CCCAGCCCCT CCTCCCTCAG ACCCAGGAGT CCAGACCCCC CAGCCCCTCC TCCCTCAGAC	900<br>
CCAGGAGTOC AGCCCCTCCT CCCTCAGACC CAGGAGTCCA GACCCCCCAG CCCCTCCTCC	960<br>
CTCAGACCCA GGGGTCCAGG CCCCCAACCC CTCCTCCCTC AGACTCAGAG GTCCAAGCCC	1020<br>
CCAACCCNTC ATTCCCCAGA CCCAGAGGTC CAGGTCCCAG CCCCTCNTCC CTCAGACCCA	1080<br>
GCGGTCCAAT GCCACCTAGA CTNTCCCTGT ACACAGTGCC CCCTTGTGGC ACGTTGACCC	1140<br>
AACCTTACCA GTTGGTTTTT CATTTTTNGT CCCTTTCCCC TAGATCCAGA AATAAAGTTT	1200<br>
AAGAGAAGNG CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA	1248<br>
(2) INFORMATION FOR SEQ ID NO:172: (i) SEQUENCE CHARACTERISTICS:<br><br>
(A)	LENGTH: 159 amirio acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:<br>
Met Val Glu Ala Ser Leu Her Val Arg His Pro Glu Tyr Asn Arg Pro<br>
15	10	15<br>
Leu Leu Ala Asn Asp Leu Met Leu lie Lys Leu Asp Glu Ser Val Ser<br>
20	25	30<br>
Glu Ser Asp Thr lie Arg Ser He Ser He Ala Ser Gin Cys Pro Thr<br>
35	40	4 5<br>
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly<br>
50	55	60<br>
Arg Met Pro Thr Val Leu Gin Cys Val Asn Val Ser Val Val Ser Glu<br>
65	70	75	80<br>
Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe<br>
85	. 90	95<br>
Cys Ala Gly Gly Gly Gin Xaa Gin Xaa Asp Ser Cys Asn Gly Asp Ser<br>
100	105	110<br>
Gly Gly Pro Leu lie Cys Asn Gly Tyr Leu Gin Gly Leu Val Ser Phe<br>
US	120	125<br>
Gly Lys Ala Pro Cys Gly Gin Val Gly Val Pro Gly Val Tyr Thr Asn<br>
130	135	140<br>
Leu Cys Lys Phe Thr Glu Trp He Glu Lys Thr Val Gin Ala Ser<br>
145	150	155<br>
(2) INFORMATION FOR SEQ ID NO:173:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1265 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULF TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(x.i) SEQUENCE DESCRIPTION: SEQ ID N0:173:<br>
GGCAGCCCGC ACTCGOAGCC CTGGCAGGCG GCACTGGTCA TGGAAAACGA ATTGTTCTGC	60<br>
TCGGGCGTCC TGGTGCATCC GCAGTGGGTG CTGTCAGCCG CACACTGTTT CCAGAACTCC	120<br>
TACACCATCG GGCTGGGCCT GCACAGTCTT GAGGCCGACC AAGAGCCAGG GAGCCAGATG	180<br>
GTGGAGGCCA GCCTCTCCGT ACGGCACCCA GAGTACAACA GACCCTTGCT CGCTAACGAC	240<br><br>
CTCATGCTCA TCAAGTTGGA CGAATCCGTG TCCGAGTCTG ACACCATCCG GAGCATCAGC	300<br>
ATTGCTTCGC AGTGCCCTAC CGCGGGGAAC TCTTGCCTCG TTTCTGGCTG GGGTCTGCTG	360<br>
GCGAACGGTG AGCTCACGGG TGTGTGTCTG CCCTCTTCAA GGAGGTCCTC TGCCCAGTCG	420<br>
CGGGGGCTGA CCCAGAGCTC TGCGTCCCAG GCAGAATGCC TACCGTGCTG CAGTGCGTGA	480<br>
ACGTGTCGGT GGTGTCTGAG GAGGTCTGCA GTAAGCTCTA TGACCCGCTG TACCACCCCA	540<br>
GCATGTTCTG CGCCGGCGGA GGGCAAGACC AGAAGGACTC CTGCAACGGT GACTCTGGGG	600<br>
GGCCCCTGAT CTGCAACGGG TACTTGCAGG GCCTTGTGTC TTTCGGAAAA GCCCCGTGTG	660<br>
GCCAAGTTGG CGTGCCAGGT GTCTACACCA ACCTCTGCAA ATTCACTGAG TGGATAGAGA	720<br>
AAACCGTCCA GGCCAGTTAA CTCTGGGGAC TGGGAACCCA TGAAATTGAC CCCCAAATAC	780<br>
ATCCTGCGGA AGGAATTCAG GAATATCTGT TCCCAGCCCC TCCTCCCTCA GGCCCAGGAG	840<br>
TCCAGGCCCC CAGCCCCTCC TCCCTCAAAC CAAGGGTACA GATCCCCAGC CCCTCCTCCC	900<br>
TCAGACCCAG GAGTCCAGAC CCCCCAGCCC CTCCTCCCTC AGACCCAGGA GTCCAGCCCC	960<br>
TCCTCCNTCA GACCCAGGAG TCCAGACCCC CCAGCCCCTC CTCCCTCAGA CCCAGGGGTT	1020<br>
GAGGCCCCCA ACCCCTCCTC CTTCAGAGTC AGAGGTCCAA GCCCCCAACC CCTCGTTCCC	1080<br>
CAGACCCAGA GGTNNAGGTC CCAGCCCCTC TTCCNTCAGA CCCAGNGGTC CAATGCCACC	1140<br>
TAGATTTTCC CTGNACACAG TGCCCCCTTG TGGNANGTTG ACCCAACCTT ACCAGTTGGT	1200<br>
TTTTCATTTT TNGTCCCTTT CCCCTAGATC CAGAAATAAA GTTTAAGAGA NGNGCAAAAA	1260<br>
AAAAA	1265<br>
(2) INFORMATION FOR SEQ ID NO:174:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1459 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE: CDNA<br>
(v i ) OR IGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:<br>
GGTCAGCCGC ACACTGTTTC CAGAAGTGAG TGCAGAGCTC CTACACCATC GGGCTGGGCC	60<br>
TGCACAGTCT TGAGGCCGAC CAAGAGCCAG GGAGCCAGAT GGTGGAGGCC AGCCTCTCCG	120<br>
TACGGCACCC AGAGTACAAC AGACCCTTGC TCGCTAACGA CCTCATGCTC ATCAAGTTGG	180<br>
ACGAATCCGT GTCCGAGTCT GACACCATCC GGAGCATCAG CATTGCTTCG CAGTGCCCTA	240<br>
CCGCGGGGAA CTCTTGCCTC GTTTCTGGCT GGGGTCTGCT GGCGAACGGT GAGCTCACGG	300<br>
GTGTGTGTCT GCCCTCTTCA AGGAGGTCCT CTGCCCAGTC GCGGGGGCTG ACCCAGAGCT	360<br>
CTGCGTCCCA GGCAGAATGC CTACCGTGCT GCAGTGCGTG AACGTGTCGG TGGTGTCTGA	420<br>
NGAGGTCTGC ANTAAGCTCT ATGACCCGCT GTACCACCCC ANCATGTTCT GCGCCGGCGG	480<br>
AGGGCAAGAC CAGAAGGACT CCTGCAACGT GAGAGAGGGG AAAGGGGAGG GCAGGCGACT	540<br>
CAGGGAAGGG TGGAGAAGGG GGAGACAGAG ACACACAGGG CCGCATGGCG AGATGCAGAG	600<br>
ATGGAGAGAC ACACAGGGAG ACAGTGACAA CTAGAGAGAG AAACTGAGAG AAACAGAGAA	660<br>
ATAAACACAG GAATAAAGAG AAGCAAAGGA AGAGAGAAAC AGAAACAGAC ATGGGGAGGC	720<br>
AGAAACACAC ACACATAGAA ATGCAGTTGA CCTTCCAACA GCATGGGGCC TGAGGGCGGT	780<br>
GACCTCCACC CAATAGAAAA TCCTCTTATA ACTTTTGACT CCCCAAAAAC CTGACTAGAA	840<br>
ATAGCCTACT GTTGACGGGG AGCCTTACCA ATAACATAAA TAGTCGATTT ATGCATACGT	900<br>
TTTATGCATT CATGATATAC CTTTGTTGGA ATTTTTTGAT ATTTCTAAGC TACACAGTTC	960<br>
GTCTGTGAAT TTTTTTAAAT TGTTGCAACT CTCCTAAAAT TTTTCTGATG TGTTTATTGA	1020<br>
AAAAATCCAA GTATAAGTGG ACTTGTGCAT TCAAACCAGG GTTGTTCAAG GGTCAACTGT	1080<br>
GTACCCAGAG GGAAACAGTG ACACAGATTC ATAGAGGTGA AACACGAAGA GAAACAGGAA	1140<br>
AAATCAAGAC TCTACAAAGA GGCTGGGCAG GGTGGCTCAT GCCTGTAATC CCAGCACTTT	1200<br>
GGGAGGCGAG GCAGGCAGAT CACTTGAGGT AAGGAGTTCA AGACCAGCCT GGCCAAAATG	1260<br>
GTGAAATCCT GTCTGTACTA AAAATACAAA AGTTAGCTGG ATATGGTGGC AGGCGCCTGT	1320<br>
AATCCCAGCT ACTTGGGAGG CTGAGGCAGG AGAATTGCTT GAATATGGGA GGCAGAGGTT	1380<br>
GAAGTGAGTT GAGATCACAC CACTATACTC CAGCTGGGGC AACAGAGTAA GACTCTGTCT	1440<br>
CAAAAAAAAA AAAAAAAAA	1459<br>
(2) INFORMATION FOR SEQ ID NO:175:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 1167 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:<br>
GCGCAGCCCT GGCAGGCGGC ACTGGTCATG GAAAACGAAT TGTTCTGCTC GGGCGTCCTG	60<br>
GTGCATCCGC AGTGGGTGCT GTCAGCCGCA CACTGTTTCC AGAACTCCTA CACCATCGGG	120<br>
CTGGGCCTGC ACAGTCTTGA GGCCGACCAA GAGCCAGGGA GCCAGATGGT GGAGGCCAGC	180<br>
CTCTCCGTAC GGCACCCAGA GTACAACAGA CTCTTGCTCG CTAACGACCT CATGCTCATC	240<br>
AAGTTGGACG AATCCGTGTC CGAGTCTGAC ACCATCCGGA GCATCAGCAT TGCTTCGCAG	300<br>
TGCCCTACCG CGGGGAACTC TTGCCTCGTN TCTGGCTGGG GTCTGCTGGC GAACGGCAGA	360<br>
ATGCCTACCG TGCTGCACTG CGTGAACGTG TCGGTGGTGT CTGAGGANGT CTGCAGTAAG	420<br>
CTCTATGACC CGCTGTACCA CCCCAGCATG TTCTGCGCCG GCGGAGGGCA AGACCAGAAG	480<br>
GACTCCTGCA ACGGTGACTC TGGGGGGCCC CTGATCTGCA ACGGGTACTT GCAGGGCCTT	540<br>
GTGTCTTTCG GAAAAGCCCC GTGTGGCCAA CTTGGCGTGC CAGGTGTCTA CACCAACCTC	600<br>
TGCAAATTCA CTGAGTGGAT AGAGAAAACC GTCCAGNCCA GTTAACTCTG GGGACTGGGA	660<br>
ACCCATGAAA TTGACCCCCA AATACATCCT GCGGAANGAA TTCAGGAATA TCTGTTCCCA	720<br>
GCCCCTCCTC CCTCAGGCCC AGGAGTCCAG GCCCCCAGCC CCTCCTCCCT CAAACCAAGG	780<br>
GTACAGATCC CCAGCCCCTC CTCCCTCAGA CCCAGGAGTC CAGACCCCCC AGCCCCTCNT	840<br>
CCNTCAGACC CAGGAGTCCA GCCCCTCCTC CNTCAGACGC AGGAGTCCAG ACCCCCCAGC	900<br>
CCNTCNTCCG TCAGACCCAG GGGTGCAGGC CCCCAACCCC TCNTCCNTCA GAGTCAGAGG	960<br>
TCCAAGCCCC CAACCCCTCG TTCCCCAGAC CCAGAGGTNC AGGTCCCAGC CCCTCCTCCC	1020<br>
TCAGACCCAG CGGTCCAATG CCACCTAGAN TNTCCCTGTA CACAGTGCCC CCTTGTGGCA	1080<br>
NGTTGACCCA ACCTTACCAG TTGGTTTTTC ATTTTTTGTC CCTTTCCCCT AGATCCAGAA	1140<br>
ATAAAGTNTA AGAGAAGCGC AAAAAAA	1167<br>
(2) INFORMATION FOR SEQ ID NO:176:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 205 amino acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(.ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:<br>
Met Gin Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gin Trp<br>
1	5	10	15<br>
Val Leu Ser Ala Ala His Cys Phe Gin Asn Ser Tyr Thr He Gly Leu<br>
20	25	30<br>
Gly Leu His Ser Leu Glu Ala Asp Gin Glu Pro Gly Ser Gin Met Val<br>
35	40	45<br>
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu<br>
50	55	60<br><br>
Ala Asn Asp Leu Met Leu lie Lys Leu Asp Glu Ser Val Ser Glu Ser<br>
65	70	75	80<br>
Asp Thr lie Arg Ser He Ser lie Ala Ser Gin Cys Pro Thr Ala Gly<br>
85	90	95<br>
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met<br>
100	105	110<br>
Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val<br>
115	120	125<br>
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala<br>
130	135	140<br>
Gly Gly Gly Gin Asp Gin Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly<br>
145	150	155	160<br>
Pro Leu He Cys Asn Gly Tyr Leu Gin Gly Leu Val Ser Phe Gly Lys<br>
165	170	175<br>
Ala Pro Cys Gly Gin Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys<br>
180	185	190<br>
Lys Phe Thr Glu Trp He Glu Lys Thr Val Gin Xaa Ser<br>
195	200	205<br>
(2) INFORMATION FOR SEQ ID NO:177:<br>
(i) SEQUENCE: CHARACTERISTICS:<br>
(A)	LENGTH: 1119 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE: TYPE: CDNA<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:177:<br>
GCGCACTCGC AGCCCTGGCA GGCGGCACTG GTCATGGAAA ACGAATTGTT CTGCTCGGGC	60<br>
GTCCTGGTGC ATCCGCAGTG GGTGCTGTCA GCCGCACACT GTTTCCAGAA CTCCTACACC	120<br>
ATCGGGCTGG GCCTGCACAG TCTTGAGGCC GACCAAGAGC CAGGGAGCCA GATGGTGGAG	180<br>
GCCAGCCTCT CCGTACGGCA CCCAGAGTAC AACAGACCCT TGCTCGCTAA CGACCTCATG	240<br>
CTCATCAAGT TGGACGAATC CGTGTCCGAG TCTGACACCA TCCGGAGCAT CAGCATTGCT	300<br>
TCGCAGTGCC CTACCGCGGG GAACTCTTGC CTCGTTTCTG GCTGGGGTCT GCTGGCGAAC	360<br>
GATGCTGTGA TTGCCATCCA GTCCCAGACT GTGGGAGGCT GGGAGTGTGA GAAGCTTTCC	420<br>
CAACCCTGGC AGGGTTGTAC CATTTCGGCA ACTTCCAGTG CAAGGACGTC CTGCTGCATC	480<br>
CTCACTGGGT GCTCACTACT GCTCACTGCA TCACCCGGAA CACTGTGATC AACTAGCCAG	540<br>
CACCATAGTT CTCCGAAGTC AGACTATCAT GATTACTGTG TTGACTGTGC TGTCTATTGT	600<br>
ACTAACCATG CCGATGTTTA GGTGAAATTA GCGTCACTTG GCCTCAACCA TCTTGGTATC	660<br>
CAGTTATCCT CACTGAATTG AGATTTCCTG CTTCAGTGTC AGCCATTCCC ACATAATTTC	720<br>
TGACCTACAG AGGTGAGGGA TCATATAGCT CTTCAAGGAT GCTGGTACTC CCCTCACAAA	780<br>
TTCATTTCTC CTGTTGTAGT GAAAGGTGCG CCCTCTGGAG CCTCCCAGGG TGGGTGTGCA	840<br>
GGTCACAATG ATGAATGTAT GATCGTGTTC CCATTACCCA AAGCCTTTAA ATCCCTCATG	900<br>
CTCAGTACAC CAGGGCAGGT CTAGCATTTC TTCATTTAGT GTATGCTGTC CATTCATGCA	960<br>
ACCACCTCAG GACTCCTGGA TTCTCTGCCT AGTTGAGCTC CTGCATGCTG CCTCCTTGGG	1020<br>
GAGGTGAGGG AGAGGGCCCA TGGTTCAATG GGATCTGTGC AGTTGTAACA CATTAGGTGC	1080<br><br>
TTAATAAACA GAAGCTGTGA TGTTAAAAAA AAAAAAAAA	1119<br>
(2) INFORMATION FOR SEQ ID NO:178:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 164 ammo acids<br>
(B)	TYPE: amino acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: protein<br>
(vi) ORIGINAL SOURCE:<br>
(A) ORGANISM: Homo sapiens<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:<br>
Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gin Trp<br>
15	10	15<br>
Val Leu Ser Ala Ala His Cys Phe Gin Asn Ser Tyr Thr lie Gly Leu<br>
20	25	30<br>
Gly Leu His Ser Leu Glu Ala Asp Gin Glu Pro Gly Ser Gin Met Val<br>
35	40	45<br>
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu<br>
50	55	60<br>
Ala Asn Asp Leu Met Leu lie Lys Leu Asp Glu Ser Val Ser Glu Ser<br>
65	70	75	80<br>
Asp Thr lie Arg Ser lie Ser He Ala Ser Gin Cys Pro Thr Ala Gly<br>
85	'    90	95<br>
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val<br>
100	105	110<br>
lie Ala He Gin Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu<br>
115	120	125<br>
Ser Gin Pro Trp Gin Gly Cys Thr He Ser Ala Thr Ser Ser Ala Arg<br>
130	135	140<br>
Thr Ser Cys Cys He Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser<br>
145	150	155	160<br>
Pro Gly Thr Leu (2) INFORMATION FOR SEQ ID NO:179:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 250 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(Di TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:179: CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT     60<br><br>
CCAGCTGCCC CCGGCCGGGG GATGCGAGGC TCGGAGCACC CTTGCCCGGC TGTGATTGCT	120<br>
GCCAGGCACT GTTCATCTCA GCTTTTCTGT CCCTTTGCTC CCGGCAAGCG CTTCTGCTGA	180<br>
AAGTTCATAT CTGGAGCCTG ATGTCTTAAC GAATAAAGGT CCCATGCTCC ACCCGAAAAA	240<br>
AAAAAAAAAA	2 5 0<br>
(2) INFORMATION FOR SEQ ID NO:180:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 202 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xii SEQUENCE: DESCRIPTION: SEQ ID N0:i80:<br>
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA	60<br>
TCACCCAGAC CCCGCCCCTG CCCGTGCCCC ACGCTGCTGC TAACGACAGT ATGATGCTTA	120<br>
CTCTGCTACT CGGAAACTAT TTTTATGTAA TTAATGTATG CTTTCTTGTT TATAAATGCC	180<br>
TGATTTAAAA AAAAAAAAAA AA	202<br>
(2) INFORMATION FOR SEQ ID NO:181:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 558 base pairs<br>
(B)	TYPE: nucleic acid<br>
(0) STRANDEDNESS: single<br>
(D) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:<br>
TCCYTTTGKT NAGGTTTKKG AGACAMCCCK AGACCTWAAN CTGTGTCACA GACTTCYNGG	60<br>
AATGTTTAGG CAGTGCTAGT AATTTCYTCG TAATGATTCT GTTATTACTT TCCTNATTCT	120<br>
TTATTCCTCT TTCTTCTGAA GATTAATGAA GTTGAAAATT GAGGTGGATA AATACAAAAA	180<br>
GGTAGTGTGA TAGTATAAGT ATCTAAGTGC AGATGAAAGT GTGTTATATA TATCCATTCA	240<br>
AAATTATGCA AGTTAGTAAT TACTCAGGGT TAACTAAATT ACTTTAATAT GCTGTTGAAC	300<br>
CTACTCTGTT CCTTGGCTAG AAAAAATTAT AAACAGGACT TTGTTAGTTT GGGAAGCCAA	360<br>
ATTGATAATA TTCTATGTTC TAAAAGTTGG GCTATACATA AATTATTAAG AAATATGGAW	420<br>
TTTTATTCCC AGGAATATGG KGTTCATTTT ATGAATATTA CSCRGGATAG AWGTWTGAGT	480<br>
AAAAYCAGTT TTGGTWAATA YGTWAATATG TCMTAAATAA ACAAKGCTTT GACTTATTTC	540<br>
CAAAAAAAAA AAAAAAAA	558<br>
(2) INFORMATION FOR SEQ ID NO:182:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 479 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TO PO LOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:<br>
ACAGGGWTTK GRGGATGCTA AGSCCCCRGA RWTYGTTTGA TCCAACCCTG GCTTWTTTTC	60<br>
AGAGGGGAAA ATGGGGCCTA GAAGTTACAG MSCATYTAGY TGGTGCGMTG GCACCCCTGG	120<br>
CSTCACACAG ASTCCCGAGT AGCTGGGACT ACAGGCACAC AGTCACTGAA GCAGGCCCTG	180<br>
TTWGCAATTC ACGTTGCCAC CTCCAACTTA AACATTCTTC ATATGTGATG TCCTTAGTCA	240<br>
CTAAGGTTAA ACTT'l CCCAC CCAGAAAAGG CAACTTAGAT AAAATCTTAG AGTACTTTCA	300<br>
TACTMTTCTA AGTCTTCTTO CAGCCTCACT KKGAGTCCTM CYTGGGGGTT GATAGGAANT	360<br>
NTCTCTTGGC TTTCTCAATA AARTCTCTAT YCATCTCATG TTTAATTTGG TACGCATARA	420<br><br>
AWTGSTGARA AAATTAAAAT GTTCTGGTTY MACTTTAAAA ARAAAAAAAA AAAAAAAAA     479 (2) INFORMATION FOR SEQ ID NO:183:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 384 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:<br>
AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC	60<br>
AGTACCAGTA CCAATAACAG TGCCAGTGCC AGTGCCAGCA CCAGTGGTGG CTTCAGTGCT	120<br>
GGTGCCAGCC TGACCGCCAC TCTCACATTT GGGCTCTTCG CTGGCCTTGG TGGAGCTGGT	180<br>
GCCAGCACCA GTGGCAGCTC TGGTGCCTGT GGTTTCTCCT ACAAGTGAGA TTTTAGATAT	240<br>
TGTTAATCCT GCCAGTCTTT CTCTTCAAGC CAGGGTGCAT CCTCAGAAAC CTACTCAACA	300<br>
CAGCACTCTA GGCAGCCACT ATCAATCAAT TGAAGTTGAC ACTCTGCATT ARATCTATTT	360<br>
GCCATTTCAA AAAAAAAAAA AAAA	384<br>
(2) INFORMATION FOR SEQ ID NO:184:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 496 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:<br>
ACCGAATTGG GACCGCTGGC TTATAAGCGA	TCATGTYYNT CCRGTATKAC CTCAACGAGC	60<br>
AGGGAGATCG AGTCTATACG CTGAAGAAAT	TTGACCCGAT GGGACAACAG ACCTGCTCAG	120<br>
CCCATCCTGC TCGGTTCTCC CCAGATGACA	AATACTCTSG ACACCGAATC ACCATCAAGA	180<br>
AACGCTTCAA GGTGCTCATG ACCCAGCAAC	CGCGCCCTGT CCTCTGAGGG TCCCTTAAAC	240<br>
TGATGTCTTT TCTGCCACCT GTTACCCCTC	GGAGACTCCG TAACCAAACT CTTCGGACTG	300<br>
TGAGCCCTGA TGCCTTTTTG CCAGCCATAC	TCTTTGGCAT CCAGTCTCTC GTGGCGATTG	360<br>
ATTATGCTTG TGTGAGGCAA TCATGGTGGC	ATCACCCATA AAGGGAACAC ATTTGACTTT	420<br>
TTTTTCTCAT ATTTTAAATT ACTACMAGAW TATTWMAGAW WAAATGAWTT GAAAAACTST	480<br>
TAAAAAAAAA AAAAAA	496<br>
(2) INFORMATION FOR SEQ ID NO:185:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 384 base pairs<br>
(B)	TYPE:: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(n) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:<br>
GCTGGTAGCC TATGGCGKGG CCCACGGAGG GGCTCCTGAG GCCACGGRAC AGTGACTTCC	60<br>
CAAGTATCYT GCGCSGCGTC TTCTACCGTC CCTACCTGCA GATCTTCGGG CAGATTCCCC	120<br>
AGGAGGACAT GGACGTGGCC CTCATGGAGC ACAGCAACTG YTCGTCGGAG CCCGGCTTCT	180<br>
GGGCACACCC TCCTGGGGCC CAGGCGGGCA CCTGCGTCTC CCAGTATGCC AACTGGCTGG	240<br>
TGGTGCTGCT CCTCGTCATC TTCCTGCTCG TGGCCAACAT CCTGCTGGTC AACTTGCTCA	300<br>
TTGCCATGTT CAGTTACACA TTCGGCAAAG TACAGGGCAA CAGCGATCTC TACTGGGAAG	360<br>
GCGCAGCGTT ACCGCCTCAT CCGG	384<br><br>
(2) INFORMATION FOR SEQ ID NO:186:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 577 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:<br>
GAGTTAGCTC CTCCACAACC TTGATGAGGT CGTCTGCAGT GGCCTCTCGC TTCATACCGC	60<br>
TNCCATCGTC ATACTGTAGG TTTGCCACCA CYTCCTGGCA TCTTGGGGCG GCNTAATATT	120<br>
CCAGGAAACT CTCAATCAAG TCACCGTCGA TGAAACCTGT GGGCTGGTTC TGTCTTCCGC	180<br>
TCGGTGTGAA AGGATCTCCC AGAAGGAGTG CTCGATCTTC CCCACACTTT TGATGACTTT	240<br>
ATTGAGTCGA TTCTGCATGT CCAGCAGGAG GTTGTACCAG CTCTCTGACA GTGAGGTCAC	300<br>
CAGCCCTATC ATGCCGTTGA MCGTGCCGAA GARCACCGAG CCTTGTGTGG GGGKKGAAGT	360<br>
CTCACCCAGA TTCTGCATTA CCAGAGAGCC GTGGCAAAAG ACATTGACAA ACTCGCCCAG	420<br>
GTGGAAAAAG AMCAMCTCCT GGARGTGCTN GCCGCTCCTC GTCMGTTGGT GGCAGCGCTW	480<br>
TCCTTTTGAC ACACAAACAA GTTAAAGGCA TTTTCAGCCC CCAGAAANTT GTCATCATCC	540<br>
AAGATNTCGC ACAGCACTNA TCCAGTTGGG ATTAAAT	577<br>
(2) INFORMATION FOR SEQ ID NO:187:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 534 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:<br>
AACATCTTCC TGTATAATGC TGTGTAATAT CGATCCGATN TTGTCTGSTG AGAATYCATW	60<br>
ACTKGGAAAA GMAACATTAA AGCCTGGACA CTGGTATTAA AATTCACAAT ATGCAACACT	120<br>
TTAAACAGTG TGTCAATCTG CTCCCYYNAC TTTGTCATCA CCAGTCTGGG AAKAAGGGTA	180<br>
TGCCCTATTC ACACCTGTTA AAAGGGCGCT AAGCATTTTT GATTCAACAT CTTTTTTTTT	240<br>
GACACAAGTC CGAAAAAAGC AAAAGTAAAC AGTTATYAAT TTGTTAGCCA ATTCACTTTC	300<br>
TTCATGGGAC AGAGCCATYT GATTTAAAAA GCAAATTGCA TAATATTGAG CTTYGGGAGC	360<br>
TGATATTTGA GCGGAAGAGT AGCCTTTCTA CTTCACCAGA CACAACTCCC TTTCATATTG	420<br>
GGATGTTNAC NAAAGTWATG TCTCTWACAG ATGGGATGCT TTTGTGGCAA TTCTGTTCTG	480<br>
AGGATCTCCC AGTTTATTTA CCACTTGCAC AAGAAGGCGT TTTCTTCCTC AGGC	534<br>
(2) INFORMATION FOR SEQ ID NO:188:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 761 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:<br>
AGAAACCAGT ATC'TCTNAAA ACAACCTCTC ATACCTTGTG GACCTAATTT TGTGTGCGTG	60<br>
TGTGTGTGCG CGCATATTAT ATAGACAGGC ACATCTTTTT TACTTTTGTA AAAGCTTATG	120<br>
CCTCTVTGGT ATCTATATCT GTGAAAGTTT TAATGATCTG CCATAATGTC TTGGGGACCT	180<br>
TTGTCTTCTG TGTAAATGGT ACTAGAGAAA ACACCTATNT TATGAGTCAA TCTAGTTNGT	240<br>
TTTATTCGAC ATGAAGGAAA TTTCCAGATN ACAACACTNA CAAACTCTCC CTKGACKARG	300<br>
GGGGACAAAG AAAAGCAAAA CTGAMCATAA RAAACAATWA CCTGGTGAGA ARTTGCATAA	360<br>
ACAGAAATWR GGTAGTATAT TGAARNACAG CATCATTAAA RMGTTWTKTT WTTCTCCCTT	420<br><br>
GCAAAAAACA TGTACNGACT TCCCGTTGAG TAATGCCAAG TTGTTTTTTT TATNATAAAA	480<br>
CTTGCCCTTC ATTAGATGTT TNAAAGTGGT GTGGTGGGCC AAAATATTGA AATGATGGAA	540<br>
CTGACTGATA AAGCTGTACA AATAAGCAGT GTGCCTAACA AGCAACACAG TAATGTTGAC	600<br>
ATGCTTAATT CACAAATGCT AATTTCATTA TAAATGTTTG CTAAAATACA CTTTGAACTA	660<br>
TTTTTCTGTN TTCCCAGAGC TGAGATNTTA GATTTTATGT AGTATNAAGT GAAAAANTAC	720<br>
GAAAATAATA ACATTGAAGA AAAANANAAA AAANAAAAAA A	761<br>
(21 INFORMATION FOR SEQ ID NO:189:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 482 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:189:<br>
TTTTTTTTTT TTTGCCGATN CTACTATTTT ATTGCAGGAN GTGGGGGTGT ATGCACCGCA	60<br>
CACCGGGGCT ATNAGAAGCA AGAAGGAAGG AGGGAGGGCA CAGCCCCTTG CTGAGCAACA	120<br>
AAGCCGCCTG CTGCCTTCTC TGTCTGTCTC CTGGTGCAGG CACATGGGGA GACCTTCCCC	180<br>
AAGGCAGGGG CCACCAGTCC AGGGGTGGGA ATACAGGGGG TGGGANGTGT GCATAAGAAG	240<br>
TGATAGGCAC AGGCCACCCG GTACAGACCC CTCGGCTCCT GACAGGTNGA TTTCGACCAG	300<br>
GTCATTGTGC CCTGCCCAGG CACAGCGTAN ATCTGGAAAA GACAGAATGC TTTCCTTTTC	360<br>
AAATTTGGCT NGTCATNGAA NGGGCANTTT TCCAANTTNG GCTNGGTCTT GGTACNCTTG	420<br>
GTTCGGCCCA GCTCCNCGTC CAAAAANTAT TCACCCNNCT CCNAATTGCT TGCNGGNCCC	480<br>
CC	482<br>
(2) INFORMATION FOR SEQ ID NO: 190:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 471 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:<br>
TTTTTTTTTT TTTTAAAACA GTTTTTCACA ACAAAATTTA TTAGAAGAAT AGTGGTTTTG	60<br>
AAAACTCTCG CATCf'AGTGA GAACTACCAT ACACCACATT ACAGCTNGGA ATGTNCTCCA	120<br>
AATGTCTGGT CAAATGATAC AATGGAACCA TTCAATCTTA CACATGCACG AAAGAACAAG	180<br>
CGCTTTTGAC ATACAATGCA CAAAAAAAAA AGGGGGGGGG GACCACATGG ATTAAAATTT	240<br>
TAAGTACTCA TCACATACAT TAAGACACAG TTCTAGTCCA GTCNAAAATC AGAACTGCNT	300<br>
TGAAAAATTT CATGTATGCA ATCCAACCAA AGAACTTNAT TGGTGATCAT GANTNCTCTA	360<br>
CTACATCNAC CTTGATCATT GCCAGGAACN AAAAGTTNAA ANCACNCNGT ACAAAAANAA	420<br>
TCTGTAATTN ANTTCAACCT CCGTACNGAA AAATNTTNNT TATACACTCC C	471<br>
(2) INFORMATION FOR SEQ ID NO:191:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 402 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:<br>
GAGGGATTGA AGGTCTGTTC TASTGTCGGM CTGTTCAGCC ACCAACTCTA ACAAGTTGCT     60 GTCTTCCACT CACTGTCTGT AAGCTTTTTA ACCCAGACWG TATCTTCATA AATAGAACAA    120<br><br>
ATTCTTCACC AGTCACATCT TCTAGGACCT TTTTGGATTC AGTTAGTATA AGCTCTTCCA	180<br>
CTTCCTTTGT TAAGACTTCA TCTGGTAAAG TCTTAAGTTT TGTAGAAAGG AATTYAATTG	240<br>
CTCGTTCTCT AACAATGTCC TCTCCTTGAA GTATTTGGCT GAACAACCCA CCTAAAGTCC	300<br>
CTTTGTGCAT CCATTTTAAA TATACTTAAT AGGGCATTGK TNCACTAGGT TAAATTCTGC	360<br>
AAGAGTCATC TGTCTGCAAA AGTTGCGTTA GTATATCTGC CA	402<br>
!2) INFORMATION FOR SEQ ID NO:192: (i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 601 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:<br>
GAGCTCGGAT CCAA7AATCT TTGTCTGAGG GCAGCACACA TATNCAGTGC CATGGNAACT	60<br>
GGTCTACCCC ACATGGGAGC AGCATGCCGT AGNTATATAA GGTCATTCCC TGAGTCAGAC	120<br>
ATGCYTYTTT GAYTACCGTG TGCCAAGTGC TGGTGATTCT YAACACACYT CCATCCCGYT	180<br>
CTTTTGTGGA AAAACTGGCA CTTKTCTGGA ACTAGCARGA CATCACTTAC AAATTCACCC	240<br>
ACGAGACACT TGAAAGGTGT AACAAAGCGA YTCTTGCATT GCTTTTTGTC CCTCCGGCAC	300<br>
CAGTTGTCAA TACTAACCCG CTGGTTTGCC TCCATCACAT TTGTGATCTG TAGCTCTGGA	360<br>
TACATCTCCT GACAGTACTG AAGAACTTCT TCTTTTGTTT CAAAAGCARC TCTTGGTGCC	420<br>
TGTTGGATCA GGTTCCCATT TCCCAGTCYG AATGTTCACA TGGCATATTT WACTTCCCAC	480<br>
AAAACATTGC GATTTGAGGC TCAGCAACAG CAAATCCTGT TCCGGCATTG GCTGCAAGAG	540<br>
CCTCGATGTA GCCGGCCAGC GCCAAGGCAG GCGCCGTGAG CCCCACCAGC AGCAGAAGCA	600<br>
G	601<br>
(2) INFORMATION FOR SEQ ID NO:193:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 608 base pairs<br>
(B)	TYPE; nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:<br>
ATACAGCCCA NATCCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT	60<br>
GGTCCCGCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCYTT	120<br>
CCCAACGCAG GCAGMAGCGG GSCCGGTCAA TGAACTCCAY TCGTGGCTTG GGGTKGACGG	180<br>
TKAAGTGCAG GAAGAGGCTG ACCACCTCGC GGTCCACCAG GATGCCCGAC TGTGCGGGAC	240<br>
CTGCAGCGAA ACTCCTCGAT GGTCATGAGC GGGAAGCGAA TGAGGCCCAG GGCCTTGCCC	300<br>
AGAACCTTCC GCCTGTTCTC TGGCGTCACC TGCAGCTGCT GCCGCTGACA CTCGGCCTCG	360<br>
GACCAGCGGA CAAACGGCRT TGAACAGCCG CACCTCACGG ATGCCCAGTG TGTCGCGCTC	420<br>
CAGGAMMGSC ACCAGCGTGT CCAGGTCAAT GTCGGTGAAG CCCTCCGCGG GTRATGGCGT	480<br>
CTGCAGTGTT TTTGTCGATG TTCTCCAGGC ACAGGCTGGC CAGCTGCGGT TCATCGAAGA	540<br>
GTCGCGCCTG CGTGAGCAGC ATGAAGGCGT TGTCGGCTCG CAGTTCTTCT TCAGGAACTC	600<br>
CACGCAAT	608<br>
(2) INFORMATION FOR SEQ ID NO:194:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 392 base pairs<br>
(B)	TYPt: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br><br>
(xi) SEQUENCE DESCRIPTION; SEQ ID NO:194:<br>
GAACGGCTGG ACCTTGCCTC GCATTGTGCT TGCTGGCAGG GAATACCTTG GCAAGCAGYT	60<br>
CCAGTCCGAG CAGCCCCAGA CCGCTGCCGC CCGAAGCTAA GCCTGCCTCT GGCCTTCCCC	120<br>
TCCGCCTCAA TGCAGAACCA GTAGTGGGAG CACTGTGTTT AGAGTTAAGA GTGAACACTG	180<br>
TTTGATTTTA CT'I'GGGAATT TCCTCTGTTA TATAGCTTTT CCCAATGCTA ATTTCCAAAC	240<br>
AACAACAACA AAATAACATG TTTGCCTGTT AAGTTGTATA AAAGTAGGTG ATTCTGTATT	300<br>
TAAAGAAAAT ATTACTGTTA CATATACTGC TTGCAATTTC TGTATTTATT GKTNCTSTGG	360<br>
AAATAAATAT AGTTATTAAA GGTTGTCANT CC	392<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 502 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(T)) TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:<br>
CCSTTKGAGG GGTKAGGKYC CAGTTYCCGA GTGGAAGAAA CAGGCCAGGA GAAGTGCGTG	60<br>
CCGAGCTGAG GCAGATGTTC CCACAGTGAC CCCCAGAGCC STGGGSTATA GTYTCTGACC	120<br>
CCTCNCAAGG AAAGACCACS TTCTGGGGAC ATGGGCTGGA GGGCAGGACC TAGAGGCACC	180<br>
AAGGGAAGGC CCCATTCCGG GGSTGTTCCC CGAGGAGGAA GGGAAGGGGC TCTGTGTGCC	240<br>
CCCCASGAGG AAGAGGCCCT GAGTCCTGGG ATCAGACACC CCTTCACGTG TATCCCCACA	300<br>
CAAATGCAAG CTCACCAAGG TCCCCTCTCA GTCCCCTTCC STACACCCTG AMCGGCCACT	360<br>
GSCSCACACC CACCCAGAGC ACGCCACCCG CCATGGGGAR TGTGCTCAAG GARTCGCNGG	420<br>
GCARCGTGGA CATC7NGTCC CAGAAGGGGG CAGAATCTCC AATAGANGGA CTGARCMSTT	480<br>
GCTNANAAAA AAAAANAAAA AA	502<br>
(2) INFORMATION FOR SEQ ID NO:196:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 665 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:<br>
GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT	TTGTCTGCTC     60<br>
CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT	GCTGAATTTT    120<br>
WAGCTGTTTK GAGTTGATTS GCACCACTGC ACCCACAACT TCAATATGAA	AACYAWTTGA    180<br>
ACTWATTTAT TATCTTGTGA AAAGTATAAC AATGAAAATT TTGTTCATAC	TGTATTKATC    240<br>
AAGTATGATG AAAAGCAAWA GATATATATT CTTTTATTAT GTTAAATTAT	GATTGCCATT    300<br>
ATTAATCGGC AAAATGTGGA GTGTATGTTC TTTTCACAGT AATATATGCC	TTTTGTAACT    360<br>
TCACTTGGTT ATTTTATTGT AAATGARTTA CAAAATTCTT AATTTAAGAR	AATGGTATGT    420<br>
WATATTTATT TCATTAATTT CTTTCCTKGT TTACGTWAAT TTTGAAAAGA	WTGCATGATT    480<br>
TCTTGACAGA AATCGATCTT GATGCTGTGG AAGTAGTTTG ACCCACATCC	CTATGAGTTT    540<br>
TTCTTAGAAT GTATAAAGGT TGTAGCCCAT CNAACTTCAA AGAAAAAAAT	GACCACATAC    600<br>
TTTGCAATCA GGCTGAAATG TGGCATGCTN TTCTAATTCC AACTTTATAA	ACTAGCAAAN    660<br>
AAGTG	665<br>
(2) INFORMATION FOR SEQ ID NO:197:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 492 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br><br>
TOPOLOGY: linear<br>
(Ki) SEQUENCE DESCRIPTION: SEQ ID NO:197:<br>
TTTTNTTTTT TTTTTTTTGC AGGAAGGATT CCATTTATTG TGGATGCATT TTCACAATAT	60<br>
ATGTTTATTG GAGCGATCCA TTATCAGTGA AAAGTATCAA GTGTTTATAA NATTTTTAGG	120<br>
AAGGCAGATT CACAGAACAT GCTNGTCNGC TTGCAGTTTT ACCTCGTANA GATNACAGAG	180<br>
AATTATAGTC NAACCAGTAA ACNAGGAATT TACTTTTCAA AAGATTAAAT CCAAACTGAA	240<br>
CAAAATTCTA CCCTGAAACT TACTCCATCC AAATATTGGA ATAANAGTCA GCAGTGATAC	300<br>
ATTCTCTTCT GAACTTTAGA TTTTCTAGAA AAATATGTAA TAGTGATCAG GAAGAGCTCT	360<br>
TGTTCAAAAG TACAACNAAG CAATGTTCCC TTACCATAGG CCTTAATTCA AACTTTGATC	420<br>
CATTTCACTC CCATCACGGG AGTCAATGCT ACCTGGGACA CTTGTATTTT GTTCATNCTG	480<br>
ANCNTGGCTT AA	492<br>
(2) INFORMATION FOR SEQ ID NO:198:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 478 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:<br>
TTTNTTTTGN ATTTCANTCT GTANNAANTA TTTTCATTAT GTTTATTANA AAAATATNAA	60<br>
TGTNTCCACN ACAAATCATN TTACNTNAGT AAGAGGCCAN CTACATTGTA CAACATACAC	120<br>
TGAGTATATT TTGAAAAGGA CAAGTTTAAA GTANACNCAT ATTGCCGANC ATANCACATT	180<br>
TATACATGGC TTGATTGATA TTTAGCACAG CANAAACTGA GTGAGTTACC AGAAANAAAT	240<br>
NATATATGTC AATCNGATTT AAGATACAAA ACAGATCCTA TGGTACATAN CATCNTGTAG	300<br>
GAGTTGTGGC TTTATGTTTA CTGAAAGTCA ATGCAGTTCC TGTACAAAGA GATGGCCGTA	360<br>
AGCATTCTAG TACCTCTACT CCATGGTTAA GAATCGTACA CTTATGTTTA CATATGTNCA	420<br>
GGGTAAGAAT TGTGTTAAGT NAANTTATGG AGAGGTCCAN GAGAAAAATT TGATNCAA	478<br>
(2) INFORMATION FOR SEQ ID NO:199:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 482 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRA.NDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(XI) SEQUENCE DESCRIPTION: SEQ ID NO:199:<br>
AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCACTGACA ATCAGACCTA    60<br>
TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA	120<br>
TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA	180<br>
AGTGATTCAG TTTCCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA	240<br>
TGAAGCCNAC TCTGAACACG CTGGTTATCT NAGATGAGAA NCAGAGAAAT AAAGTCNAGA	300<br>
AAATTTACCT GGANGAAAAG AGGCTTTNGG CTGGGGACCA TCCCATTGAA CCTTCTCTTA	360<br>
ANGGACTTTA AGAANAAACT ACCACATGTN TGTNGTATCC TGGTGCCNGG CCGTTTANTG	420<br>
AACNTNGACN NCACCCTTNT GGAATANANT CTTGACNGCN TCCTGAACTT GCTCCTCTGC	4 BO<br>
GA	482<br>
(2) INFORMATION FOR SEQ ID NO:200:<br>
(i) SEQUENCE CHARACTERISTICS: (AS LENGTH: 270 base pairs (B) TYPE: nucleic acid<br><br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:<br>
CGGCOGCAAO TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC	60<br>
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC	120<br>
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA	180<br>
CAGCCGGAAC AGAGCCCGGT GAANGCGGGA GGCCTCGGGG AGCCCCTCGG GAAGGGCGGC	240<br>
CCGAGAGATA CGCAGGTGCA GGTGGCCGCC	270<br>
i2) INFORMATION FOR SEQ ID N0:201:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 419 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:<br>
TTTTTTTTTT TTTTGGAATC	TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA	50<br>
GCTAGCAAGG TAACAGGGTA	GGGCATGGTT ACATGTTCAG GTCAACTTCC TTTGTCGTGG	120<br>
TTGATTGGTT TGTCTTTATG	GGGGCGGGGT GGGGTAGGGG AAANCGAAGC ANAANTAACA	180<br>
TGGAGTGGGT GCACCCTCCC	TGTAGAACCT GGTTACNAAA GCTTGGGGCA GTTCACCTGG	240<br>
TCTGTGACCG TCATT'TTCTT	GACATCAATG TTATTAGAAG TCAGGATATC TTTTAGAGAG	300<br>
TCCACTGTNT CTGGAGGGAG	ATTAGGGTTT CTTGCCAANA TCCAANCAAA ATCCACNTGA	360<br>
AAAAGTTGGA TGATNCANGT	ACNGAATACC GANGGCATAN TTCTCATANT CGGTGGCCA	419<br>
(2)  INFORMATION FOR SEQ ID NO:202:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 509 base pairs<br>
(B)	TYPE;: nucleic acid<br>
(C)	S TRANDE DN E S S: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:202:<br>
rrlrprriiprprprprprprp      rprprprprprrirprpfTirp      rprprprprprrirprprprp      rTirprprTirprpmrprprp      rTirprnrj-irnrpmrrirrirri	f- rTGGCACTTAA TCCATTTTTA TTTCAAAATG TCTACAAANT TTNAATNCNC CATTATACNG	120<br>
GTNATTTTNC AAAATCTAAA NNTTATTCAA ATNTNAGCCA AANTCCTTAC NCAAATNNAA	180<br>
TACNCNCAAA AATCAAAAAT ATACNTNTCT TTCAGCAAAC TTNGTTACAT AAATTAAAAA	240<br>
AATATATACG GCTGGTGTTT TCAAAGTACA ATTATCTTAA CACTGCAAAC ATNTTTNNAA	300<br>
GGAACTAAAA TAAAAAAAAA CACTNCCGCA AAGGTTAAAG GGAACAACAA ATTCNTTTTA	360<br>
CAACANCNNC NATTATAAAA ATCATATCTC AAATCTTAGG GGAATATATA CTTCACACNG	420<br>
GGATCTTAAC TTTTACTNCA CTTTGTTTAT TTTTTTANAA CCATTGTNTT GGGCCCAACA	480<br>
CAATGGNAAT NCCNCCNCNC TGGACTAGT	509<br>
(2) INFORMATION FOR SEQ ID NO: 203:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 583 base pairs<br>
(B)	TYPK : nucleic acid<br>
(C)	STRANDEDNESS: single<br>
( D ) TO PC) LOGY : linear<br><br>
(xi! SEQUENCE DESCRIPTION: SEQ ID N0:203:<br>
TTTTTTTTTT TTTTTTTTGA CCCCCCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT	60<br>
TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC	120<br>
TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT	180<br>
GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTTGACT CTTGTAAAAC ATCCAAATTC	240<br>
ATTTTTCTTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT	300<br>
GCTTCTCTAG CCTCATTTCC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA	360<br>
AGGGAAAACA GGAAGAGANA ATGGCACACA AAACAAACAT TTTATATTCA TATTTCTACC	420<br>
TACGTTAATA AAATAGCATT TTGTGAAGCC AGCTCAAAAG AAGGCTTAGA TCCTTTTATG	480<br>
TCCATTTTAG TCACTAAACG ATATCNAAAG TGCCAGAATG CAAAAGGTTT GTGAACATTT	540<br>
ATTCAAAAGC TAATATAAGA TATTTCACAT ACTCATCTTT CTG	583<br>
(2) INFORMATION FOR SEC ID NO:204:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 589 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:204:<br>
TTTTTTTTNT TTTTTTTTTT TTTTTTNCTC TTCTTTTTTT TTGANAATGA GGATCGAGTT	60<br>
TTTCACTCTC TAGATAGGGC ATGAAGAAAA CTCATCTTTC CAGCTTTAAA ATAACAATCA	120<br>
AATCTCTTAT GCTATATCAT ATTTTAAGTT AAACTAATGA GTCACTGGCT TATCTTCTCC	180<br>
TGAAGGAAAT CTGTTCATTC TTCTCATTCA TATAGTTATA TCAAGTACTA CCTTGCATAT	240<br>
T'GAGAGGTTT TTCTTCTCTA TTTACACATA TATTTCCATG TGAATTTGTA TCAAACCTTT	300<br>
ATTTTCATGC AAACTAGAAA ATAATGTNTT CTTTTGCATA AGAGAAGAGA ACAATATNAG	360<br>
CATTACAAAA CTGCTCAAAT TGTTTGTTAA GNTTATCCAT TATAATTAGT TNGGCAGGAG	420<br>
CTAATACAAA TCACATTTAC NGACNAGCAA TAATAAAACT GAAGTACCAG TTAAATATCC	480<br>
AAAATAATTA AAGGAACATT TTTAGCCTGG GTATAATTAG CTAATTCACT TTACAAGCAT	540<br>
TTATTNAGAA TGAATTCACA TGTTATTATT CCNTAGCCCA ACACAATGG	589<br>
(2) INFORMATION FOR SEQ ID N0:205:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 545 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:205:<br>
TTTTTNTTTT TTTTTTCAGT AATAATCAGA ACAATATTTA TTTTTATATT TAAAATTCAT	60<br>
AGAAAAGTGC CTTACATTTA ATAAAAGTTT GTTTCTCAAA GTGATCAGAG GAATTAGATA	120<br>
TNGTCTTGAA CACCAATATT AATTTGAGGA AAATACACCA AAATACATTA AGTAAATTAT	180<br>
TTAAGATCAT AGAGCTTGTA AGTGAAAAGA TAAAATTTGA CCTCAGAAAC TCTGAGCATT	240<br>
AAAAATCCAC TATTAGCAAA TAAATTACTA TGGACTTCTT GCTTTAATTT TGTGATGAAT	300<br>
ATGGGGTGTC ACTGGTAAAC CAACACATTC TGAAGGATAC ATTACTTAGT GATAGATTCT	360<br>
TATGTACTTT GCTANATNAC GTGGATATGA GTTGACAAGT TTCTCTTTCT TCAATCTTTT	420<br>
AAGGGGCNGA NGAAATGAGG AAGAAAAGAA AAGGATTACG CATACTGTTC TTTCTATNGG	480<br>
AA.GGATTAGA TATGTTTCCT TTGCCAATAT TAAAAAAATA ATAATGTTTA CTACTAGTGA	540<br>
AACCC	545<br>
(2) INFORMATION FOR SEQ ID N0:206:<br>
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 487 base pairs<br><br>
(B) TYPE: nucleic acid ((') STRANDEDNESS: single (D) TOPOLOGY: linear<br>
(:i.i! MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:206:<br>
TTTTTTTTTT TTTTTTAGTC AAGTTTCTNA TTTTTATTAT AATTAAAGTC TTGGTCATTT	60<br>
CATTTATTAG CTC'TGCAACT TACATATTTA AATTAAAGAA ACGTTNTTAG ACAACTGTNA	120<br>
CAATTTATAA ATGTAAGGTG CCATTATTGA GTANATATAT TCCTCCAAGA GTGGATGTGT	180<br>
CCCTTCTCCC ACCAACTAAT GAANCAGCAA CATTAGTTTA ATTTTATTAG TAGATNATAC	240<br>
ACTGCTGCAA ACGCTAATTC TCTTCTCCAT CCCCATGTNG ATATTGTGTA TATGTGTGAG	300<br>
TTGGTNAGAA TGCATCANCA ATCTNACAAT CAACAGCAAG ATGAAGCTAG GCNTGGGCTT	360<br>
TCGGTGAAAA TAGACTGTGT CTGTCTGAAT CAAATGATCT GACCTATCCT CGGTGGCAAG	420<br>
AACTCTTCGA ACCGOTTCCT CAAAGGCNGC TGCCACATTT GTGGCNTCTN TTGCACTTGT	480<br>
TTCAAAA	487<br>
!2) INFORMATION FOR SEQ ID NO:207:<br>
(i) SEQUEWCE CHARACTERISTICS:<br>
(A)	LENGTH: 332 base pairs<br>
(B)	TYPK: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:207:<br>
TGAATTGGCT AAAAGACTGC ATTTTTANAA CTAGCAACTC TTATTTCTTT CCTTTAAAAA	60<br>
TACATAGCAT TAAATCCCAA ATCCTATTTA AAGACCTGAC AGCTTGAGAA GGTCACTACT	120<br>
GCATTTATAG GACCTTCTGG TGGTTCTGCT GTTACNTTTG AANTCTGACA ATCCTTGANA	180<br>
ATCTTTGCAT GCAGAGGAGG TAAAAGGTAT TGGATTTTCA CAGAGGAANA ACACAGCGCA	240<br>
GAAATGAAGG GGCCAGGCTT ACTGAGCTTG TCCACTGGAG GGCTCATGGG TGGGACATGG	300<br>
AAAAGAAGGC AGCCTAGGCC CTGGGGAGCC CA	332<br>
(2) INFORMATION FOR SEQ ID N0:208:<br>
(i) SEQUENCE CHARACTERISTICS: (A! LENGTH: 524 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii.) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:<br>
AGGGCGTGGT	GCGGAGGGCG TTACTGTTTT GTCTCAGTAA CAATAAATAC AAAAAGACTG	60<br>
GTTGTGTTCC	GGCCCCATCC AACCACGAAG TTGATTTCTC TTGTGTGCAG AGTGACTGAT	120<br>
TTTAAAGGAC	ATGGAGCTTG TCACAATGTC ACAATGTCAC AGTGTGAAGG GCACACTCAC	180<br>
TCCCGCGTGA	TTCACATTTA GCAACCAACA ATAGCTCATG AGTCCATACT TGTAAATACT	240<br>
TTTGGCAGAA	TACTTNTTGA AACTTGCAGA TGATAACTAA GATCCAAGAT ATTTCCCAAA	300<br>
GTAAATAGAA	GTGGGTCATA ATATTAATTA CCTGTTCACA TCAGCTTCCA TTTACAAGTC	360<br>
ATGAGCCCAG	ACACTGACAT CAAACTAAGC CCACTTAGAC TCCTCACCAC CAGTCTGTCC	420<br>
TGTCATCAGA	CAGGAGGCTG TCACCTTGAC CAAATTCTCA CCAGTCAATC ATCTATCCAA	480<br>
AAACCATTAC	CTGATCCACT TCCGGTAATG CACCACCTTG GTGA	524<br>
(.•::} INFORMATION FOR SEQ ID NO.-209:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 159 base pairs<br>
(B)	TYPE: nucleic acid<br>
(0) STRANDEDNESS: single<br>
(D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi! SEQUENCE DESCRIPTION: SEQ ID N0:209:<br>
GGGTGAGGAA ATCCAGAGTT GCCATGGAGA AAATTCCAGT GTCAGCATTC TTGCTCCTTG 60<br>
TGGCCCTCTC CTACACTCTG GCCAGAGATA CCACAGTCAA ACCTGGAGCC AAAAAGGACA 120<br>
CAAAGGACTO TCGACCCAAA CTGCCCCAGA CCCTCTCCA	159<br>
(2) INFORMATION FOR SEQ ID NO:210:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 256 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:<br>
ACTCCCTGGC AGACAAAGGC AGAGGAGAGA GCTCTGTTAG TTCTGTGTTG TTGAACTGCC	60<br>
ACTGAATTTC TTTCOACTTG GACTATTACA TGCCANTTGA GGGACTAATG GAAAAACGTA	120<br>
TGGGGAGATT TTANCCAATT TANGTNTGTA AATGGGGAGA CTGGGGCAGG CGGGAGAGAT	180<br>
TTGCAGGGTG NAAATGGGAN GGCTGGTTTG TTANATGAAC AGGGACATAG GAGGTAGGCA	240<br>
CCAGGATGCT AAATC'A	256<br>
(2) INFORMATION FOR SEQ ID N0:211:<br>
1,1) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 264 base pairs<br>
(B)	TYPE: nucleic acid<br>
1C) STRANDEDNESS: single<br>
(D) TOPOLOGY: linear<br>
ill) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:<br>
ACATTGTTTT TTTGAGATAA AGCATTGAGA GAGCTCTCCT TAACGTGACA CAATGGAAGG	60<br>
ACTGGAACAC ATACCCACAT CTTTGTTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT	120<br>
ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTTAAGGAGA	180<br>
GGGGAGATAC ATTCNGAAAG AGGACTGAAA GAAATACTCA AGTNGGAAAA CAGAAAAAGA	240<br>
AAAAAAGGAG CAAATGAGAA GCCT	264<br>
(J) INFORMATION FOR SEQ ID N0:212:<br>
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 328 base pairs (Bi TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D: TOPOLOGY: 1inear<br>
(ii) MOLECULE TYPE: CDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:<br><br>
ACCCAAAAAT CCAATGCTGA ATATTTGGCT TCATTATTCC CANATTCTTT GATTGTCAAA	60<br>
GGATTTAATG TTGTCTCAGC TTGGGCACTT CAGTTAGGAC CTAAGGATGC CAGCCGGCAG	120<br>
GTTTATATAT GCAGCAACAA TATTCAAGCG CGACAACAGG TTATTGAACT TGCCCGCCAG	180<br>
TTNAATTTCA TTCCCATTGA CTTGGGATCC TTATCATCAG CCAGAGAGAT TGAAAATTTA	240<br>
CCCCTACNAC TCTTTACTCT CTGGANAGGG CCAGTGGTGG TAGCTATAAG CTTGGCCACA	300<br>
TTTTTTTTTC CTTTATTCCT TTGTCAGA	328<br>
(2) INFORMATION FOR SEQ ID NO:213:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 250 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:213:<br>
ACTTATGAGC AGAGCGACAT	ATCCNAGTGT AGACTGAATA AAACTGAATT CTCTCCAGTT	60<br>
TAAAGCATTG CTCACTGAAG	GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT	120<br>
CATTATGCCA AAGGANATAT	ACATTTCAAT TCTCCAAACT TCTTCCTCAT TCCAAGAGTT	180<br>
TTCAATATTT GCATGAACCT	GCTGATAANC CATGTTAANA AACAAATATC TCTCTNACCT	240<br>
TCTCATCGGT	250<br>
(2) INFORMATION FOR SEQ ID NO:214:<br>
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 444 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear<br>
(i i ) MOLECULE TYPE: cDNA<br>
ixi) SEQUENCE DESCRIPTION: SEQ ID NO:214:<br>
ACCCAGAATC	CAATGCTGAA TATTTGGCTT	CATTATTCCC AGATTCTTTG ATTGTCAAAG	60<br>
GATTTAATGT	TGTCTCAGCT TGGGCACTTC	AGTTAGGACC TAAGGATGCC AGCCGGCAGG	120<br>
TTTATATATG	CAGCAACAAT ATTCAAGCGC	GACAACAGGT TATTGAACTT GCCCGCCAGT	180<br>
TGAATTTCAT	TCCCATTGAC TTGGGATCCT	TATCATCAGC CANAGAGATT GAAAATTTAC	240<br>
CCCTACGACT	CTTTACTCTC TGGAGAGGGC	CAGTGGTGGT AGCTATAAGC TTGGCCACAT	300<br>
TTTTTTTTCC	TTTATTCCTT TGTCAGAGAT	GCGATTCATC CATATGCTAN AAACCAACAG	360<br>
AGTGACTTTT	ACAAAATTCC TATAGANATT	GTGAATAAAA CCTTACCTAT AGTTGCCATT	420<br>
ACTTTGCTCT	CCCTAATATA CCTC	444<br>
(2) INFORMATION FOR SEQ ID NO:215:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 366 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D! TOPOLOGY: linear<br>
( i i ) MOLECULE TYPE : C'DNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:<br>
ACTTATGAGC AGAGCGACAT ATCCAAGTGT ANACTGAATA AAACTGAATT CTCTCCAGTT     60 TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT    120<br><br>
CATTATGCCA AAGGANATAT ACATTTCAAT TCTCCAAACT TCTTCCTCAT TCCAAGAGTT	180<br>
TTCAATATTT GCATGAACCT GCTGATAAGC CATGTTGAGA AACAAATATC TCTCTGACCT	240<br>
TCTCATCGGT AAGCAGAGGC TGTAGGCAAC ATGGACCATA GCGAANAAAA AACTTAGTAA	300<br>
TCCAAGCTGT TTTCTACACT GTAACCAGGT TTCCAACCAA GGTGGAAATC TCCTATACTT	360<br>
GGTGCC	366<br>
(2) INFORMATION FOR SEQ ID NO:216:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 260 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: .single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: CDMA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:216:<br>
CTGTATAAAC AGAACTCCAC TGCANGAGGG AGGGCCGGGC CAGGAGAATC TCCGCTTGTC	60<br>
CAAGACAGGG GCCTAAGGAG GGTCTCCACA CTGCTNNTAA GGGCTNTTNC ATTTTTTTAT	120<br>
TAATAAAAAG TNNAAAAGGC CTCTTCTCAA CTTTTTTCCC TTNGGCTGGA AAATTTAAAA	180<br>
ATCAAAAATT TCCTNAAGTT NTCAAGCTAT CATATATACT NTATCCTGAA AAAGCAACAT	240<br>
AATTCTTCCT TCCCTCCTTT	260<br>
(2) INFORMATION FOR SEQ ID NO:217:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 262 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:217:<br>
ACCTACGTGG GTAAGTTTAN AAATGTTATA ATTTCAGGAA NAGGAACGCA	TATAATTGTA	60<br>
TCTTGCCTAT AATTTTCTAT TTTAATAAGG AAATAGCAAA TTGGGGTGGG	GGGAATGTAG	120<br>
GGCATTCTAC AGTTTGAGCA AAATGCAATT AAATGTGGAA GGACAGCACT	GAAAAATTTT	180<br>
ATGAATAATC TGTATGATTA TATGTCTCTA GAGTAGATTT ATAATTAGCC	ACTTACCCTA	240<br>
ATATCCTTCA TGCTTGTAAA GT	262<br>
(2) INFORMATION FOR SEQ ID NO:218:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 205 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:<br>
ACCAAGGTGG TGCATTACCG GAANTGGATC AANGACACCA TCGTGGCCAA CCCCTGAGCA	60<br>
CCCCTATCAA CTCCCTTTTG TAGTAAACTT GGAACCTTGG AAATGACCAG GCCAAGACTC	120<br>
AGGCCTCCCC AGTTCTACTG ACCTTTGTCC TTANGTNTNA NGTCCAGGGT TGCTAGGAAA	180<br>
ANAAATCAGC AGACACAGGT GTAAA	205<br>
(2) INFORMATION FOR SEQ ID NO:219:<br><br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 114 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
Hi) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:<br>
TACTGTTTTG TCTCAGTAAC AATAAATACA AAAAGACTGG TTGTGTTCCG GCCCCATCCA 60<br>
ACCACGAAGT TGATTTCTCT TGTGTGCAGA GTGACTGATT TTAAAGGACA TGGA	114<br>
(2) INFORMATION FOR SEQ ID NO:220:<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 93 base pairs<br>
(B)	TYPE: nucleic acid<br>
(0) STRANDEDNESS: single<br>
(D) TOPOLOGY: linear<br>
(ii) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:<br>
ACTAGCCAGC ACAAAAGGCA GGGTAGCCTG AATTGCTTTC TGCTCTTTAC ATTTCTTTTA 60<br>
AAATAAGCAT TTAGTGCTCA GTCCCTACTG ACT	93<br>
(2) INFORMATION FOR SEQ ID NO:221:<br>
(l) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 167 base pairs<br>
(B)	TYPE:: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(i i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:<br>
ACTANGTGCA GGTGCGCACA AATATTTGTC GATATTCCCT TCATCTTGGA TTCCATGAGG 60<br>
TCTTTTGCCC AGCCTGTGGC TCTACTGTAG TAAGTTTCTG CTGATGAGGA GCCAGNATGC 120<br>
CCCCCACTAC CTTCCCTGAC GCTCCCCANA AATCACCCAA CCTCTGT	167<br>
(2) INFORMATION FOR SEQ ID NO:222:<br>
(L) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 351 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
( i i) MOLECULE TYPE: cDNA<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:<br>
AGGGCGTGGT GCGGAGGGCG GTACTGACCT CATTAGTAGG AGGATGCATT CTGGCACCCC	60<br>
GTTCTTCACC TGTCCCCCAA TCCTTAAAAG GCCATACTGC ATAAAGTCAA CAACAGATAA	120<br>
ATGTTTGCTG AATTAAAGGA TGGATGAAAA AAATTAATAA TGAATTTTTG CATAATCCAA	180<br>
TTTTCTCTTT TATATTTCTA GAAGAAGTTT CTTTGAGCCT ATTAGATCCC GGGAATCTTT	240<br>
TAGGTGAGCA TGATTAGAGA GCTTGTAGGT TGCTTTTACA TATATCTGGC ATATTTGAGT	300<br><br>
CTCGTATCAA AACAATAGAT TGGTAAAGGT GGTATTATTG TATTGATAAG T	351<br>
(2) INFORMATION FOR SEQ ID NO:223<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 383 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:223:<br>
AAAACAAACA AACAAAAAAA ACAATTCTTC ATTCAGAAAA ATTATCTTAG GGACTGATAT	60<br>
TGGTAATTAT GGTCAATTTA ATWRTRTTKT GGGGCATTTC CTTACATTGT CTTGACAAGA	120<br>
TTAAAATGTC TGTGCCAAAA TTTTGTATTT TATTTGGAGA CTTCTTATCA AAAGTAATGC	180<br>
TGCCAAAGGA AGTCTAAGGA ATTAGTAGTG TTCCCMTCAC TTGTTTGGAG TGTGCTATTC	240<br>
TAAAAGATTT TGATTTCCTG GAATGACAAT TATATTTTAA CTTTGGTGGG GGAAANAGTT	300<br>
ATAGGACCAC AGTCTTCACT TCTGATACTT GTAAATTAAT CTTTTATTGC ACTTGTTTTG	360<br>
ACCATTAAGC TATATGTTTA AAA	383<br>
(2) INFORMATION FOR SEQ ID N0:224<br>
(i) SEQUENCE CHARACTERISTICS:<br>
(A)	LENGTH: 320 base pairs<br>
(B)	TYPE: nucleic acid<br>
(C)	STRANDEDNESS: single<br>
(D)	TOPOLOGY: linear<br>
(XI) SEQUENCE DESCRIPTION: SEQ ID NO:224<br>
CCCCTGAAGG CTTCTTGTTA GAAAATAGTA CAGTTACAAC CAATAGGAAC AACAAAAAGA	60<br>
AAAAGTTTGT GACATTGTAG TAGGGAGTGT GTACCCCTTA CTCCCCATCA AAAAAAAAAT	120<br>
GGATACATGG TTAAAGGATA RAAGGGCAAT ATTTTATCAT ATGTTCTAAA AGAGAAGGAA	180<br>
GAGAAAATAC TACTTTCTCR AAATGGAAGC CCTTAAAGGT GCTTTGATAC TGAAGGACAC	240<br>
AAATGTGGCC GTCCATCCTC CTTTARAGTT GCATGACTTG GACACGGTAA CTGTTGCAGT	300<br>
TTTARACTCM GCATTGTGAC	320<br><br><br><br>
We claim:<br>
1.	A polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence recited in SEQ ID NO: 10 or 110, or a variant of said polypeptide that differs only in conservative substitutions and/or modifications, and exhibits at least 90% identity thereto, wherein the therapeutic, antigenic and/or immunogenic properties of the variant are retained.<br>
2.	A DNA molecule comprising a nucleotide sequence encoding the polypeptide as claimed in claim 1.<br>
3.	A DNA molecule as claimed in claim 2 having a sequence provided in SEQ ID NO: 10 or 110.<br>
4.	An expression vector comprising the DNA molecule as claimed in claim 2.<br>
5.	A prokaryote or yeast host cell transformed with the expression vector as claimed in claim 4.<br>
6.	A host cell as claimed in claim 5 wherein the host cell is an E.coli cell.<br>
7.	A pharmaceutical composition comprising the polypeptide as claimed in claim 1 and a physiologically acceptable carrier.	<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1hYnN0cmFjdC0oMDYtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-abstract-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1145-del-2001-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1jbGFpbXMtKDA2LTA4LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1145-del-2001-claims-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUwtMjAwMS1Db3JyZXNwb25kZW5jZS1PdGhlcnMtKDE5LTA4LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1145-DEL-2001-Correspondence-Others-(19-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1jb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1jb3JyZXNwb25kZW5jZS1wby5wZGY=" target="_blank" style="word-wrap:break-word;">1145-del-2001-correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1kZXNjcmlwdGlvbiAoY29tcGxldGUpLTA2LTA4LTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-description (complete)-06-08-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1kZXNjcmlwdGlvbiAoY29tcGxldGUpLTE2LTA2LTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-description (complete)-16-06-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1145-del-2001-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTEtKDA2LTA4LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-1-(06-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTMucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1mb3JtLTUucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1kZWwtMjAwMS1ncGEucGRm" target="_blank" style="word-wrap:break-word;">1145-del-2001-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUFic3RyYWN0LSgxNi0wNi0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Abstract-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUNsYWltcy0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Claims-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Correspondence-Others-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUZvcm0tMi0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Form-2-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUZvcm0tMy0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Form-3-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLUdQQS0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-GPA-(16-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE0NS1ERUxOUC0yMDAxLVBldGl0aW9uLTEzNy0oMTYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1145-DELNP-2001-Petition-137-(16-06-2008).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="233264-waterless-waterwashable-offset-printing-ink-and-method-of-production-thereof.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="233266-a-method-of-quality-control-using-an-internal-control-nucleic-acid-sequence-encasulated-within-liposome-particles.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>233265</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1145/DEL/2001</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>13-Nov-2001</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>CORIXA CORPORATION.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>1124 COLUMBIA STREET, SUITE 200, SEATTLE,WASHINGTON 98104, UNITED STATES OF AMERICA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>JIANGCHUN XU</td>
											<td>15805 SOUTHEAST 43RD PLACE,BELLEVUE, WASHINGTON 98006, UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>DAVIN C DILLON</td>
											<td>21607 NE 24TH STREET, REDMOND WASHINGTON 98053, UNITED STATES OF AMERICA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 38/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>09/920,956</td>
									<td>1998-02-09</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>08/806,099</td>
									<td>1997-02-25</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>3</td>
									<td>08/904,804</td>
									<td>1997-08-01</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/233265-a-polypeptide-comprising-an-immunogenic-portion-of-a-prostate-protein by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:36:50 GMT -->
</html>
